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Abstract 
 
The functionalized γ-butenolide (2-(5H) furanone) motif is found in various natural 
products and hence the synthesis of butenolides is of considerable interest. The organocatalytic 
direct Mannich reaction of γ-crotonolactone with cyclic imines or in-situ generated iminium ions, 
to provide the functionalized butenolides is not reported. Several new bifunctional thiourea 
catalysts incorporating a chiral phosphoramide functionality, were prepared and examined in these 
reactions. These furanones are potential precursors for the synthesis of functionalized 
quinolizidines such as the homopumiliotoxins and indolizidines such as the pumiliotoxins. Details 
of these studies are described in Chapter 1. 
The organocatalytic Michael addition of cyclic ketones and aldehydes to -nitrostyrenes, 
generated in-situ from the corresponding nitroacetates, was investigated. The use of pyrrolidine-
based amine catalysts in the presence of a protonic acid was found to be optimal and provided 
enantiomerically enriched -nitro ketones or -nitro aldehydes in good yield. The utility of -nitro 
aldehydes in the synthesis of pyrrolidines was also established. Details of these studies are 
described in Chapter 2. 
The aspulvinones, 3-aryl-5-arylidene tetronic acids, are a major group of fungal 
metabolites which have attracted considerable interest due to their biological activity. A modular 
synthesis of aspulvinones B, D and the recently isolated aspulvinone Q was developed. The 
methodology features a stereoselective aldol condensation of diazotetronic acid with aldehydes to 
provide the 5-arylidene diazotetronates. A catalytic, intermolecular C-H insertion reaction of 5-
arylidene diazotetronates with arenes provides the aspulvinones. Variation of the aldehyde and the 
arene components furnishes synthetic analogues of the aspulvinones. These results are presented 
in Chapter 3. 
iv 
 
The first organocatalytic asymmetric direct vinylogous aldol reaction of isatin with -
angelicalactone for the construction of 3-substituted-3-hydroxyindoles by using various 
phosphoramide-thiourea catalysts was developed. Details of these studies are described in Chapter 
4. 
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Synthesis and Evaluation of Phosphoramide-Thiourea Organocatalysts in Direct 
Vinylogous Mannich Reaction of -Crotonolactone with Cyclic Imines 
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1.1 Introduction: 
The Mannich reaction and the related Mukaiyama Mannich reaction are among the most 
powerful carbon-carbon bond forming tools in synthetic organic chemistry. An extension of the 
Mannich reaction, namely, the vinylogous Mannich reaction is of considerable interest and has 
gained significant attention in strategies developed for the synthesis of several alkaloids.1 In 
contrast to the Mannich reaction, its vinylogous variant typically involves the reaction of 
nucleophilic dienolate derivatives with imines or iminium ions. For example, the addition of 
acyclic dienol ether D to cyclic or acyclic imines A to generate -aminocarbonyl compounds E 
(Figure 1.1) is an example of a vinylogous Mannich reaction that is related to the addition of an 
enol ether nucleophile to an iminium ion (B to A Figure 1.1). The dienol derivatives may also be 
cyclic, as exemplified by the addition of alkoxy furan F to cyclic or acyclic imines A to generate 
aminoalkyl-substituted -butenolide G, an active sub-unit that is found in a number of alkaloids.1 
Cyclization of E or of G leads to a functionalised quinolizidine (n = 1) or indolizidine (n = 2) 
skeleton H which is a characteristic motif found in a variety of alkaloids (Figure 1.1).1 It may be 
noted that the conversion of G to H involves the rearrangement of a lactone to a lactam. 
 
Figure 1.1 Mukaiyama Mannich vs. vinylogous Mannich reactions 
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1.2 Objectives: 
We were interested in the development of a direct organocatalytic vinylogous Mannich 
reaction of -crotonolactone 1 and its analogs (Figure 1.2). The advantage of this approach was 
that it avoids the synthesis of dienol intermediates (Figure 1.1) which were often difficult to purify 
and have a limited shelf life. If successful, the organocatalytic procedure would generate a 
dienolate 2 in situ which would then react with an imine 3 (Figure 1.2). Only a few reports of such 
direct vinylogous Mannich reactions are available1 and the reaction continues to be a synthetic 
challenge. Our specific objective was the development of an organocatalytic vinylogous Mannich 
reaction of -butenolides 2 and cyclic iminium ions 3 that are obtained in situ from suitably 
functionalized piperidine and pyrrolidine derivatives. 
 
Figure 1.2 Direct vinylogous Mannich reaction of -crotonolactone with cyclic imines 
A second objective was the conversion of the Mannich products 4 and 5 obtained from  
-crotonolactone 1 and a piperidine or pyrrolidine-based iminium ion 3 to provide the indolizidine 
or quinolizidine ring systems 6 and 8, respectively.  
 
Figure 1.3 Conversion of Mannich products in some useful alkaloids 
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While the indolizidine 6 is potentially a key intermediate to the several pumiliotoxins 
alkaloids 7, the quinolizidine 8 has been employed as a key synthetic intermediate to several 
homopumiliotoxin alkaloids 9 (Figure 1.3).2   
The pumiliotoxin alkaloids are isolated in trace amounts from the skin of amphibians and 
more than 800 different alkaloids, consisting of more than 20 structural groups, have been 
identified.2 Among them the pumiliotoxins 7, featuring an indolizidine ring system, have been 
known since 19673 and were isolated from a population of a small neotropical Panamanian 
dendrobatid frog, the brightly colored (orange or red) Dendrobates pumilo2,4 (Figure 1.4).  In 1987, 
homopumiliotoxin 223G (9a), another bicyclic alkaloid in which the indolizidine moiety of the 
pumiliotoxin is replaced with a quinolizidine ring, was isolated in trace amounts from the 
Panamanian frog Dendrobates pumilo2,5 and appeared to be unique to this family of amphibians. 
However, recent examination of skin extracts from nondendrobatid amphibians revealed that 
homopumiliotoxin 223G (9a) also occurs in the New World genus of bufonid toads 
Melanophryniscus6 and the Madagascan genus of mantelline frogs Mantella.7  
 
Figure 1.4 Structure of some poison frog alkaloids.  
The former genus contains new members of the homopumiliotoxin class alkaloids and were 
characterized as homopumiliotoxins 319A, 319B, 321B7 (Figure 1.4). The relative configuration 
of these homopumiliotoxin alkaloids has been tentatively established (except for the configuration 
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of the hydroxy group in the side chain in homopumiliotoxin 321B). These alkaloids have received 
much attention due to their biological activities such as myotonic and cardiotonic activity.8 It is 
found that these alkaloids are ingested by the frogs in their diet consisting of small arthropods,9 
and then accumulate in the skin of the frog. The alkaloids are stored in granular skin glands and 
serve as a passive defense against predators and/or microorganisms.10 Several synthetic 
approaches to the pumiliotoxins have been reported.11 However, unlike pumiliotoxins, very few 
syntheses of ()-homopumiliotoxin,12 and more importantly of (+)- or (-)-homopumiliotoxin 
223G, are reported.13 The structural diversity and remarkable biological activities exhibited by 
these alkaloids, and their scarcity have made them interesting synthetic targets. 
Since the objective of the present study was to develop methodology that would greatly 
simplify the synthesis of pumiliotoxins and homopumilitoxins, a brief survey of the known 
syntheses of a selection of these alkaloids is provided in the following section. 
1.3 Known syntheses of homopumiliotoxin Alkaloids 
1.3.1 Total synthesis of ()-homopumiliotoxin 223G by Pilli 
 In 2001, Pilli and co-workers12a achieved the total synthesis of ()-homopumiliotoxin 223G 
in six steps and 14% overall yield (Scheme 1.01). The addition of 5-methyl-2-
triisopropylsilyloxyfuran 11 to the iminium ion generated in situ from a 2-alkoxypiperidine 10 
provided the addition products 12 and 13. Hydrogenation of the double bond followed by a 
cyclization reaction provided bicyclic lactams 16 and 17 as key intermediates. Mukaiyama aldol 
reaction of 17 and isobutyraldehyde catalyzed by TMSOTf afforded a 3:1 mixture of diastereomers 
of 18. Stereospecific syn elimination of the major diastereomer using DCC and CuCl14 gave 19. 
Reduction of the amide in 19, with AlH3 (generated in situ with LiAlH4/AlCl3), provided ()-
homopumiliotoxin 223G which was converted into the hydrochloride salt 20 in 87% yield. 
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Scheme 1.01 
1.3.2 Formal synthesis of ()-homopumiliotoxin 223G by Chang  
 In 2004, Chang and co-workers12b reported a formal synthesis of ()-homopumiliotoxin 
223G in eleven steps and 9% overall yield (Scheme 1.02). They started their synthesis by a 
stepwise [3+3] reaction of -sulfonyl acetamide 21 and ester 22 to provide the functionalized 
imide 23. Regioselective reduction of the imide with LiAlH4 afforded hydroxy lactam 24 which 
was converted to 25 by reaction with methanol in the presence of BF3·Et2O. Allylation of 25 in 
presence of BF3·Et2O provided 26 as a mixture of three diastereomers (33:33:34 by 
1H NMR) due 
to the unexpected epimerization of the C-3 stereocenter under the reaction conditions. These 
diastereomers were not individually isolated and the mixture was subjected to a ring closing 
metathesis reaction with the Grubbs (I) catalyst at room temperature to provide a mixture of 
quinolizidines 27. Hydrogenation of 27 followed by demethylation with NaI and TMSCl afforded 
28. Detosylation with Na/Hg provided hydroxy lactam 29 as a mixture of two isomers (30:70 by 
1H NMR). Oxidation of the secondary alcohol in 29 with Jones reagent provided ketone 30. 
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Subsequent stereoselective addition of methyl magnesium bromide to 30 afforded 31 as the only 
product. The conversion of 31 into ()-homopumiliotoxin 223G in four steps was previously 
reported.12a  
 
Scheme 1.02 
1.3.3 Total synthesis of (+)-homopumiliotoxin 223G by Kibayashi 
 In 1998, the first total synthesis of (+)-homopumiliotoxin 223G, in eleven steps and 27% 
overall yield from N-Cbz-L-pipecolic acid 33, was reported by Kibayashi.13b There are two key 
steps in this synthesis which involve 1) Lewis acid induced chelation controlled propargylation of 
36 using silylallene for the direct construction of propargylic alcohol 37 with complete 
diastereoselectivity, and 2) palladium-catalyzed carbonylation of vinyl iodide 41 (CO, Bu3N,  
Pd(OAc)2 and Ph3P) to provide lactone 42 with the required (Z)-alkylidene side chain. 
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Scheme 1.03 
Removal of the Boc group with trifluoroacetic acid followed by DIBAL-H reduction provided diol 
43. Conversion of 43 to the allylic bromide (CBr4, Ph3P)
15 induced ring closure, involving the 
secondary amine, to provide (+)-homopumiliotoxin 223G in 82% yield. 
1.3.4 Total synthesis of (+)-homopumiliotoxin 223G by Kibayashi 
In 2000, Kibayashi and co-workers13a accomplished the total synthesis of  
(+)-homopumiliotoxin 223G (9a) in twelve steps and 3% overall yield. Their synthesis begins with 
the N-(iodoalkenyl) aldehyde 45 which was prepared using (S)-N-Boc-2-acetyl-piperidine 44 
according to the literature procedure in 9 steps.16 Aldehyde 45 was then subjected to intramolecular 
chromium mediated cyclization to give the trans-quinolizidine intermediate 46 which was 
acetylated to give 47. Reduction of 47 with lithium in liquid ammonia resulted in deacetoxylation 
and debenzylation to provide (+)-homopumiliotoxin 223G (9a). 
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Scheme 1.04 
1.3.5 Formal enantioselective synthesis of pumiliotoxin alkaloids by Lin 
 In 2003, Lin and Co-workers13e achieved the enantioselective formal synthesis of the 
pumiliotoxins in seventeen steps in overall 18% yield featuring a novel one-pot substitution ring-
opening sequence and an efficient Claisen type condensation. They started their synthesis from 
trisubstituted olefin 48 which was readily prepared from 1,4-butanediol.17 Sharpless asymmetric 
dihydroxylation of 48 with (AD-mix-) followed by selective mesylation of the sterically 
unhindered hydroxyl group in the product diol afforded 49. Treatment of 49 with K2CO3 afforded 
the epoxide with an inversion of configuration at the secondary stereocenter. Removal of the 
benzyl group by hydrogenation followed by mesylation afforded 50. Displacement of the mesylate 
with benzylamine followed by regioselective intramolecular opening of the epoxide provided 
pyrrolidine or piperidine derivatives 51 in good yield. A series of protection/deprotection reactions 
furnished the acetamides 53. The construction of the indolizidine/quinolizidine core was achieved 
by an intramolecular Claisen-type cyclization of 53. Subsequent reduction of the Claisen product 
afforded bicyclic hydroxy lactams 54 without any change in enantiomeric excess with respect to 
that of 49. Conversion of 54 to the enones 55 followed by a one-pot reduction of the alkene and 
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debenzylation gave the bicyclic lactams 56 which have been employed as the key intermediates in 
several syntheses of pumiliotoxins and homopumiliotoxins. 
 
Scheme 1.05 
1.3.6 Formal asymmetric synthesis of (-)-homopumiliotoxin 223G by Huang 
 In 2006, Huang and co-workers13c reported their formal asymmetric synthesis of  
(-)-homopumiliotoxin 223G in eight steps and 18% overall yield. This synthesis involves the 
flexible introduction of a functionalized C4 side chain to (S)-3-benzyloxyglutarimide 57 (Scheme 
1.06), easily prepared from 1,4-butanediol. The addition of Grignard reagent to 57 afforded a 
separable diastereomeric mixture of 58 and ring-opened -keto amide 59 in a combined yield of 
93%. These two isomers are interconvertible through an N-acyliminium ion intermediate18 and 
were used in the subsequent step without purification. Treatment of the mixture 58 and 59 with 
Et3SiH/ BF3·Et2O provided the desilylated product 60 in 60% yield. Tosylation of 60 followed by  
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N-deprotection using ceric ammonium nitrate provided 62. Intramolecular nucleophilic 
displacement of the tosyl group and removal of the benzyl group by catalytic hydrogenation 
afforded the key intermediate 64. Utilization of a tandem Swern oxidation-Grignard reaction 
strategy afforded 66 as a single diastereomer with 90% ee. The conversion of 66 into (-)-
homopumiliotoxin 223G is reported in the literature.12a 
 
Scheme 1.06 
 
1.3.7 Formal asymmetric synthesis of (-)-homopumiliotoxin 223G by Chemla 
 In 2007, Chemla and co-workers13b achieved the asymmetric synthesis of a key 
homopumiliotoxin intermediate, (-)-1-hydroxyquinolizidinone, in seven steps and in 25% overall 
yield from readily available 5-chloropentanal. Their synthesis started with (Ss)-sulfinimine 67 
derived from 5-chloropentanal and (Ss)-N-tert-butanesulfinamide.19 Reaction of 67 with the in situ 
generated racemic allenylzinc reagent  6820 afforded a mixture of two inseparable major and minor 
isomers of 69 in 90% yield (dr = 24:1, Scheme 1.07). Intramolecular displacement of chloride and 
desilylation of the terminal alkyne were achieved in a single step to provide 70 as a single isomer 
after purification. Acylation of the acetylene with methyl chloroformate led to intermediate 71. 
Treatment of 71 with methanolic HCl resulted in the removal of the tert-butanesulfinyl auxiliary 
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on the nitrogen. Hydrogenation of the triple bond and subsequent cyclization afforded the 
corresponding bicyclic lactam which was deprotected (MOM removal) with methanolic HCl to 
give (-)-1-hydroxyquinolizidinone 72 which is a key intermediate in the synthesis of  
(-)-homopumiliotoxin 223G.13   
 
Scheme 1.07 
 
1.3.8 Formal asymmetric synthesis of (-) and (+)-homopumiliotoxin 223G by Kim 
 In 2010, Kim and co-workers21 developed an efficient and stereoselective route to the key 
intermediate 1-hydroxyquinolizidinone for the synthesis of homopumiliotoxin 223G in six steps 
and 25% overall yield (Scheme 1.08). Their synthesis started with commercially available alcohol 
73 which was oxidized by PCC to the corresponding aldehyde. Subsequent addition of vinyl 
magnesium bromide provided allylic alcohol 74. Claisen rearrangement of 74 with 
triethylorthoacetate afforded the (E)-alkene 75, which upon dihydroxylation generated a hydroxy 
lactone. Subsequent heating of this lactone with sodium azide followed by mesylation afforded 76. 
Exclusive formation of 77a was observed when a more nucleophilic solvent (MeOH) was used. 
However, the other diastereomer 77b was observed when a less nucleophilic solvent (MeCN) was 
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used. Lactams 77a and 77b are useful for the synthesis of (+) and (-) homopumiliotoxin 223G, 
respectively.13 
 
Scheme 1.08 
1.4 Studies on an organocatalytic vinylogous Mannich approach to key pumiliotoxin 
alkaloid intermediates: 
As described above, there are several known syntheses of pumiliotoxin alkaloids. 
Kibayashi13a, b and Lin13e achieved their synthesis of pumiliotoxin alkaloids in eleven and fourteen 
steps, respectively. Huang13c and Chang12b achieved the formal synthesis of pumiliotoxin alkaloids 
in eight and eleven steps, but the synthesis of the starting material 21, 22 and 57 was ignored in 
both the claims. Pilli and co-workers12a achieved the total synthesis of () homopumiliotoxin 223G 
in just six steps, which is considered to be the shortest total synthesis of pumiliotoxin alkaloids. 
All of these methods are primarily limited by the multiple steps needed for the synthesis of key 
bicyclic lactam intermediates.  
As outlined in the objectives of this study, we decided to examine the organocatalytic direct 
vinylogous Mannich (ODVM) reaction of a cyclic imine, or an iminium ion that is generated in 
situ from its stable precursor, and -crotonolactone 1 (Figure 1.5) as the key step in our approach 
to bicyclic lactams leading to the pumiliotoxins. Notably, there are no reports on the vinylogous 
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Mannich reaction of imines or in situ generated iminium ions and crotonolactone 1. If successful, 
our strategy would give access to the key lactam intermediate H in just five steps (Figure 1.5). 
 
Figure 1.5 Retrosynthetic analysis 
We chose to examine the possibility of using bifunctional organocatalysts for the proposed 
Mannich reaction. These catalysts contain a hydrogen bond donor functionality in the form of a 
thiourea, and also a Lewis basic tertiary amine functionality. It was anticipated that the hydrogen 
bond donor would either assist in generating an imine or it would activate a preformed imine 
electrophile, whereas the Lewis base would assist in the deprotonation of the butyrolactone to 
generate a nucleophilic furanoate (Figure 1.6). 
 
Figure 1.6 Activation of electrophile and nucleophile with phosphoramide-thiourea catalyst 
1.5 Results and Discussion 
Organocatalysis has been shown to be a useful and important technique to induce 
stereoselectivity in a wide variety of chemical transformations.22 We have designed a new class of 
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phosphoramide-thiourea organocatalysts based on the Takemoto catalyst (catalyst II, Figure 1.8) 
as shown in Figure 1.7. 
 
Figure 1.7. Design of a new class of phosphoramide-thiourea catalyst 
Compared to the Takemoto catalyst II, our catalysts contain a chiral 1,2-diamine based 
amidophosphoryl moiety (for example compounds VI-VIII, Figure 1.8) instead of the 1,3-
bis(trifluoromethyl)phenyl moiety. These catalysts have sites that can potentially activate 
electrophiles through hydrogen bonding23 and also a basic site to activate the nucleophile.  
 
Figure 1.8 Organocatalysts used for the direct vinylogous Mannich reaction 
In short, simultaneous activation of the electrophile and nucleophile can be potentially 
achieved with these bifunctional catalysts. In addition to the phosphoramide-thiourea catalysts, we 
also planned to study the effect of other bifunctional catalysts as well as chiral acids in the direct 
vinylogous Mannich reaction (Figure.1.8). The synthesis of several novel phosphoramide-thiourea 
catalysts is described below. 
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Our studies began with the preparation of building blocks required for the synthesis of the 
phosphoramide catalyst (V) from commercially available (1S,2S)-cyclohexane-1,2-diamine 78. 
Reductive amination24 of benzaldehyde with 78 afforded (1S,2S)-N,N’-dibenzylcyclohexane-1,2-
diamine 79, which on condensation with phosphorous oxychloride furnished diaminophosphoryl 
chloride 80. Treatment of 80 with potassium isothiocyanate25 afforded intermediate 81. 
Simultaneously, (1R,2R)-N,N-dimethyl-1,2-diphenylethane-1,2-diamine 85 was prepared 
according to the procedure reported in the literature.26  
Scheme 1.09  
The protection of (1R,2R)-1,2-diphenylethane-1,2-diamine 82 with phthalic anhydride 
produced the mono-phthalimido derivative 83. Dimethylation of 83 followed by removal of the 
imide functionality with hydrazine hydrate afforded 85. The coupling of intermediates 81 and 85 
afforded catalyst V as a white solid in 96% yield (Scheme 1.09).  
We have also synthesized several “switched” phosphoramide catalysts where the stilbene 
diamine moiety is on the phosphorous side and the cyclohexane diamine group is on the other side 
of the catalysts with respect to catalyst V. The building blocks required for the preparation of 
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switched phosphoramide catalysts were obtained by following different routes depending on the 
substituents on the nitrogen.  
 
Scheme 1.10  
The synthesis of the catalyst VI started with (1S,2S)-1,2-diphenylethane-1,2-diamine 
which on reaction with benzaldehyde followed by reduction with sodium cyanoborohydride 
afforded 8727a. Treatment of 87 with phosphorous oxychloride followed by reaction with 
tetrabutylammonium thiocyanate afforded intermediate 89. The coupling of intermediate 89 and 
(1S,2S)-N,N-dimethylcyclohexane-1,2-diamine 9027b afforded catalyst VI as a white solid in 76% 
yield (Scheme 1.10). 
The synthesis of the catalysts VII and VIII started with the preparation of the intermediates 
91 and 93 which were made easily from commercially available (1R,2R)-1,2-diphenylethane-1,2-
diamine. Reductive amination of acetone with stilbene diamine using Adam’s catalyst in the 
presence of acetic acid and hydrogen afforded 91.28a Alternatively, formylation of stilbene diamine 
with formic acetic anhydride followed by reduction of the bis-amide with lithium aluminium 
hydride afforded 93.28b Once we had these intermediates in hand, the rest of the steps to achieve 
the syntheses of the catalysts VII and VIII were identical to the synthesis of catalyst VI. The 
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condensation of disubstituted diamines 91 and 93 with phosphorous oxychloride afforded 
diaminophosphoryl chlorides29 94 and 95, respectively. The isothiocyanates 96 and 97 obtained 
by the reaction of the corresponding phosphoryl chlorides with Bu4NSCN and were used without 
purification in the next step. The coupling of 96 and 97 with 90 afforded the phosphoramide 
catalysts VII and VIII as a white solids in 47% (94% based on recovered starting material 96) and 
62% respectively (Scheme 1.11). 
 
Scheme 1.11  
Analysis of the 1H NMR spectra of the phosphoramide-based catalysts revealed an 
interesting feature of their conformations in solution. We had anticipated that the N-Ha proton 
(Figure 1.9), which is flanked by the thiocarbonyl and the phosphoryl group would resonate more 
downfield than the N-Hb proton. However, we observed that the N-Hb proton was more downfield 
shifted than N-Ha proton. It should be mentioned that, in catalyst VI-VIII, N-Ha and N-Hb can be 
readily distinguished by their chemical shift; whereas in catalyst V Hb appears as a broad singlet 
and the peak for Ha merges with aromatic protons (see Table 1.1).   
 
Figure 1.9 Intramolecular H-bonding in phosphoramide catalysts 
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A plausible reason for this observation is a preference for the thiourea conformation in 
which N-Hb is internally hydrogen bonded to the P=O oxygen. It is well known that hydrogen 
bonding induces a downfield shift in the hydrogen-bonded hydrogen atom.30a  
 
Table 1.1 NMR characteristics of the thiourea protons (Ha and Hb) in phosphoramide catalysts. 
 
Catalysts 
 
Ha 
 
 
Hb 
 
 
 
merges with ArH 
 
10.40 (br s, 1H), 
 
 
 
6.99 (d, J = 9.8 Hz) 
 
 
9.91 (d, 3JH-H = 7.9 Hz) 
 
 
6.35 (d, J = 8.6 Hz) 
 
9.90 (d, 3JH-H = 7.5 Hz) 
 
 
6.59 (br s, 1H) 
 
9.63 (d, 3JH-H = 7.7 Hz) 
 
The N-Hb proton appears in the range of 9.90-10.41 ppm, whereas the N-Ha appears in the 
range of 6.35-6.99 ppm (see the experimental section) in the 1H NMR spectrum of the catalysts as 
shown in Table 1.1. This observation was also confirmed by heteronuclear 1H-13C correlation 
spectroscopy (HSQC). 
These observations suggest that our phosphoramide-containing catalysts may not function 
as double-hydrogen bonding catalysts although they contain a thiourea functional group which is 
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a well-established double-hydrogen bond donor functionality.30b Instead, they may function as 
catalysts that engage in single hydrogen bond activation of suitable H-bond donor functional 
groups (Figure 1.10). It may be noted that the thiocarbonyl group is known to function as a 
hydrogen-bond acceptor.30c 
 
Figure 1.10 Hydrogen bonding of iminium ion precursor with phosphoramide-thiourea catalyst 
With the catalysts V-VIII in hand, we initiated our investigation of an organocatalytic 
vinylogous Mannich reaction of a piperidine-derived imine or in-situ generated iminium ion with 
crotonolactone 1, the key step in our planned synthesis of homopumiliotoxin alkaloids.  
 
Figure 1.11: Organocatalytic vinylogous Mannich reaction as a key step of the synthesis 
The requisite imine was readily obtained from piperidine by adaptation of the reported 
procedure.31 N-Chlorination of piperidine 98 with N-chlorosuccinimide afforded  
N-chloropiperidine 99. Treatment of 99 with ethanolic KOH gave a mixture of monomeric (minor) 
and trimeric (major) forms (1H NMR) of 10031 (Scheme 1.12). The trimeric form is a convenient 
source of Δ1-piperideine 100 which is generated by dissociation in solution. This material was used 
as such without purification. 
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Scheme 1.12  
We initially examined the reaction of imine 100 and crotonolactone 1 with stilbene diamine 
derived aminosquaramide catalyst I (entry 1, Table 1.2,). This reaction led to a complex mixture 
of products which did not contain any of the required product 101. The use of Takemoto catalyst 
II and phosphoramide catalyst V (entries 2 and 3, Table 1.2) was not beneficial, and the required 
product was not obtained in either case. 
Table 1.2 Vinylogous Mannich reaction of imine 100 with crotonolactone 1 
 
Entrya Catalyst Time Result 
 
1 
 
 
24 h 
 
No required  
product 
 
2 
 
 
24 h 
 
No required  
product 
 
3 
 
 
24 h 
 
No required  
product 
a 2 equiv of crotonolactone.  
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Given the failure of the vinylogous Mannich reaction of the imine 100 with crotonolactone 
1, we chose to prepare some other substrates that could generate an iminium ion in-situ under the 
reaction conditions. Selected iminium ion precursors were synthesized from commercially 
available glutarimide and valerolactam according to the literature procedures.32-35 The yields of all 
these precursors were good, and they were bench-stable compounds. 
The reduction of glutarimide 102 with sodium borohydride in MeOH afforded  
6-hydoxypiperidin-2-one 103.32 Conversion of the hydroxyl group in 103 into a methoxy group 
followed by protection with di-tert-butyl dicarbonate (Boc anhydride, Boc2O) afforded 104. 
Reduction of 102 with sodium borohydride in EtOH provided 6-ethoxypiperidin-2-one 105.33  
N-benzylation of glutarimide with benzyl bromide followed by reduction with DIBAL-H afforded 
1-benzyl-6-hydroxypiperidin-2-one 107.34 The acetylation of 107 with acetic anhydride gave  
1-benzyl-6-oxopiperidin-2-yl acetate 108.35 However, the reaction of 107 with 
trichloroacetonitrile in the presence of DBU was unsuccessful, and the required product was not 
obtained (Scheme 1.13). Compounds 103, 104, 105, 107 and 108 are known to generate the 
corresponding iminium ions when treated with a Lewis acid or a protic acid.32-35  
 
Scheme 1.13 
Since the phosphoramides V-VIII have a hydrogen-bond donor functionality, we 
anticipated that they would also facilitate the formation of iminium ions by H-bonding with the 
23 
 
hemiaminal oxygen in compounds 103, 104, 105 and 107, and with the acetate carbonyl oxygen 
in compound 108. 
A pyrrolidone-based iminium ion precursor was also synthesized from succinimide. Thus, 
N-benzylation of succinimide 110 followed by reduction with sodium borohydride afforded 112.36 
(Scheme 1.14)  
 
Scheme 1.14  
The valerolactam (113)-based iminium ion precursors were prepared by N-acylation of the 
valerolactam 113 with di-tert-butyl dicarbonate (Boc2O) or benzyl chloroformate, followed by 
reduction with sodium borohydride which afforded 11537 and 11938 respectively. The reaction of 
115 and 119 with trichloroacetonitrile in the presence of a stoichiometric amount of DBU afforded 
the hitherto unreported trichlroacetimidates 117 and 120, respectively. The conversion of the 
hydroxyl group in 115 into its methoxy derivative afforded 116 in good yield (Scheme 1.15). 
Compounds 115, 116, 117, 119 and 120 were anticipated to provide the corresponding iminium 
ions in the presence of H-bond donor containing organocatalysts.  
 
Scheme 1.15 
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Our studies of the organocatalytic vinylogous Mannich reaction began with the reaction of 
iminium ion precursor 103 with crotonolactone 1 in the presence of the aminosquaramide catalyst 
I. Initially, CH2Cl2 was chosen as a solvent to check the feasibility of the key step (entry 1, Table 
1.3). However, this reaction provided a complex mixture which did not contain any of the required 
product (1H NMR spectrum of the crude product).  
Table 1.3 Vinylogous Mannich reaction of glutarimide derivatives and crotonolactone 1 
 
Entrya Precursor Catalyst 
 
Additive 
 
Time Result 
 
1 
 
 
 
- 
 
24 h 
 
No required 
product 
 
2 
 
 
 
Sc(OTf)3 
 
24 h 
 
No required 
product 
 
3 
 
 
 
- 
 
24 h 
 
No required 
product 
 
4 
 
 
 
- 
 
24 h 
 
No required 
product 
 
5 
 
 
 
- 
 
24 h 
 
25%b 
25 
 
 
6 
 
 
 
- 
 
24 h 
 
No required 
product 
 
7 
 
 
 
- 
 
24 h 
 
No required 
product 
 
8 
 
 
 
- 
 
24 h 
 
No required 
product 
 
9 
 
 
 
- 
 
24 h 
 
No required 
product 
a 2 equiv. of crotonolactone. b Isolated by flash column chromatography. 
Other bifunctional catalysts and chiral acids (as co-catalysts) for the vinylogous Mannich 
reaction were examined next. In the presence of Takemoto catalyst II and stilbene derived thiourea 
catalyst III, the vinylogous Mannich reaction of 103 with crotonolactone 1 was not fruitful and 
failed to provide the required product 121. The starting material 103 was recovered from the 
reaction mixture (entries 2 and 3, Table 1.3). Adding Sc(OTf)3, as a Lewis acid that would promote 
the generation of an iminium ion from 103 or 105, (entry 2, Table 1.3) did not alter the course of 
the reaction and the required product was not detected. It was confirmed from 1H NMR of the 
crude and the starting material 103 or 105 was recovered from the reaction mixture. The effect of 
Sc(OTf)3 was examined only when it was observed that there was no reaction (TLC) in the 
presence of the organocatalyst alone.  
The use of (1S)-10-camphorsulfonic acid in the vinylogous Mannich reaction of 103 with 
crotonolactone 1 provided a complex mixture which did not contain any of the required product 
(entry 4 Table 1.3). A by-product enamide 122 was isolated in 25% yield when the binol 
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phosphoric acid derivative IX was used as a chiral acid catalyst. Spectroscopic data for 122 was 
in agreement with the reported data in the literature.38c The ethoxy lactam 105 also failed to give 
the required product with the use of the bifunctional catalysts I and III (entries 7 and 8, Table 1.3). 
The use of chiral acids IV and IX (entries 6 and 9, Table 1.3) did not have a substantial effect on 
the vinylogous Mannich reaction of 105 with crotonolactone 1 and these reactions also failed to 
provide the product required for the synthesis of homopumiliotoxin alkaloids. Only unreacted 
starting materials were observed in the crude reaction mixtures (1H NMR) in both the cases. 
We then studied the reaction of various N-benzylated glutarimide and succinimide iminium 
ion precursors. The reaction of 107 with crotonolactone 1 was examined using bifunctional 
catalysts I and II and afforded N-benzyl enamide 124 as the only by-product in both the cases 
(entries 1 and 2, Table 1.4), respectively.  
Table 1.4 Vinylogous Mannich reaction of N-benzylated iminium ion precursors and 
crotonolactone 1 
 
 
Entry Precursor Catalyst Additive Base Time Result 
 
1 
 
 
I 
 
- 
 
- 
 
12 h 
 
(95%)a 
 
2 
 
 
II 
 
- 
 
- 
 
12 h 
 
27 
 
(90%)a 
 
3 
 
 
V 
 
Sc(OTf)3 
 
- 
 
48 h 
 
     (90%)a 
 
4 
 
 
VI 
 
Sc(OTf)3 
 
- 
 
48 h 
 
     (90%)a 
5 
 
 
- 
 
Sc(OTf)3 
 
- 
 
12 h 
              
(95%)a 
6 
 
 
I 
 
- 
 
- 
 
12 h 
 
No required 
product  
7 
 
 
II 
 
- 
 
- 
 
12 h 
 
     43% 
8 
 
 
II 
 
Sc(OTf)3 
 
TEA, DBU 
 
48 h 
 
SM 
recoveredb 
9 
 
 
II 
 
Sc(OTf)3 
 
TEA, DBU 
 
48 h 
 
SM 
recoveredb 
10 
 
 
I 
 
Sc(OTf)3 
 
- 
 
12 h 
 
No required 
product 
11 
 
 
II 
 
Sc(OTf)3 
 
- 
 
12 h 
 
No required 
product 
aYield of crude product, bCarried out at 0 ℃. 
The vinylogous Mannich reaction of 107 with crotonolactone 1 in the presence of the 
phosphoramide catalyst V or VI and Sc(OTf)3 afforded only the N-benzyl enamide 124 (Table 1.4, 
entries 3 and 4) and none of the required product. The formation of the N-benzyl enamide 124 was 
not detected in the absence of Sc(OTf)3 in these reactions. Notably, the N-benzyl enamide 124 was 
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also observed in the reaction of 107 with crotonolactone 1 in the presence of Sc(OTf)3 without the 
addition of catalyst V or VI (entry 5, Table 1.4). These observations suggests that the formation 
of 124 observed in the reactions involving catalyst V or VI and Sc(OTf)3 (entries 3 and 4, Table 
1.4) is due to Sc(OTf)3 and that the organocatalysts V and VI are not involved in this dehydration. 
In the presence of catalyst I, the reaction of 108 with crotonolactone 1 provided a mixture of 
products with no traces of the required product (entry 6, Table 1.3). However, a reaction with 
Takemoto catalyst II afforded N-benzyl enamide 124 as a by-product in 43% yield but failed to 
provide the required product.  
As described above, formation of the by-product 124 could not be avoided in several of the 
reactions examined. Nonetheless, the formation of 124 indicated that the required iminium ion was 
formed under the examined conditions, but it failed to react with the nucleophile present in the 
reaction mixture. Instead, the iminium ion formed in the reaction mixture loses a proton to generate 
the N-benzyl enamide 124 (Figure 1.12). This process is presumably faster than addition of the 
crotonolactone-derived enolate at ambient temperature. 
 
Figure 1.12 Formation of N-benzyl enamide 119 
Assuming that ambient temperature promotes elimination from the iminium ion, a few 
reactions with catalyst II were conducted at lower temperature (0 oC). Unfortunately, although this 
prevented the formation of 124, the required Mannich product product 123 was not observed 
(entries 8 and 9, Table 1.4). The possibility of the lack of enolization of the crotonolactone was 
also considered and the effect of added bases such as triethyl amine and DBU was also examined. 
Unfortunately, and unexpectedly, this change had no effect and the starting materials were 
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recovered from the reaction mixture (entries 8 and 9, Table 1.3). Because of the formation of 
moderate amount of undesired by-product 124, the succinimide-derived iminium ion precursor 
112 was also investigated in the presence of catalysts I and II to examine the influence of the ring 
size on the course of the reaction. Unfortunately, there was no reaction at all, and the desired 
product was not obtained (entries 10 and 11, Table 1.3). Unreacted starting material was recovered 
from the reaction mixture in both cases. 
We also investigated the vinylogous Mannich reaction of N-Boc protected iminium ion 
precursor 104 with crotonolactone 1 (Table 1.5). In the presence of bifunctional catalysts, I, III, 
or camphorsulfonic acid IV, the reaction of 104 with crotonolactone 1 failed to give the desired 
product (entries 1, 2 and 3, Table 1.5). 
Table 1.5 Vinylogous Mannich reaction of N-Boc protected iminium ion precursor with 
crotonolactone 1 
 
Entrya Catalyst Additive Time Result 
 
1 
 
 
- 
 
 
72 h 
 
No required 
product 
 
2 
 
 
- 
 
 
72 h 
 
No required 
product 
 
3 
 
 
- 
 
 
72 h 
 
No required 
product 
 
4 
 
- 
 
InCl3 
 
48 h 
 
30 
 
No required 
product 
 
5 
 
- 
 
Sc(OTf)3 
 
48 h 
 
No required 
product 
     a 2 equiv. of crotonolactone 
In addition, the use of Lewis acids such as InCl3 and Sc(OTf)3 in the vinylogous Mannich 
reaction of 104 with crotonolactone 1 was not fruitful (entries 4 and 5, Table 1.5) and the starting 
material 104 was recovered from the reaction mixture in both cases. These results suggest that the 
iminium ion precursor 104 does not provide the iminium ion under the examined conditions. 
 Given the failure of reactions involving crotonolactone, a few other carbon nucleophiles 
were tested for their reactivity in the desired vinylogous Mannich reaction. We noted that ,-
unsaturated allylic ketone 126 was used as a nucleophile in several catalytic asymmetric reactions 
such as vinylogous aldol, Mannich reactions and Michael addition reactions.39 In addition, (furan-
2-yloxy)triisopropylsilane40 127 and dimethoxy benzene 128 were also tested as nucleophiles. 
These nucleophiles were synthesized by the adaptation of known methods reported in the 
literature. The allyl phenyl ketone 126 was prepared by the treatment of benzaldehyde with allyl 
zinc bromide followed by oxidation with the Dess martin periodinane reagent (DMP).41 O-
protection of crotonolactone with iPr3SiOTf provided 94% of (furan-2-yloxy)triisopropylsilane 
127 (Scheme 1.16). 
 
 
Scheme 1.16  
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We then explored the reaction of these more reactive nucleophiles in the presence of 
bifunctional catalysts and chiral acid with iminium ion precursors derived from glutarimide and 
succinimide (Table 1.6). 
Table 1.6 Reactions of Iminium Ion Precursor with Various Nucleophiles 
 
 
Entry Precursor Nucleophile Catalyst Additive Time Result 
 
1 
 
107 
 
 
I 
 
 
Sc(OTf)3 
 
24 h 
 
No required 
product 
 
2 
 
107 
 
 
I 
 
- 
 
24 h 
 
No required 
product 
 
3 
 
107 
 
 
IX 
 
- 
 
24 h 
 
No required 
product 
 
4 
 
107 
 
 
I 
 
Sc(OTf)3 
 
 
24 h 
 
No required 
product 
 
5 
 
107 
 
 
II 
 
Sc(OTf)3 
 
 
24 h 
 
No required 
product 
 
6 
 
107 
 
 
IX 
 
Sc(OTf)3 
 
 
24 h 
 
No required 
product 
 
7 
 
112 
 
 
II 
 
Sc(OTf)3 
 
 
24 h 
 
No required 
product 
 
8 
 
112 
  
II 
 
Sc(OTf)3 
 
24 h 
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 No required 
product 
 
 
9 
 
 
108 
 
 
 
 
I 
 
 
 
- 
 
 
48 h 
 
 
 
10 
 
 
108 
 
 
 
 
II 
 
 
- 
 
 
48 h 
 
 
The reaction of allyl phenyl ketone 126 with the iminium ion precursor 107 in the presence 
of the Takemoto catalyst and Sc(OTf)3 did not provide the required product (Table 1.6, entry 1). 
The reaction of 107 with the siloxyfuran 127 in the presence of aminosqaramide catalyst I and 
chiral acid IX failed to produce the required product (entries 2 and 3, Table 1.6). The use of 
dimethoxy benzene 128 as the nucleophile in the presence of bifunctional catalyst I, II and chiral 
acid IX with the iminium ion precursor 107 did not provide the required product. Surprisingly, no 
by-product (enamide) was observed after the introduction of Sc(OTf)3 (entries 4, 5 and 6, Table 
1.6). Unreacted starting material 107 was isolated from all of the above reactions. The reaction of 
112 with allyl phenyl ketone 126 and siloxyfuran 127, in the presence of Takemoto catalyst and 
Sc(OTf)3 respectively (entries 7 and 8, Table 1.6), was also unsuccessful. Nevertheless, in the 
presence of bifunctional catalysts I and II, the reaction of the iminium ion precursor 108 with allyl 
phenyl ketone 126 resulted in a complex mixture of products that did not contain any of the 
required product. In both the cases, the by-product N-benzyl enamide 124 was isolated in 3% and 
7% from the reaction mixture, respectively.  
 We next examined the valerolactam-derived iminium ion precursors with the nucleophiles 
previously used in the vinylogous Mannich reaction as shown in Table 1.7. 
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Table 1.7 Attempted reactions of benzyl 2-hydroxypiperidine-1-carboxylate 119 with 
crotonolactone 1 
 
Entry Catalyst Additive Time Yield (%) 
129 
Yield (%) 
130 
 
1 
 
 
Sc(OTf)3 
 
10 mins 
 
36 
 
19 
 
2a 
 
 
Sc(OTf)3 
 
30 mins 
 
31 
 
20 
 
3 
 
- 
 
Sc(OTf)3 
 
6 h 
 
>95b 
 
- 
 
4 
 
 
Sc(OTf)3 
 
6 h 
 
20 
 
10 
 
5 
 
 
Sc(OTf)3 
 
1h 
 
7 
 
- 
 
6 
 
 
Sc(OTf)3 
 
48 h 
 
- 
 
90%b 
 
7 
 
 
Sc(OTf)3 
 
48 h 
 
- 
 
90%b 
a-20 ℃ - 1h, 0 ℃ - 1h, rt - 30 mins, byield of crude product.  
 
Our investigations began with the reaction of the iminium ion precursor 119 with 
crotonolactone 1 in the presence of Takemoto catalyst II and Sc(OTf)3. It was noted that the 
34 
 
starting material in the reaction mixture did not change before Sc(OTf)3 was added to the reaction 
mixture. Notably, formation of the enecarbamate 129 (1:1 mixture of rotamers by 1H NMR) and 
the dimeric product 130 (1:1 mixture of rotamers by 1H NMR) was observed only after the addition 
of Sc(OTf)3 in 36% and 19% respectively (entry 1, Table 1.7). Since these by-products were 
obtained at room temperature, the same reaction was therefore repeated at lower temperature in 
order avoid the side reactions. Unfortunately, no reaction was observed at lower temperature and 
formation of 129 (31%) and 130 (20%) was observed only after stirring the reaction mixture at 
ambient temperature for 30 min (entry 2, Table 1.7). The only product observed in the presence of 
Sc(OTf)3, catalysts III, V and VI (entries 3 and 5-7 Table 1.7) was enecarbamate 129 (no dimeric 
product 130). The use of aminosquaramide catalyst I produced enecarbamate 129 and dimeric 
product 130 in 20% and 10% respectively and failed to provide the required product. 
The plausible mechanism for the formation of the dimeric product is shown in Figure 1.13 
and it involves the nucleophilic addition of the enecarbamate 129 to its precursor iminium ion. 
 
Figure 1.13 Formation of enecarbamate 129 and its side reaction  
We also investigated the reaction of the iminium ion precursor 119 with other nucleophiles 
such as allyl phenyl ketone 126, (furan-2-yloxy)triisopropylsilane 127, commercially available 
dimethoxy benzene 128 and methoxy benzene 132 in the presence of various bifunctional catalysts 
(Table 1.8). The synthesis of 126 and 127 has been described in Scheme 1.16. 
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Table 1.8 Attempted reactions of the iminium ion precursor 119 with various nucleophiles 
 
 
Entry Nucleophile Catalyst Additive Time Yield (%) 
129 
Yield (%) 
130 
 
1 
 
 
I 
 
- 
 
12 h 
 
- 
 
- 
 
2 
 
 
IX 
 
- 
 
12 h 
 
17 
 
- 
 
3 
 
 
I 
 
- 
 
2 h 
 
>95a  
 
 
4 
 
 
II 
 
Sc(OTf)3 
 
6 h 
 
- 
 
10 
 
5 
 
 
II 
 
Sc(OTf)3 
 
12 h 
 
31 
 
21 
ayield of crude product. 
 In the presence of aminosquaramide catalyst I, the reaction of the iminium ion precursor 
119 with siloxyfuran 127 did not provide the required product and the starting material 119 was 
recovered from the reaction mixture (entry 1, Table 1.8). The use of chiral binol phosphoric acid 
IX, however, afforded a complex mixture which did not contain any of the required product but 
the enecarbamate 129 was isolated in 17% from this mixture (entry 2, Table 1.8). The reaction 
with allyl phenyl ketone 126 in the presence of aminosquaramide catalyst I only provided the 
enecarbamate 129. The use of Takemoto catalyst along with Sc(OTf)3 in the vinylogous Mannich 
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reaction of 119 with dimethoxy benzene 128 together afforded a complex mixture of products. The 
dimeric product 130 was isolated in 10% yield from this mixture (entry 4, Table 1.8). The use of 
anisole (132) provided only enecarbamate 129 and dimeric product 130 in 31% and 21% yields 
respectively (entry 5, Table 1.8). 
 We also investigated reactions of the iminium ion precursors derived from valerolactam 
(116, 117 and 120) with crotonolactone 1 in the presence of various bifunctional catalyst as shown 
in Table 1.9. In the presence of aminosquaramide catalyst I and Sc(OTf)3 at ambient temperature, 
the  reaction of 120 with crotonolactone 1 resulted in a complex mixture that did not contain any 
of the required product. At lower temperature, unreacted starting material was recovered from the 
reaction mixture (entries 1 and 2, Table 1.9). 
Table 1.9 Attempted reactions of valerolactam derivatives with crotonolactone 72 
 
Entry Precursor Catalyst Temp Time Result 
 
1 
 
 
 
 
rt 
 
48 h 
 
No required 
product 
 
2 
 
 
 
 
-78 oC - rt 
 
5 h 
 
No required 
product 
 
3 
 
 
 
 
rt 
 
48 h 
 
No required 
product 
37 
 
 
4 
 
  
 
rt 
 
48 h 
 
No required 
product 
 
5 
 
 
 
 
reflux 
 
4 h 
 
No required 
product 
 
6 
 
  
 
reflux 
 
4 h 
 
No required 
product 
 
7 
 
  
 
rt 
 
24 h 
 
No required 
product 
 
8 
 
 
 
 
rt 
 
24 h 
 
No required 
product 
a 2 equiv. of crotonolactone 
In the presence of bifunctional catalysts I and III and Sc(OTf)3 at ambient temperature, the 
reaction of the iminium ion precursor 117 with crotonolactone 1 did not give the required product. 
There was also no change in the reaction mixture at reflux and, in all cases, unreacted starting 
material was recovered from the reaction mixture (entries 3-6, Table 1.9). The iminium ion 
precursor 116 did not react with crotonolactone 1 and was recovered from the reaction mixture 
(entries 7 and 8, Table 1.9). 
 As seen above, some of the iminium ion precursors were able to generate the iminium ion 
which provided the enecarbamate by loss of a proton. However, there is no Mannich reaction 
involving nucleophilic addition of the carbon nucleophile (crotonolactone) used in the reaction. 
There are two possibilities that may explain this observation: 1) the crotonolactone enolate is not 
formed under the reaction conditions, and 2) the enolate is formed, but it does not react with the 
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iminium ion. Of these possibilities, the first was considered unlikely since we had previously 
shown that vinylogous aldol reactions of crotonolactone with aromatic42a and aliphatic42b 
aldehydes can be achieved with aminothiourea catalysts (Figure 1.14).  
 
Figure 1.14 Vinylogous Aldol reaction of various aliphatic and aromatic aldehydes 
In order to examine the possibility of the lack of deprotonation of the nucleophile, the 
vinylogous Mannich reaction of 108 and the ketone 126 was examined in the presence of the 
aminosquaramide catalyst I. Interestingly, although the desired Mannich product was not obtained, 
the enecarbamate 124 and the isomerized ketone 135 were obtained in trace amounts from the 
reaction mixture (Scheme 1.17). 
 
Scheme 1.17  
These observations confirmed the formation of an iminium ion from 108 and of an enolate 
from 126. The reasons for the lack of reaction between these two species are not known at this 
time.  
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1.6 Studies on the Mannich reactions of indoles: 
Since the above studies had provided some evidence of the formation of reactive iminium 
ions from cyclic precursors, the possibility of their reactions with indoles was examined. The main 
reason for these investigations was the well-known nucleophilicity of electron rich or electron-
neutral indoles. In addition, these reactions would provide direct access to functionalized indole 
frameworks with established biological activity,43 and could also provide potential precursors to 
more complex alkaloid natural products.44  
In preliminary studies, N-methyl indole 136 was examined as the nucleophile with the best 
iminium ion precursors in the presence of a bifunctional catalyst and a Lewis acid (Scheme 1.18). 
 
Scheme 1.18  
  As anticipated, the reaction of the iminium ion precursor 107 with N-methyl indole 136 in 
the presence of the Takemoto catalyst II and Sc(OTf)3 furnished the required product 137 in 51% 
yield, but with no enantiomeric excess (racemic product). In comparison, the reaction of 119 with 
N-methyl indole 136 provided 138 with high enantiomeric excess (96% ee) but in low yield (17%, 
Scheme 1.18). Spurred by the success with N-methyl indole, we examined N-benzyl indole 139 as 
a nucleophile with the iminium ion precursor 119. Satisfyingly, the required product 140 was 
obtained in good yield (77%) and with excellent enantioselectivity (96% ee, entry 1, Table 1.10). 
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Table 1.10 Mannich reactions of N-benzyl indoles 
 
Entry  R1 Catalyst Product Yield (%)      ee (%)a 
1 H II 140 77 96 
2 5-Br II 141 70 15 
3 5-MeO II 142 57 0.5 
4 6-F II 143 52 1.0 
5 6-F X 143 40 0.6 
6 6-F L1 143 48 1.4 
                   a Determined by chiral HPLC 
This promising result encouraged us to try the reaction with a selection of electron rich and 
electron deficient indoles. Unfortunately, although the required Mannich products were obtained 
in reasonable yields (entries 2-6, Table 1.10), they were all racemic. An explanation for these 
unusual results is not available at this time.  
1.7 Conclusion: 
In conclusion, we have synthesized a selection of novel phosphoramide-aminothiourea 
catalysts and examined them in selected vinylogous Mannich reactions. Piperidine based iminium 
ion precursors along with crotonolactone and phenyl allyl ketone as the nucleophilic component 
were examined in the presence of the phosphoramide-thiourea catalysts as well as other 
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bifunctional catalysts such as aminothioureas and aminosquaramides. The vast majority of the 
reactions that were examined either did not provide the required product or provided unwanted  
by-products arising from side reactions of the iminium ions generated in situ. Although evidence 
was obtained for enolate formation from allyl phenyl ketone, this enolate did not react with the 
iminium ion that was also generated in the same reaction. The precise reasons for the failure of the 
vinylogous Mannich reaction are not known at this time. Finally, the Mannich reaction of indoles 
and in situ generated iminium ions was also achieved. Although some of these reactions proceeded 
with high enantioselectivity, small changes in the substitution of the indole nucleus at sites remote 
to the reaction site had a drastic effect on the enantioselection and racemic products were obtained. 
The use of phosphoramide-thiourea catalysts in the addition of indole nucleophiles to  
N-Cbz-2-hydroxy piperidine 114 will be further investigated in the Pansare group.  
1.8 Experimental Section 
2,3,4,5-Tetrahydropyridine (100):31 
 
 To a solution of N-chlorosuccinimide (3.78 g, 27.9 mmol) in diethyl ether (75 mL) was 
added a solution of distilled piperidine (2.48 mL, 25.2 mmol) in ether (50 mL) over 30 min at room 
temperature. The reaction mixture was stirred for 3 h at ambient temperature after which it was 
filtered through a pad of celite and the residue was washed with ether (1 x 25 mL). The combined 
filtrates were washed with water (3 x 25 mL), dried over anhydrous Na2SO4 and concentrated 
without heating to give N-chloropiperidine 99.  
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An ethereal solution of the above N-chloropiperidine was added dropwise to ethanolic 
KOH (prepared by heating 2.1 equiv of solid KOH in ethanol (15.0 mL) to 85 ℃) at room 
temperature and the reaction was left to stir overnight. The white precipitate of KCl formed was 
then separated by filtration through a pad of Celite. The filtrate was concentrated to remove ethanol 
and the residue was diluted with ethyl acetate. The resulting solution was washed with water (3 x 
20 mL) to provide the piperidine 100 (1.45 g, 70% yield over two steps). 
Synthesis of glutarimide derivatives: 
 
 
tert-Butyl 2-methoxy-6-oxopiperidine-1-carboxylate (104): 
A glutarimide 102 (226 mg, 1.99 mmol) was dissolved in MeOH (5 mL) at 0 °C and sodium 
borohydride (189 mg, 4.97 mmol) as added portionwise. After the end of the addition, the reaction 
mixture was stirred at 0 °C for 2 h. The excess of sodium borohydride was destroyed in 15-20 mins 
at the temperature of the reaction by adding an aqueous solution of sodium bicarbonate. Reaction 
mixture evaporated to dryness and purified by flash column chromatography on silica gel using 
5% MeOH/CH2Cl2 afforded 6-hydroxypiperidin-2-one 103 (83 mg, 36%). Rf = 0.28 
(MeOH/CH2Cl2 95:5)  
To the solution of 6-hydroxypiperidin-2-one (55 mg, 0.470 mmol) in CH2Cl2 (2 mL) and 
MeOH (1 mL), scandium triflate (2.3 mg, 0.004 mmol) was added. The reaction mixture was 
stirred at room temperature for 3 h. The reaction mixture was evaporated to dryness and was used 
as such in the next step without any purification. 
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To a solution 6-methoxypiperidin-2-one (365 mg, 2.82 mmol) in CH2Cl2 (8 mL) were 
added DMAP (344 mg, 2.82 mmol), NEt3 (0.40 mL, 2.82 mmol), Boc2O (1.23 g, 5.65 mmol). The 
reaction mixture was stirred at room temperature for 12 h. The solvent was then evaporated under 
reduced pressure and the residue was purified by flash column chromatography on silica gel using 
20% EtOAc/hexanes afforded tert-butyl 2-methoxy-6-oxopiperidine-1-carboxylate 104 (452 mg, 
70%). Rf = 0.28 (EtOAc/hexanes, 1:4). 
1H NMR (300 MHz, CDCl3) δ 5.47-5.42 (m, 1H, NCH), 3.37 (s, 3H, OCH3), 2.70-2.58 (m, 1H, 
CH2), 2.50-2.37 (m, 1H, CH2), 2.16-2.00 (m, 2H, CH2), 1.89-1.67 (m, 2H, CH2), 1.54 (s, 9H, 
C(CH3)3). 
6-Ethoxypiperidin-2-one (105):33 
 
A glutarimide (500 mg, 1.76 mmol) was dissolved in EtOH (9 mL) at 0 °C and sodium 
borohydride (244 mg, 6.45 mmol) as added portion wise. After the end of the addition, the reaction 
mixture was stirred at 0 °C for 2 h. The excess of sodium borohydride was destroyed in 15-20 mins 
at the temperature of the reaction by adding 2N HCl solution till pH = 3. Reaction mixture was 
then neutralized with 1% KOH in ethanol. The reaction mixture was evaporated to dryness. 
Extraction of residue with CHCl3 and evaporation of extract afforded 6-methoxypiperidin-2-one 
105 (358 mg, 57%). 
1-Benzyl-6-oxopiperidin-2-yl acetate (108):35 
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To a solution of glutarimide (0.50 g, 4.42 mmol) in DMF (8 mL) was added potassium 
carbonate (1.80 g, 13.26 mmol) at room temperature. After stirring it for 30 mins at room 
temperature, benzyl bromide (1.00 mL, 8.84 mmol) was added dropwise and the reaction mixture 
was stirred for 12 h at ambient temperature. Ice cold water (15 mL) and EtOAc (20 mL) were then 
added. The organic layer was separated, and the aqueous phase was extracted with ethyl acetate 
(20 mL). The combined organic layers were washed with cold water (2 x 15 mL), then dried over 
magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by 
flash column chromatography on silica gel using 30% EtOAc/hexanes affording 1-
benzylpiperidine-2,6-dione 106 (888 mg, 98%) as a white solid. 
DIBAL-H (2.84 mmol, 1M solution in toluene) was added dropwise at -78 °C to a stirred solution 
of 1-benzylpiperidine-2,6-dione 106 (290 mg, 1.42 mmol) in CH2Cl2 (5 mL). The reaction mixture 
was stirred at -78 °C for 1h. Water (1.4 mL), NaOH (2 N, 0.4 mL) were cautiously added and the 
reaction mixture was poured into a saturated solution of Rochelle’s salt (10 mL). The mixture was 
then extracted with CH2Cl2 (10mL). The combined extracts were then washed with brine (5 mL), 
dried with anhydrous magnesium sulfate and concentrated under reduced pressure to yield a crude 
residue, which was purified by flash chromatography on silica gel (EtOAc/hexanes mixtures) 
affording 1-benzyl-6-hydroxypiperidin-2-one 107 (181 mg, 62%). 
To a solution of 1-benzyl-6-hydroxypiperidin-2-one 107 (500 mg, 2.43 mmol) in CH2Cl2, 
DMAP (30 mg, 0.24 mmol), NEt3 (0.40 mL, 3.14 mmol) were added, followed by dropwise 
addition of acetic anhydride (0.50 mL, 4.86 mmol). The reaction mixture was stirred for 1 h at 
room temperature. Water was added to the reaction mixture (5 mL) and the resulting solution was 
extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were concentrated, and the 
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residue was purified by flash column chromatography on silica gel using (70% EtOAc/hexanes) 
affording 1-benzyl-6-oxopiperidin-2-yl acetate 108 (549 mg, 92%). 
1-Benzyl-5-hydroxypyrrolidin-2-one (112):36 
 
To a solution of succinimide (0.50 g, 5.04 mmol) in DMF (8 mL) was added potassium 
carbonate (2.86 g, 15.1 mmol) at room temperature. After stirring it for 30 mins at room 
temperature, benzyl bromide (1.20 mL, 10.1 mmol) was added dropwise and the reaction mixture 
was stirred for 12 h at ambient temperature. Ice cold water (15 mL) and EtOAc (20 mL) were then 
added. The organic layer was separated, and the aqueous phase was extracted with ethyl acetate 
(20 mL). The combined organic layers were washed with cold water (2 x 15 mL), then dried over 
magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by 
flash column chromatography on silica gel using 50% EtOAc/hexanes affording 1-
benzylpiperidine-2,6-dione 111 (931 mg, 99%) as a white solid. 
Succinimide (200 mg, 1.05 mmol) was dissolved in MeOH (5 mL) at 0 ℃ and sodium 
borohydride (198 mg, 5.25 mmol) as added portion wise. After the end of the addition, the reaction 
mixture was stirred at 0 °C for 3 h. afforded 6-methoxypiperidin-2-one 102 (132 mg, 66%). Upon 
complete conversion of the imide, methanol was removed under reduced pressure and the reaction 
mixture was poured into a saturated aqueous solution of NaHCO3 (5 mL) and then extracted with 
ethyl acetate (3 x 10 mL). The combined organic layers were dried over anhydrous magnesium 
sulfate concentrated under reduced pressure to yield 1-benzyl-5-hydroxypyrrolidin-2-one 112 (154 
mg, 77%).  
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tert-Butyl 2-hydroxypiperidine-1-carboxylate (115):37 
 
To a solution of δ-valerolactam 113 (1.00 g, 10.0 mmol) in CH2Cl2 (20 mL) were added 
DMAP (1.23 g, 10.0 mmol), NEt3 (1.40 mL, 10.0 mmol), Boc2O (4.40 g, 20.1 mmol). The reaction 
mixture was stirred at room temperature for 12 h. The solvent was then evaporated under reduced 
pressure and the residue was purified by flash column chromatography on silica gel using 40% 
EtOAc/hexanes affording tert-butyl 2-oxopyrrolidine-1-carboxylate 114 (1.45 g, 72%) as a white 
amorphous powder. Rf = 0.34 (EtOAc/hexanes, 2:3). 
Protected lactam 114 (1.00 g, 5.01 mmol) was dissolved in methanol (20 mL) at 0 °C and 
sodium borohydride (379 mg, 10.03 mmol) was added portion wise. After the end of the addition, 
the reaction mixture was stirred at 0 °C for 2 h and poured onto ice-water (15 mL). The reaction 
mixture was extracted with EtOAc (3 x 20 mL). The organic layers were washed with brine (10 
mL), the combined organic layers were dried over MgSO4 and the solvent was removed under 
reduced pressure to give tert-butyl 2-hydroxypiperidine-1-carboxylate 115 (818 mg, 81%) which 
was used without purification. 
Benzyl 2-(2,2,2-trichloro-1-iminoethoxy)piperidine-1-carboxylate (120): 
 
  δ-Valerolactam 113 (500 mg, 5.04 mmol) was dissolved in THF (10 mL). The reaction 
mixture was cooled to -78 °C and n-BuLi (2.5 M in hexane, 2 mL, 5.04 mmol) was added dropwise 
to the resulting suspension. After 30 min at -78 °C, a solution of benzylchloroformate (0.7 mL, 
5.04 mmol) in THF (5 mL) was added dropwise. After 4 h at -78 ℃, the reaction mixture was 
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quenched with sat. NH4Cl (10 mL) and warmed to room temperature. The reaction mixture was 
extracted with Et2O (3 x 10 mL). The combined organic layers were washed with brine (10 mL), 
dried over MgSO4, solvent was removed under reduced pressure and the residue was purified by 
flash column chromatography on silica gel to give the Cbz protected lactam 118 (794 mg, 68%). 
Rf = 0.34 (EtOAc/hexanes, 3:2) 
Protected lactam 118 (750 mg, 3.21 mmol) was dissolved in methanol (7 mL) at 0 °C and 
sodium borohydride (243 mg, 6.43 mmol) was added portionwise. After the end of the addition, 
the reaction mixture was stirred at 0 °C for 2 h and poured onto ice-water (15 mL). The reaction 
mixture was extracted with EtOAc (3 x 20 mL). The organic layers were washed with brine (10 
mL), the combined organic layers were dried over MgSO4 and the solvent was removed under 
reduced pressure to give benzyl 2-hydroxypiperidine-1-carboxylate 119 (639 mg, 85%) which was 
used without purification. 
To the solution of benzyl 2-hydroxypiperidine-1-carboxylate 119 (400 mg, 1.70 mmol) and 
DBU (0.50 mL, 3.40 mmol) in CH2Cl2 (3 mL) at 0 °C, trichloroacetonitrile (0.3 mL, 3.40 mmol) 
was added dropwise. The reaction mixture was allowed to stir for 1.5 h. The reaction mixture was 
concentrated to dryness on rota vapour and purified by flash column chromatography on silica gel 
to give benzyl 2-(2,2,2-trichloro-1-iminoethoxy)piperidine-1-carboxylate 120 (450 mg, 70%) as 
colourless liquid. Rf = 0.31 (EtOAc/hexanes, 1:4).  
1H NMR (300 MHz, CDCl3): δ 7.43-7.27 (m, 5H, ArH), 7.11 (br s, 1H, NH), 6.15-6.05 (m, 1H, 
NCH), 5.18 (s, 2H, CH2Ph), 4.08 (d, 1H, J = 13.5 Hz, NCH2), 3.06-2.90 (m, 1H, NCH2), 2.02-1.90 
(m, 1H, CH2), 1.86-1.65 (m, 3H, CH2), 1.64-1.46 (m, 2H, CH2). 
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Synthesis of valerolactam derivatives: 
 
tert-Butyl 2-methoxypiperidine-1-carboxylate (116): 
To a solution of tert-butyl 2-hydroxypiperidine-1-carboxylate 115 (250 mg, 1.25 mmol) in 
CH2Cl2/MeOH (2:1) (4ml), was added scandium triflate (6.00 g, 0.01 mmol). The reaction mixture 
was stirred at room temperature for 3 h. Reaction mixture was concentrated to dryness and the 
residue was quenched with saturated solution of sodium bicarbonate (5 mL). The reaction mixture 
was extracted with EtOAc (3 x 10 mL). The combined organic layers were concentrated, and 
residue was purified by flash column chromatography on silica gel to give tert-butyl 2-
methoxypiperidine-1-carboxylate 116 (160 mg, 74%). Rf = 0.2 (EtOAc/hexanes, 3:7). 
1H NMR (300 MHz, CDCl3): δ 5.48-5.17 (m, 1H NCH), 4.03-3.73 (m, 1H, NCH2), 3.23 (s, 3H, 
OCH3), 3.02-2.80 (m, 1H, NCH2), 1.91-1.79 (m, 1H, NCHCH2), 1.78-1.65 (m, 1H, NCHCH2), 
1.63-1.51 (m, 2H CH2), 1.47 (br s, 11H, CH2 and C(CH3)3). 
tert-Butyl 2-(2,2,2-trichloro-1-iminoethoxy)piperidine-1-carboxylate (117): 
To the solution of tert-butyl 2-hydroxypiperidine-1-carboxylate 115 (450 mg, 2.25 mmol) 
and DBU (0.70 ml, 4.51 mmol) in CH2Cl2 (5 mL) at 0 °C, trichloroacetonitrile (0.45 mL, 4.51 
mmol) was added dropwise. The reaction mixture was allowed to stir for 1.5 h. The reaction 
mixture was concentrated to dryness on rota vapour and purified by flash column chromatography 
on silica gel to give tert-butyl 2-(2,2,2-trichloro-1-iminoethoxy)piperidine-1-carboxylate 117 (517 
mg, 66%) as a white solid. Rf = 0.32 (EtOAc/hexanes, 1:4). 
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1H NMR (300 MHz, CDCl3): δ 7.08 (br s, 1H, NH), 6.06-5.97 (m, 1H, NCH), 4.02 (d, 1H, J = 
13.5 Hz, NCH2), 2.87 (ddd, 1H, J = 13.5, 12.1, 3.0 Hz, NCH2), 1.99-1.87 (m, 1H, CH2), 1.85-1.67 
(m, 3H, CH2), 1.63-1.50 (m, 2H, CH2), 1.48 (s, 9H, C(CH3)3).  
1-Phenylbut-3-en-1-one (126):41 
 
Allyl bromide (0.81 ml, 9.42 mmol) in THF (2 ml) was added dropwise to a stirred 
suspension of commercial zinc dust (615 mg, 9.42 mmol) in THF (5 mL) at room temperature and 
the mixture was stirred for half an hour after which the benzaldehyde (1.00 g, 9.42 mmol) in THF 
(5ml) and NH4OAc ( 2.17 g, 28.2 mmol) were added. The reaction mixture was quenched by 
saturated NaHCO3 solution and extracted with ethyl acetate. The combined extract was dried over 
MgSO4 and evaporated to give crude product which was purified by flash column chromatography 
on silica gel, afforded 1-phenylbut-3-en-1-ol (831 mg, 60%) as a clear colourless liquid. Rf = 0.3 
(EtOAc/hexanes, 1:9). 
To a solution of DMP (3.66 g, 8.63 mmol) in CH2Cl2 (4 mL) at room temperature was 
added a solution of allyl alcohol (800 mg, 5.39 mmol) in CH2Cl2 (4 mL). After 4 hours of stirring, 
the mixture was diluted with ether (20 mL) and washed with 1/1 10% Na2S2O3 and saturated 
aqueous NaHCO3 solution, followed by brine solution (5 mL). The combined extracts were dried 
over anhydrous MgSO4 and concentrated under reduced pressure. The residue was purified by 
flash column chromatography on silica gel, afforded 1-phenylbut-3-en-1-one 126 (570 mg, 72%) 
as a colourless oil. Rf = 0.2 (EtOAc/hexanes, 5:95). 
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General procedure for the direct vinylogous Mannich reaction: 
To the catalyst (0.1 mmol, in a standard 3 mL vial) was added the imine or iminium ion 
precursor (1 mmol) followed by respective nucleophile (2 mmol) in dichloromethane (1mL). The 
reaction mixture was stirred at ambient temperature for the specified period and was monitored by 
TLC. After completion, the reaction mixture was concentrated, and the residue was purified by 
flash chromatography on silica gel (EtOAc/hexanes) to provide the corresponding products. 
Benzyl 3,4-dihydropyridine-1(2H)-carboxylate (129): 
 
The reaction of 2-hydroxypiperidine-1-carboxylate 114 (100 mg, 0.42 mmol),  
-crotonolactone (2-(5H)-furanone, 60 µL, 0.85 mmol), Takemoto catalyst II (18 mg, 0.04 mmol) 
and Sc(OTf)3 (21 mg, 0.04 mmol)  in CH2Cl2 (2 mL) at ambient temperature for 30 mins, according 
to the general procedure provided, after purification by flash column chromatography on silica gel 
(EtOAc/hexanes 2:8), 46 mg (35%) of 129 as a colorless solid. Rf = 0.23 (EtOAc/hexanes 2:8). 
1H NMR (300 MHz, CDCl3): δ 7.43-7.28 (m, 5H, ArH), 6.79 (d, 1H, J = 8.4 Hz, NCH), 5.18 (s, 
2H, CH2Ph), 4.90-4.81 (m, 1H, CH2CH), 3.69-3.55 (m, 2H, NCH2), 2.09-1.98 (m, 2H, CH2), 1.90-
1.73 (m, 2H, CH2).  
1H NMR (300 MHz, CDCl3): minor rotamers δ 7.43-7.28 (m, 5H, ArH), 6.88 (d, 1H, J = 8.4 Hz, 
NCH), 5.18 (s, 2H, CH2Ph), 5.02-4.92 (m, 1H, CH2CH), 3.69-3.55 (m, 2H, NCH2), 2.09-1.98 (m, 
2H, CH2), 1.90-1.73 (m, 2H, CH2).   
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Benzyl 5-(1-((benzyloxy)carbonyl)piperidin-2-yl)-3,4-dihydropyridine-1(2H)-carboxylate 
(130): 
 
 
1H NMR (300 MHz, CDCl3): Major rotamer δ 7.43-7.26 (m, 10H, ArH), 6.85 (s, 1H, NCH=C), 
5.18 (br s, 4H, CH2Ph), 4.82 (br s, 1H, NCHCH2), 4.04 (d, 1H, J = 13.0 Hz, NCH2), 3.66-3.48 (m, 
2H, NCH2),  2.78 (t, 1H, J = 13.0 Hz, NCH2),  2.10-1.73 (m, 5H, CH2), 1.71-1.34 (m, 5H, CH2). 
1H NMR (300 MHz, CDCl3): Minor rotamer δ 7.43-7.26 (m, 10H, ArH), 6.71 (s, 1H, NCH=C), 
5.17-5.05 (m, 4H, CH2Ph), 4.82 (br s, 1H, NCHCH2), 4.04 (d, 1H, J = 13.0 Hz, NCH2), 3.66-3.48 
(m, 2H, NCH2), 2.78 (t, 1H, J = 13.0 Hz, NCH2), 2.10-1.73 (m, 5H, CH2), 1.71-1.34 (m, 5H, CH2). 
1-Benzyl-3,4-dihydropyridin-2(1H)-one (124): 
 
The reaction of 1-benzyl-6-hydroxypiperidin-2-one 107 (50 mg, 0.20 mmol), 
-crotonolactone (2-(5H)-furanone, 29 µL, 0.40 mmol) and Takemoto catalyst II (10 mg, 0.02 
mmol) in CH2Cl2 (2 mL) at ambient temperature for 30 mins, according to the general procedure 
provided, after purification by flash column chromatography on silica gel (EtOAc/hexanes 2:3), 
46 mg (35%) of 124 as a colorless solid. Rf = 0.23 (EtOAc/hexanes 2:3). 
1H NMR (300 MHz, CDCl3): δ 7.36-7.27 (m, 3H, ArH), 7.25-7.20 (m, 2H, ArH), 6.02 (dt, 1H, J 
= 7.7, 1.6 Hz, NCH), (dt, 1H, J = 7.7, 4.4 Hz, NCHCH), 4.69 (s, 2H, CH2Ph),  2.59 (t, 2H, J = 8.0 
Hz, CH2), 2.28-2.40 (m, 2H, CH2).  
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(1S,2S)-N,N-Dibenzylcyclohexane-1,2-diamine (79): 
 
Prepared from (1S,2S)-1,2-cyclohexanediamine and benzaldehyde according to the 
literature procedure.24 Spectroscopic data for 79 was in agreement with the reported data.24 
(1S,2S)-N,N’-Dibenzyl-1,2-diphenylethane-1,2-diamine (87): 
 
Prepared from (1S,2S)-1,2-diphenylethane-1,2-diamine and benzaldehyde according to the 
literature procedure.27a Spectroscopic data for 87 was in agreement with the reported data.27a 
(1R,2R)-N,N’-Diisopropyl-1,2-diphenylethane-1,2-diamine (91): 
 
To the mixture of (1R,2R)-1,2-diphenylethane-1,2-diamine (500 mg, 2.35 mmol) in 
acetone (5mL) were added PtO2 (53 mg 0.2 mmol) and acetic acid (26 µL, 0.4 mmol). The 
hydrogenation reaction proceeded at room temperature under a pressure of H2 balloon for 48 h. 
After completion, the crude product was filtered through a pad of celite and the filtrate was 
concentrated under reduced pressure to yield (695 mg, 99%) of 91 as a white solid. Spectroscopic 
data for 91 was in agreement with the reported data.28a 
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(1R,2R)-N,N’-Dimethyl-1,2-diphenylethane-1,2-diamine (93): 
 
Prepared from (1R,2R)-1,2-diphenylethane-1,2-diamine and acetic formic anhydride according to 
the literature procedure.28b Spectroscopic data for 93 was in agreement with the reported data.28b 
 
(3aS,7aS)-1,3-Dibenzyl-2-chlorooctahydro-1H-benzo[d][1,3,2]diazaphosphole 2-oxide (80): 
 
To a solution of the diamine 79 (2.30 g, 7.81 mmol) in CH2Cl2 was added POCl3 (1.04 ml, 
10.9 mmol). Triethylamine (2.7 ml, 18.7 mmol) was added dropwise, and the reaction mixture was 
stirred at room temperature for 24 h. After completion, reaction mixture was passed through a 
thick pad of silica gel and washed with CH2Cl2 until all the product was obtained. Evaporation of 
the solvent under vacuum to give white thick solid which was then dissolved in CH2Cl2  and water. 
The solution was poured in 250 mL separatory funnel and organic layer was extracted and 
concentrated to give 2.30 g (79%) of 80 as pure white solid. 
Mp: 206.4 - 207.1 oC; IR (neat): 3029, 2937, 2907, 2851, 1494, 1452, 1439, 1362, 1342, 1316, 
1297, 1277, 1230, 1209, 1179, 1148, 1110, 1067, 1051, 1025, 966, 926, 901, 881, 861, 841, 773, 
741, 700 cm -1; 1H NMR (300 MHz, CDCl3): δ 7.50-7.20 (m, 10H, ArH), 4.59 - 4.37 (m, 2H, 
CH2Ph), 4.21 (dd, J = 15.7, 10.7 Hz, CH2Ph), 3.74 (dd, J = 15.7, 7.7 Hz, CH2Ph), 3.03 - 2.84 (m, 
2H, CH2CHN), 1.81-1.54 (m, 4H, CH2), 1.27-0.90 (m, 4H, CH2); 
13C NMR (75 MHz, CDCl3): δ 
138.1 (d, 3JCP = 9.7 Hz, ArCipso), 137.5 (d, 
3JCP = 3.6 Hz, ArCipso), 128.5 (2 x ArC), 128.4 (2 x 
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ArC), 127.9 (2 x ArC), 127.8 (2 x ArC), 127.42 (ArC), 127.40 (ArC), 63.4 (d, 2JCP = 10.4 Hz, 
CH2CHN), 63.2 (d, 
2JCP = 10.5 Hz, CH2CHN), 47.5 (d, 
2JCP = 2.7 Hz, CH2Ph), 46.6 (d, 
2JCP = 4.5 
Hz, CH2Ph), 29.2 (d, 
3JCP = 10.0 Hz, CH2), 29.0 (d, 
3JCP = 5.1 Hz, CH2), 24.2 (d, 
4JCP = 1.1 Hz, 
CH2), 23.8 (d, 
4JCP = 1.8 Hz, CH2); HRMS (ESI, pos.): m/z 374.1303 (374.1315 calc. for 
C20H24ClN2OP (M)
+), 375.1378 (375.1393 calc. for C20H25ClN2OP (M+H)
+), 397.1191 (397.1212 
calc. for C20H24ClN2NaOP (M+Na)
+). 
General procedure for the synthesis of diaminophosphoryl chlorides 88, 94, and 95: 
To a solution of the diamine in toluene was added triethyl amine. The solution was cooled 
to 0 °C and POCl3 was added dropwise. The mixture was then warmed to room temperature, heated 
to reflux for 4 h and then cooled to room temperature. The white precipitate that was formed was 
removed by filtration, and the filter cake was washed toluene (10 mL). The combined filtrates were 
concentrated under reduced pressure and the residue was purified by flash chromatography on 
silica gel (hexane/EtOAc, 9:1) to provide the phosphoryl chlorides. 
(4S,5S)-1,3-Dibenzyl-2-chloro-4,5-diphenyl-1,3,2-diazaphospholidine 2-oxide (88): 
 
The reaction of 87 (1.71 g, 4.35 mmol), NEt3 (1.30 mL, 8.71 mmol) and POCl3 (0.42 mL, 
4.35 mmol) according to the general procedure provided, after purification by flash column 
chromatography on silica gel, 1.62 mg (79%) of 88 as a white solid; Rf  = 0.20 (hexanes/EtOAc, 
9:1). 
IR (neat): 3061, 3031, 2924, 2906, 2866, 1494, 1452, 1273, 1255, 1212, 1108, 1028, 765, 734, 
698, 517, 493 cm-1; 1H NMR (300 MHz, CDCl3): δ 7.35-7.12 (m, 16H, ArH), 7.06-6.96 (m, 4H, 
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ArH), 4.58 (dd, 1H, J = 14.8, 10.5, PhCH), 4.16 (t, 1H, J = 14.7, PhCH2), 4.10-3.94 (m, 3H, 
PhCH2) 3.65 (dd, 1H, J = 14.8, 10.9, PhCH); 
13C NMR (75 MHz, CDCl3): δ 137.7 (d, 
3JCP = 3.5, 
ArCipso), 137.3 (d, 
3J CP = 8.9, ArCipso), 135.37 (d, 
3JCP = 3.6, ArCipso), 135.32 (d, 
3JCP = 2.9, 
ArCipso), 129.4 (2 x ArC), 129.1 (2 x ArC), 128.9 (2 x ArC), 128.8 (2 x ArC), 128.69 (ArC), 128.64 
(ArC), 128.60 (2 x ArC), 128.3 (2 x ArC), 128.1 (2 x ArC), 127.94 (2 x ArC), 127.89 (ArC), 127.7 
(ArC), 68.2 (d, 2JCP = 13.6, PhCH2), 66.7 (d, 
2JCP = 12.8, PhCH2), 47.6 (d, J = 4.6, PhCH), 45.7 
(d, J = 6.0, PhCH); HRMS (ESI, pos.): m/z 472.1471 (472.1471 calc. for C28H26ClN2OP, M
+) and 
473.1543 (473.1550 calc. for C28H27ClN2OP, (M+H)
+). 
 (4R,5R)-2-Chloro-1,3-diisopropyl-4,5-diphenyl-1,3,2-diazaphospholidine 2-oxide (94): 
 
The reaction of 91 (495 mg, 1.66 mmol), NEt3 (0.50 ml, 3.34 mmol) and POCl3 (0.15 mL, 
1.67 mmol) according to the general procedure provided, after purification by flash column 
chromatography on silica gel, 357 mg (60%) of 94 as a colorless gum; Rf  = 0.21 (hexanes/EtOAc, 
9:1). 
IR (neat): 3033, 2980, 2929, 2883, 1492, 1456, 1391, 1369, 1263, 1160, 1131, 1086, 1021, 789, 
730, 699, 626, 565, 518 cm -1; 1H NMR (300 MHz, CDCl3): δ 7.37 - 7.30 (m, 6H, ArH), 7-25-7.22 
(m, 2H, ArH), 7.21-7.17 (m, 2H, ArH), 4.29 (t, 1H, J = 6.7 Hz, PhCH), 4.18 (dd, J = 6.7,  3.0 Hz, 
PhCH), 3.48 - 3.26 (m, 2H, CH(CH3)2), 1.44 (d, 3H, J = 6.9 Hz, CH3), 1.38 (d, 3H, J = 6.9 Hz, 
CH3), 1.13 (d, 3H, J = 6.6 Hz, CH3), 1.02 (d, 3H, J = 6.6 Hz, CH3); 
13C NMR (75 MHz, CDCl3): 
δ 140.2 (d, 3JCP = 4.4 Hz, ArCipso), 139.3 (d, 
3JCP = 2.7 Hz, ArCipso), 128.9 (2 x ArC), 128.8 (2 x 
ArC), 128.5 (ArC), 128.3 (ArC), 127.6 (2 x ArC), 127.3 (2 x ArC), 67.6 (d, 2JCP = 13.5 Hz, PhCH), 
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65.9 (d, 2JCP = 14.6 Hz, PhCH), 47.5 (d, 
2JCP = 4.8 Hz, CH(CH3)2), 46.7 (d, 
2JCP = 4.2 Hz, 
CH(CH3)2), 21.2 (d, 
3JCP = 1.2 Hz, CH3), 20.6 (d, 
3JCP = 2.3 Hz, CH3), 20.2 (d, 
3JCP = 3.3 Hz, CH3), 
20.1 (d, 3JCP = 2.3 Hz, CH3); HRMS (ESI, pos.): m/z 376.1477 (376.1471 calc. for C20H26ClN2OP 
(M)+), 377.1550 (377.1550 calc. for C20H27ClN2OP (M+H)
+). 
(4R,5R)-2-Chloro-1,3-dimethyl-4,5-diphenyl-1,3,2-diazaphospholidine 2-oxide (95): 
 
The reaction of 92 (1.00 g, 4.16 mmol), NEt3 (1.20 mL, 8.32 mmol) and POCl3 (0.400 mL, 
4.16 mmol) according to the general procedure, provided after purification by flash column 
chromatography 1.11 g (82%) of 95 as a colorless oil; Rf = 0.23 (hexanes/EtOAc, 9:1). 
IR (neat): 3004, 2936, 2866, 2826, 1452, 1273, 1209, 1152, 1109, 741, 697, 513, 491 cm-1; 1H 
NMR (500 MHz, CDCl3): δ 7.36-7.28  (m, 6H, ArH), 7.17-7.11 (m, 2H, ArH), 7.10-7.04 (m, 2H, 
ArH), 4.15 (dd, 1H, J = 8.6, 4.3, PhCH), 3.85 (d, 1H, J = 8.6, PhCH), 2.60 (d, 3H, J = 10.5, CH3), 
2.46 (d, 3H, J = 14.4, CH3); 
13C NMR (75 MHz, CDCl3): δ 136.8 (d, 
3JCP = 5.5, ArCipso), 135.8 (d, 
3JCP = 12.8, ArCipso), 128.75 (2 x ArC), 128.73 (ArC), 128.69 (2 x ArC), 128.5 (ArC), 127.8 (2 x 
ArC), 127.6 (2 x ArC), 70.8 (d, 2JCP = 12.1, PhCH), 70.2 (d, 
2JCP = 12.0, PhCH), 29.9 (d, 
2JCP = 
2.6, CH3), 29.0 (d, 
2JCP = 5.3, CH3); HRMS (APPI, pos.): m/z 320.0854 (320.0845 calc. for 
C16H18ClN2OP, (M)
+) and 321.0928 (321.0924 calc. for C16H19ClN2OP, (M+H)
+). 
General procedure for the synthesis of isothiocyante intermediates 81, 89, 96 and 97:  
To a solution of diaminophosphoryl chloride in dry CH3CN was added 
tetrabutylammonium thiocyanate or potassium thiocyanate. The solution was heated to reflux for 
indicated time and then cooled to room temperature and concentrated under reduced pressure. The 
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residue was purified by flash column chromatography on silica gel to provide corresponding 
isothiocyanate.  
(3aS,7aS)-1,3-Dibenzyl-2-isothiocyanatooctahydro-1H-benzo[d][1,3,2]diazaphosphole 2-
oxide (81): 
 
To a solution of diaminophosphoryl chloride 80 (300 mg, 0.80 mmol) in dry CH3CN was 
added potassium thiocyanate (156 mg, 1.60 mmol), the solution was heated to reflux for 30 h and 
then cooled to room temperature and concentrated under reduced pressure. The residue was 
purified by flash chromatography on silica gel to provide 282 mg (89%) of isothiocyanate 81 as 
white solid; Rf  = 0.22 (hexanes/EtOAc, 8:2). 
Mp: 146.2-147.2 oC; IR (neat): 3060,  3029,  2935,  2848,  2038,  1984,  1601,  1494,  1451,  1437,  
1324,  1296, 1230,  1208,  1177,  1147,  1111,  1067,  1050,  1027,  1001,  963,  924,  879,  862, 
811, 736,  696 cm -1; 1H NMR (300 MHz, CDCl3): δ 7.46-7.22 (m, 10H, ArH), 4.49-4.41 (m, 1H, 
PhCH2), 4.40-4.33 (m, 1H, PhCH2), 4.13 (dd, J = 15.7, 11.2 Hz, PhCH2), 3.89 (dd, J = 15.7, 7.9 
Hz, PhCH2), 2.99-2.84 (m, 2H, CH2CHN), 1.85-1.62 (m, 4H, CH2), 1.22-0.95 (m, 4H, CH2); 
13C 
NMR (75 MHz, CDCl3): δ 142.3 (C=S), 137.8 (d, 
3JCP = 7.2 ArCipso), 137.4 (d, 
3JCP = 3.3 ArCipso), 
128.6 (2 x ArC), 128.5 (2 x ArC), 128.0 (2 x ArC), 127.8 (2 x ArC), 127.5 (ArC), 63.9 (d, 2JCP = 
10.8 Hz, CH2CHN), 63.2 (d, 
2JCP = 11.2 Hz, CH2CHN), 46.83 (d, 
2JCP = 2.5 Hz, CH2Ph), 46.79 
(d, 2JCP = 3.6 Hz, CH2Ph),  29.2 (d, 
3JCP = 8.8 Hz, CH2), 29.5 (d, 
3JCP = 11.4 Hz, 1 CH2), 24.1 (d, 
4JCP = 1.4 Hz, CH2), 23.9 (d, 
4JCP = 1.8 Hz, CH2); HRMS (APPI, pos.): m/z 397.1393 (397.1378 
calc. for C21H24N3OPS (M)
+) and 398.1465 (398.1456 calc. for C21H24N3OPS (M+H)
+). 
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(4S,5S)-1,3-Dibenzyl-2-isothiocyanato-4,5-diphenyl-1,3,2-diazaphospholidine 2-oxide (89): 
 
To a solution of diaminophosphoryl chloride 33 (300 mg, 0.634 mmol) in dry CH3CN was 
added tetrabutylammonium thiocyanate (571 mg, 1.90 mmol), the solution was heated to reflux 
for 24 h and then cooled to room temperature and concentrated under reduced pressure. The residue 
was purified by flash column chromatography on silica gel (hexanes/EtOAc, 8:2) to provide 210 
mg (67%) of isothiocyanate 34 as colorless oil; Rf  = 0.2 (hexanes/EtOAc, 8:2). 
IR (neat): 3063, 3030, 2918, 2036, 1986, 1494, 1455, 1361, 1257, 1208, 1173, 1139, 1097, 1067, 
759, 740, 480 cm-1; 1H NMR (300 MHz, CDCl3): δ 7.35-7.17 (m, 14H, ArH), 7.16-7.08 (m, 2H, 
ArH), 7.08-6.96 (m, 4H, ArH), 4.47 (dd, 1H, J = 14.7, 10.8, PhCH2), 4.30 (dd, 1H, J = 14.9, 11.4, 
PhCH2), 4.08 (t, 1H, J = 5.7, PhCH), 3.95 (dd, 1H, J = 7.7, 5.7, PhCH), 3.84 (dd, 1H, J = 14.9, 
12.2, PhCH), 3.68 (dd, 1H, J = 14.7, 11.0, PhCH2); 
13C NMR (75 MHz, CDCl3): δ 142.1 (d, 
2JCP 
= 9.2, C=S), 137.9 (d, 3JCP = 3.9, ArCipso), 137.3 (d, 
3JCP = 6.6, ArCipso), 135.1 (d, 
3JCP = 2.4, 
ArCipso), 134.9 (d, 
3JCP = 2.8, ArCipso), 128.91 (3 x ArC), 128.89 (3 x ArC), 128.76 (2 x ArC), 
128.50 (ArC), 128.46 (3 x ArC), 128.41 (2 x ArC), 127.7 (2 x ArC), 127.48 (2 x ArC), 127.43 (2 
x ArC), 67.1 (d, 2JCP = 14.6, PhCH), 66.5 (d, 
2JCP = 14.0, PhCH), 46.6 (d, 
2JCP = 4.8, PhCH2), 45.9 
(d, 2JCP = 5.7, PhCH2); HRMS (APPI, pos.): m/z 495.1557 (495.1534 calc. for C29H26N3OPS (M)
+) 
and 496.1629 (496.1612 calc. for C29H27N3OPS (M+H)
+). 
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(4R,5R)-1,3-Diisopropyl-2-isothiocyanato-4,5-diphenyl-1,3,2-diazaphospholidine 2-oxide 
(96): 
 
To a solution of diaminophosphoryl chloride 94 (280 mg, 0.74 mmol) in dry CH3CN was 
added tetrabutylammonium thiocyanate (893 mg, 2.97 mmol), the solution was heated to reflux 
for 24 h and then cooled to room temperature and concentrated under reduced pressure. The residue 
was used in the next step without purification. 
(4R,5R)-2-Isothiocyanato-1,3-dimethyl-4,5-diphenyl-1,3,2-diazaphospholidine 2-oxide (97): 
 
To a solution of diaminophosphoryl chloride 95 (800 mg, 2.49 mmol) in dry CH3CN was 
added tetrabutylammonium thiocyanate (3.00 mg, 9.97 mmol), the solution was heated to reflux 
for 24 h and then cooled to room temperature and concentrated under reduced pressure. The residue 
was used in the next step without purification. 
General procedure for the synthesis of catalysts V-VIII: 
To the solution of corresponding isothiocyante in THF (3 ml), N,N-dimethyl diamine was 
added at ambient temperature. The mixture was stirred for 3 h, the solvent was removed, and the 
residue was purified by flash column chromatography on silica gel to provide requisite catalyst in 
good yield. 
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1-((3aS,7aS)-1,3-Dibenzyl-2-oxidohexahydro-1H-benzo[d][1,3,2]diazaphosphol-2(3H)-yl)-3-
((1S,2S)-2-(dimethylamino)-1,2-diphenylethyl)thiourea (V): 
 
The reaction of 81 (400 mg, 1.00 mmol) in THF (3 ml) was added  N,N-dimethyl stilbene 
diamine (242 mg, 1.00 mmol) according to the general procedure provided, after purification by 
flash column chromatography on silica gel, 610 mg (96%) of V as a white solid; Rf  = 0.24 
(hexanes/EtOAc, 7:3). 
M.P. - 108.6-109.2 oC; IR (neat): 3060, 3028, 2935, 2860, 2828, 2782, 1552, 1491, 1450, 1334, 
1203, 1170, 1107, 1067, 1046, 966, 852, 805, 736, 696, 608, 546 cm -1; 1H NMR (300 MHz, 
CDCl3): δ 10.41 (br s, 1H, PhCHNH), 7.50-7.44 (m, 2H, ArH), 7.40-7.28 (m, 6H, ArH), 7.26-6.85 
(m, 13H, ArH & P(O)NH), 5.88 (dd, 1H, J = 10.9, 7.8 Hz, PhCH), 4.69 (t, 1H, J = 14.7 Hz, PhCH2), 
4.24-4.01 (m, 2H, PhCH2), 3.98-3.84 (m , 2H, 1 x PhCH2 & PhCHN(CH3)2), 2.96-2.78 (m, 2H, 
CH2CHN), 1.95 (s, 6H, (CH3)2), 1.75-1.51 (m, 4H, CH2), 1.22-0.84 (m, 4H, CH2); 
13C NMR (75 
MHz, CDCl3): δ 181.7 (d, 
2JCP = 3.8 Hz, C=S), 139.8 (ArCipso) 139.3 (d, 
3JCP = 6.8, ArCipso), 136.8 
(d, 3JCP = 2.2, ArCipso), 132.9 (ArCipso), 129.7 (2 x ArC), 128.43 (2 x ArC), 128.38 (2 x ArC), 128.2 
(2 x ArC), 128.0 (2 x ArC), 127.8 (2 x ArC), 127.6 (2 x ArC), 127.5 (2 x ArC), 127.24 (ArC), 
127.23 (ArC), 127.1 (ArC), 126.8 (ArC), 73.6 (PhCHN(CH3)2), 64.0 (d, 
2JCP = 10.0 Hz, CH2CHN), 
61.6 (d, 2JCP = 11.0 Hz, CH2CHN) 59.8 (PhCH), 46.3 (d, 
2JCP = 3.9 Hz, PhCH2), 45.8 (d, 
2JCP = 
3.4 Hz, PhCH2), 40.9 (CH3)2, 29.3 (d, 
3JCP = 9.9 Hz, CH2), 28.3 (d, 
3JCP = 9.7 Hz, CH2), 24.1 
(CH2), 23.9 (CH2); HRMS (APPI, pos.): m/z 637.3019 (637.3004 calc. for C37H44N5OPS (M)+) 
and 638.3089 (638.3082 calc. for C37H45N5OPS (M+H)
+). 
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1-((4S,5S)-1,3-Dibenzyl-2-oxido-4,5-diphenyl-1,3,2-diazaphospholidin-2-yl)-3-((1S,2S)-2-
(dimethylamino)cyclohexyl)thiourea (VI): 
 
The reaction of 89 (680 mg, 1.37  mmol) in THF (7 ml) was added  N,N-dimethyl 
diaminocyclohexane (195 mg, 1.79 mmol) according to the general procedure provided, after 
purification by flash column chromatography on silica gel, 710 mg (81%) of VI as a white solid; 
Rf  = 0.22 (DCM/MeOH, 97:3). 
Mp: 101.7-102.4 oC; IR (neat): 3062, 3030, 2927, 2857, 2825, 2777, 1556, 1494, 1454, 1338, 
1289, 1203, 1170, 1133, 1063, 1028, 910, 861, 836, 757, 741, 696 cm-1; 1H NMR (300 MHz, 
CDCl3): Major rotamer δ 9.97 (d, 1H, J = 7.5 Hz, CHNH), 7.33-7.29 (m, 2H, ArH), 7.28-7.16 (m, 
12H, ArH), 7.14-7.09 (m, 1H, ArH), 7.08-7.01 (m, 3H, ArH), 6.97-6.90 (m, 1H, ArH), 6.87-6.83 
(m, 1H, ArH), 6.33 (d, 1H, J = 8.8 Hz, P(O)NH), 4.45 (dd, 2H, J = 15.5, 9.7 Hz,CH2Ph), 4.33-4.26 
(m, 1H, CHNH), 4.05 (dd, 1H, J = 8.9, 5.4 Hz, PhCH), 3.93 (t, 1H, J = 5.4 Hz, PhCH), 3.76 (dd, 
1H, J = 14.8, 8.5 Hz, CH2Ph), 3.60 (dd 1H, J = 14.8, 13.0 Hz, CH2Ph), 2.56-2.47 (m, 1H, 
CHN(CH3)2), 2.44 (d, 1H, J = 12.4 Hz, CH2), 2.21 (s, 6H, N(CH3)2), 1.88-1.75 (m, 2H, CH2), 1.75-
1.61 (m, 1H, CH2), 1.39-1.27 (m, 1H, CH2), 1.26-1.14 (m, 3H, CH2); 
1H NMR (300 MHz, CDCl3): 
Minor rotamer δ 9.84 (d, 1H, J = 8.2 Hz, CHNH), 7.33-7.29 (m, 2H, ArH), 7.28-7.16 (m, 12H, 
ArH), 7.14-7.09 (m, 1H, ArH), 7.08-7.01 (m, 3H, ArH), 6.97-6.90 (m, 1H, ArH), 6.87-6.83 (m, 
1H, ArH), 6.33 (d, 1H, J = 8.8 Hz, P(O)NH), 4.41 (dd, 1H, J = 14.9, 10.4 Hz,CH2Ph), 4.26-4.15 
(m, 1H, CHNH), 4.23 (dd, 1H, J = 14.9, 10.4 Hz,CH2Ph), 4.01 (t, 1H, J = 6.0 Hz, PhCH), 3.89 
(dd, 1H, J = 6.0, 4.1 Hz, PhCH), 3.78 (dd, 1H, J = 14.6, 11.0 Hz, CH2Ph), 3.55 (t, 1H, J = 14.6 
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Hz, CH2Ph), 2.56-2.47 (m, 1H, CHN(CH3)2), 2.38 (d, 1H, J = 12.1 Hz, CH2), 2.14 (s, 6H, 
N(CH3)2), 1.88-1.75 (m, 2H, CH2), 1.75-1.61 (m, 1H, CH2), 1.39-1.27 (m, 1H, CH2), 1.26-1.14 
(m, 3H, CH2); 
13C NMR (75 MHz, CDCl3): Major rotamer δ 181.2 (d, 
2JCP = 3.7 Hz, C=S), 138.4 
(d, 3JCP = 4.7 Hz, ArCipso), 138.2 (d, 
3JCP = 3.7 Hz, ArCipso), 137.8 (d, 
3JCP = 6.0 Hz, ArCipso), 137.7 
(d, 3JCP = 5.1 Hz, ArCipso), 129.5 (ArC), 129.22 (ArC), 129.17 (ArC), 129.1 (2 x ArC), 129.0 
(ArC), 128.8 (2 x ArC), 128.71 (ArC), 128.67 (ArC), 128.6 (ArC), 128.54 (ArC), 128.49 (ArC), 
128.0 (ArC), 127.92 (ArC), 127.85 (ArC), 127.7 (ArC), 127.64 (ArC), 127.58 (ArC), 127.3 (ArC), 
67.7 (d, 2JCP = 13.5 Hz, PhCH), 67.2 (CHN(CH3)2), 66.2 (d, 
2JCP = 13.5 Hz, PhCH), 57.0 (CHNH), 
46.5 (d, 2JCP = 5.6 Hz, CH2Ph), 46.0 (d, 
2JCP = 4.9 Hz, CH2Ph), 40.7 (N(CH3)2), 32.2 (CH2), 25.2 
(CH2), 25.0 (CH2), 22.9 (CH2); 
13C NMR (75 MHz, CDCl3): Minor rotamer δ 181.2 (d, 
2JCP = 3.7 
Hz, C=S), 135.9 (d, 3JCP = 1.6 Hz, ArCipso), 135.8 (d, 
3JCP = 2.9 Hz, ArCipso), 135.5 (d, 
3JCP = 3.5 
Hz, ArCipso), 135.4 (d, 
3JCP = 1.1 Hz, ArCipso), 129.5 (ArC), 129.22 (ArC), 129.17 (ArC), 129.1 (2 
x ArC), 129.0 (ArC), 128.8 (2 x ArC), 128.71 (ArC), 128.67 (ArC), 128.6 (ArC), 128.54 (ArC), 
128.47 (ArC), 128.0 (ArC), 127.92 (ArC), 127.85 (ArC), 127.7 (ArC), 127.64 (ArC), 127.58 
(ArC), 127.3 (ArC), 66.8 (CHN(CH3)2), 66.7 (d, 
2JCP = 11.8 Hz, PhCH), 66.6 (d, 
2JCP = 13.6 Hz, 
PhCH), 57.0 (CHNH), 45.8 (d, 2JCP = 5.7 Hz, CH2Ph), 45.6 (d, 
2JCP = 6.0 Hz, CH2Ph), 40.7 
(N(CH3)2), 32.1 (CH2), 25.2 (CH2), 24.8 (CH2), 22.2 (CH2); HRMS (ESI, pos.): m/z 637.2991 
(637.3004 calc. for C37H44N5OPS (M
+) and and 638.3077 (638.3082 calc. for C37H45N5OPS 
(M+H)+). 
 
 
 
63 
 
1-((4R,5R)-1,3-Diisopropyl-2-oxido-4,5-diphenyl-1,3,2-diazaphospholidin-2-yl)-3-((1R,2R)-
2-(dimethylamino)cyclohexyl)thiourea (VII): 
 
The reaction of 96 (269 mg, 0.67 mmol) in THF (3 ml) was added N,N-dimethyl 
diaminocyclohexane (96 mg, 0.67 mmol) according to the general procedure provided, after 
purification by flash column chromatography on silica gel, 171 mg (47%, brsm 94%) of VII as a 
white solid; Rf  = 0.22 (DCM/MeOH, 95:5). 
Mp:  180.1-181.7 ℃: IR (neat): 3030, 2967, 2929, 2858, 2824, 2776, 1556, 1493, 1454, 1387, 
1347, 1267, 1163, 1132, 1099, 1038, 1024, 1006, 874, 849, 787, 722, 697, 633, 561, 519 cm -1; 1H 
NMR (300 MHz, CDCl3): δ 9.90 (d, 1H, J = 7.5 Hz, NHCH), 7.37-7.29 (m, 6H, ArH), 7.27-7.22 
(m, 2H, ArH), 7.11-7.05 (m, 2H, ArH), 6.35 (d, 1H, J = 8.6 Hz, P(O)NH), 4.28-4.20 (m, 1H, 
NHCH), 4.24 (dd, 1H, J = 6.5, 2.5 Hz, PhCH) 4.15 (dd, 1H, J = 6.5, 4.5 Hz, PhCH), 3.26-3.01 (m, 
2H, CH(CH3)2), 2.56-2.40 (m, 2H, 1 x CH2 & CHN(CH3)2), 2.27 (s, 6H, N(CH3)2), 1.90-1.64 (m, 
3H, CH2), 1.36 (t, 6H, J = 6.7 Hz, CH(CH3)2), 1.32-1.17 (m 4H, CH2), 1.12 (d, 3H, J = 6.5 Hz, 
CH(CH3)2),  1.03 (d, 3H, J = 6.6 Hz, CH(CH3)2; 
13C NMR (75 MHz, CDCl3): δ 180.0 (d, 
2JCP = 
3.5 Hz, C=S), 139.3 (t, 3JCP = 6.4 Hz, 2 x ArCipso), 128.9 (2 x ArC), 128.8 (2 x ArC), 128.4 (2 x 
ArC), 127.5 (2 x ArC), 127.0 (2 x ArC), 67.3 (d, 2JCP = 13.4 Hz, PhCH), 67.1 (d, 
2JCP = 13.4 Hz, 
PhCH), 66.4 (CHNH), 56.7 (CHN(CH3)2), 46.9 (d, 
2JCP = 3.9 Hz, CH(CH3)2), 46.2 (d, 
2JCP = 4.7 
Hz, CH(CH3)2), 40.4 (N(CH3)2),  32.1 (CH2), 25.0 (CH2), 24.7 (CH2), 22.4 (CH2), 20.5 (4 x CH3); 
HRMS (APPI, pos.): m/z 541.3019 (541.3004 calc. for C29H44N5OPS (M)
+) and 542.3090 
(542.3080 calc. for C29H45N5OPS (M+H)
+). 
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1-((4R,5R)-1,3-Dimethyl-2-oxido-4,5-diphenyl-1,3,2-diazaphospholidin-2-yl)-3-((1R,2R)-2-
(dimethylamino)cyclohexyl)thiourea (VIII): 
 
The reaction of 97 (613 mg, 1.79  mmol) in THF (3 ml) was added  N,N-dimethyl 
diaminocyclohexane (254 mg, 1.79 mmol) according to the general procedure provided, after 
purification by flash column chromatography on silica gel, 540 mg (62%) of VIII as a white solid; 
Rf  = 0.22 (DCM/MeOH, 95:5). 
Mp: 129.3-130.6 oC; IR (neat): 3030, 2928, 2857, 2823, 2778, 1553, 1492, 1454, 1341, 1307, 
1246, 1152, 1038, 1017, 992, 863, 746, 698, 518 cm -1; 1H NMR (300 MHz, CDCl3): δ 9.63 (d, 
1H, J = 7.7 Hz,CHNH), 7.35-7.27 (m, 6H, ArH), 7.17-7.07 (m, 2H, ArH), 7.05-6.98 (m, 2H, ArH), 
6.59 (br s, 1H, P(O)NH) 4.28-4.13 (m, 1H, CHNH), 4.05 (d, 1H,  J = 8.6 Hz, PhCH), 3.90 (d, 1H,  
J = 8.6 Hz, PhCH), 2.61-2.53 (m, 1H, CHN(CH3)2), 2.50 (d, 1H, J = 6.6 Hz, NCH3), 2.52-2.43 (m, 
1H, CH2), 2.47 (d, 1H, J = 7.2 Hz, NCH3), 2.29 (s, 6H, N(CH3)2), 1.91-1.69 (m, 3H, CH2), 1.40-
1.22 (m, 4H, CH2); 
13C NMR (75 MHz, CDCl3): δ 181.4 (d, 
2JCP = 3.3 Hz, C=S), 136.6 (d, 
3JCP = 
9.0, ArCipso), 136.5 (d, 
3JCP = 9.2 ArCipso), 128.74 (2 x ArC), 128.66 (2 x ArC), 128.61 (ArC), 
128.58 (ArC), 127.9 (2 x ArC), 127.6 (2 x ArC), 71.2 (d, 2JCP = 11.9 Hz, PhCH), 70.1 (d, 
2JCP = 
11.4 Hz, PhCH), 66.6 (CHN(CH3)2), 56.7 (CHNH), 40.4 (N(CH3)2), 31.9 (CH2), 29.6 (d, 
2JCP = 
3.4 Hz, CH3), 28.5 (d, 
2JCP = 4.1 Hz, CH3), 25.0 (CH2), 24.7 (CH2), 22.5 (CH2); HRMS (ESI, pos.): 
m/z 485.2365 (485.2378 calc. for C25H36N5OPS ((M)
+) and 486.2436 (486.2456 calc. for 
C25H37N5OPS (M+H)
+). 
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General procedure for the intermolecular addition of indoles: 
To a solution of iminium ion precursor (1 equiv) and the indole (2 equiv) in CH2Cl2 (1 mL) 
were added a catalyst (10 mol%) and Sc(OTf)3 (10 mol%) at 0 °C in a sample vial. After stirring 
the reaction mixture for indicated time, the reaction mixture was concentrated and, the residue was 
purified by flash chromatography on silica gel to provide the required product.  
1-Benzyl-6-(1-methyl-1H-indol-3-yl)piperidin-2-one (137): 
 
The reaction of 1-benzyl-6-hydroxypiperidin-2-one 107 (50 mg, 0.2 mmol), N-methyl 
indole 136 (61 µL, 0.4 mmol), Takemoto catalyst II (10 mg, 0.02 mmol) and Sc(OTf)3 (12 mg, 
0.02 mmol)  in CH2Cl2 (1 mL) at ambient temperature for 30 h, according to the general procedure 
provided, after purification by flash column chromatography on silica gel (EtOAc/hexanes 2:3), 
39 mg (51%) of 137 as a colorless solid. Rf = 0.23 (EtOAc/hexanes 2:3). 
1H NMR (300 MHz, CDCl3): δ 7.45 (d, 1H, J = 8.0, ArH), 7.37-7.21 (m, 5H, ArH), 7.17 (dd, 2H, 
J = 7.6 , 1.5 ArH), 7.11 (ddd, 1H, J = 8.0, 6.9, 1.1 Hz, ArH), 6.86 (s, 1H, CH3NCH), 5.59 (d, 1H, 
J = 14.8, CH2Ph), 4.85 (t, 1H, J = 4.6 Hz, NCHCH2), 3.78 (s, 3H, CH3), 3.67 (d, 1H, J = 14.8, 
CH2Ph), 2.71-2.49 (m, 2H, CH2), 2.13-1.95 (m, 2H, CH2), 1.94-1.76 (m, 1H, CH2), 1.74-1.61 (m, 
1H, CH2). 
Benzyl 2-(1-methyl-1H-indol-3-yl)piperidine-1-carboxylate (138): 
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The reaction of 2-hydroxypiperidine-1-carboxylate 119 (50 mg, 0.2 mmol), N-methyl 
indole 136 (53 µL, 0.4 mmol), Takemoto catalyst II (9 mg, 0.02 mmol) and Sc(OTf)3 (10 mg, 0.02 
mmol) in CH2Cl2 (1 mL) at ambient temperature for 1h, according to the general procedure 
provided, after purification by flash column chromatography on silica gel (EtOAc/hexanes 2:3), 
13 mg (17%) of 138 as a colorless solid. Rf = 0.24 (EtOAc/hexanes 1:9). 
1H NMR (300 MHz, CDCl3): δ 7.54 (d, 1H, J = 8.0, ArH), 7.40-7.26 (m, 6H, ArH), 7.21 (ddd, 1H, 
J = 8.0, 6.8, 1.2 Hz, ArH), 7.02 (ddd, 1H,  J = 8.0, 6.8, 1.2 Hz, ArH), 6.92 (d, 1H, J = 1.2 Hz, 
CH3NCH), 5.83 (d, 1H, J = 5.2 Hz, NCHCH2), 5.23 (s, 2H, CH2Ph), 4.06 (d, 1H, J = 13.4 Hz, 
NCH2), 3.75 (s, 3H, CH3), 2.90 (ddd, 1H, J = 13.4, 12.2, 3.7,  Hz, NCH2), 2.25 (d, 1H, J = 12.2, 
NCH2CH2), 2.30-1.88 (m, 1H, CH2), 1.86-1.65 (m, 2H, CH2), 1.64-1.46 (m, 3H, CH2). 
Benzyl 2-(1-benzyl-1H-indol-3-yl)piperidine-1-carboxylate (140): 
 
The reaction of 2-hydroxypiperidine-1-carboxylate 119 (50 mg, 0.2 mmol), N-benzyl 
indole (88 mg, 0.4 mmol), Takemoto catalyst II (9 mg, 0.02 mmol) or cinchonidine catalyst X (9 
mg, 0.02 mmol) or bisoxazoline ligand L1 (7 mg, 0.02 mmol) and Sc(OTf)3 (10 mg, 0.02 mmol) 
in CH2Cl2 (1 mL) at 0 
oC for 20 mins, according to the general procedure provided, after 
purification by flash column chromatography on silica gel (EtOAc/hexanes 2:3), 72 mg (77%) of 
140 as a colorless solid. Rf = 0.24 (EtOAc/hexanes 1:4).  
1H NMR (300 MHz, CDCl3): δ 7.57 (d, 1H, J = 8.0 Hz, ArH), 7.40-7.25 (m, 8H. ArH), 7.25-7.20 
(m, 1H, ArH), 7.15 (ddd, 1H, J = 8.0, 6.9, 1.1 Hz, ArH), 7.11-7.06 (m, 2H, ArH), 7.05-6.98 (m, 
2H, ArH and N-CH), 5.86 (d, 1H, J = 4.7 Hz, NCHCH2),  5.29 (s, 2H, OCH2Ph), 5.23 (s, 2H, 
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CH2Ph), 4.06 (d, 1H, J = 14.2 Hz, NCH2), 2.88 (ddd, 1H, J = 14.2, 12.3, 3.6 Hz, NCH2), 2.25 (d, 
1H, J = 12.3 Hz, CH2), 2.03-188 (m, 1H, CH2), 1.87-1.64 (m, 2H, CH2),1.62-1.46 (m, 2H, CH2). 
Benzyl 2-(1-benzyl-5-bromo-1H-indol-3-yl)piperidine-1-carboxylate (141): 
 
The reaction of 2-hydroxypiperidine-1-carboxylate 119 (50 mg, 0.2 mmol), 1-benzyl-5-
bromo-1H-indole (121 mg, 0.42 mmol), Takemoto catalyst II (9 mg, 0.02 mmol) and Sc(OTf)3 
(10 mg, 0.02 mmol) in CH2Cl2 (1 mL) at 0 
oC for 30 mins, according to the general procedure 
provided, after purification by flash column chromatography on silica gel (EtOAc/hexanes 1:9), 
78 mg (70%) of 141 as a colorless solid. Rf = 0.22 (EtOAc/hexanes 1:9). 
1H NMR (300 MHz, CDCl3): δ 7.76 (d, 1H, J = 1.8 Hz, ArH), 7.40-7.27 (m, 8H, ArH), 7.23 (dd, 
1H, J = 8.7, 1.8 Hz, ArH), 7.08 (d, 1H, J = 8.7 Hz, ArH), 7.05-7.02 (m, 2H, ArH), 7.01 (d, 1H, J 
= 1.0 Hz, NCH) 5.79 (d, 1H, J = 5.9 Hz, NCHCH2), 5.33-5.16 (m, 4H, CH2Ph & OCH2Ph), 4.07 
(d, 1H, J = 12.5, NCH2), 2.85 (ddd, 1H, J = 13.6, 12.5, 4.6 Hz, NCH2), 2.26-2.16 (m, 1H, 
NCH2CH2), 2.03-1.89 (m, 1H, CH2), 1.78-1.66 (m, 2H, CH2),  1.63-1.57 (m, 2H, CH2). 
Benzyl 2-(1-benzyl-5-methoxy-1H-indol-3-yl)piperidine-1-carboxylate (142): 
 
The reaction of 2-hydroxypiperidine-1-carboxylate 119 (50 mg, 0.2 mmol), 5-methoxy-
1H-indole (101 mg, 0.42 mmol), Takemoto catalyst II (9 mg, 0.02 mmol) and Sc(OTf)3 (10 mg, 
0.02 mmol) in CH2Cl2 (1 mL) at 0 
oC for 1 h, according to the general procedure provided, after 
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purification by flash column chromatography on silica gel (EtOAc/hexanes 4:1), 55 mg (57%) of 
142 as a colorless solid. Rf = 0.23 (EtOAc/hexanes 4:1). 
Benzyl 2-(1-benzyl-5-fluoro-1H-indol-3-yl)piperidine-1-carboxylate (143): 
 
The reaction of 2-hydroxypiperidine-1-carboxylate 119 (50 mg, 0.2 mmol), 1-benzyl-6-
fluoro-1H-indole (96 mg, 0.42 mmol), Takemoto catalyst II (9 mg, 0.02 mmol) and Sc(OTf)3 (10 
mg, 0.02 mmol) in CH2Cl2 (1 mL) at 0 
oC for 30 mins, according to the general procedure provided, 
after purification by flash column chromatography on silica gel (EtOAc/hexanes 4:1), 49 mg 
(52%) of 143 as a colorless solid. Rf = 0.23 (EtOAc/hexanes 4:1). 
1H NMR (300 MHz, CDCl3): δ 7.44 (dd, 1H, J = 8.8, 5.4 Hz, ArH), 7.40-7.27 (m, 8H, ArH), 7.10-
7.04 (m, 2H, ArH), 6.99 (d, 1H, J = 1.1 Hz, NCH), 6.87 (dd, 1H, J = 9.8, 2.3 Hz, ArH), 6.75 (ddd, 
1H, J = 9.8, 8.8, 2.3 Hz, ArH), 5.82 (d, 1H, J = 4.9 Hz, NCHCH2), 5.23 (s, 2H, OCH2Ph), 5.22 (s, 
2H, CH2Ph), 4.05 (d, 1H, J = 3.4 Hz, NCH2), 2.83 (ddd, 1H, J = 13.3, 12.5, 3.4, NCH2), 2.21 (d, 
1H, J = 12.5, NCH2CH2), 2.05-1.88 (m, 1H, CH2), 1.86-1.68 (m, 2H, CH2), 1.64-1.44 (m, 2H, 
CH2). 
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1.10 Selected 1H and 13C NMR spectral data:  
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1.11 Selected HPLC traces: 
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Chapter 2 
 
 
 
 
 
 
 
Studies on the Organocatalytic Enantioselective Michael Addition of Cyclic Ketones and 
,  -Disubstituted Aldehydes to  -Nitrostyrenes 
 
 
 
 
 
 
The work described in this chapter has been published in Current Organocatalysis. 
Annadate, R. A.; N. V. G., Moorthy; Pansare, S. V. Curr. Organocatalysis, 2018, 5, 66-73. 
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2.1 Introduction 
Organocatalytic, asymmetric carbon-carbon and carbon-heteroatom bond forming 
reactions have been extensively investigated in recent years1-5 and the organocatalyzed Michael 
addition reaction has attracted significant attention.6-18 Within this category, the enamine mediated 
Michael addition reaction of ketones and aldehydes with nitroalkenes is particularly interesting 
since it generates two contiguous stereocenters in a single step. The synthetic utility of a variety 
of Michael acceptors has been documented, among which -nitrostyrenes ((2-nitrovinyl) arenes) 
have been extensively investigated.19 However, the isomeric -nitrostyrenes ((1- nitrovinyl) 
arenes) have received very little attention, and there are only a few studies with -nitroalkenes ((1-
nitrovinyl)- alkenes) as Michael acceptors reported20-22 in the literature. 
In a broader context, the use of -nitroalkenes as Michael acceptors in the stereoselective 
Michael addition reaction of various aldehyde or ketone nucleophiles is subject to 1,2-asymmetric 
induction (generation of   or   stereocenters) whereas the stereoselective Michael addition 
of an aldehyde or a ketone nucleophile to an -nitrostyrene is subject to 1,3 asymmetric induction 
(generation of ,  stereocenters, Figure. 2.1).  
 
Figure 2.1. Organocatalytic 1,2 and 1,3-asymmetric induction in nitrostyrene Michael addition 
reactions. 
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In contrast to catalytic 1,2 asymmetric induction (generation of   or   stereocenters), 
catalytic versions of 1,3-asymmetric induction processes are less established (Figure 2.1), and all 
of the recent efforts are directed towards the construction of -quaternary stereocenters.23-31  
This chapter describes the enamine-mediated enantioselective organocatalytic Michael 
addition reaction of cyclic ketones and ,- disubstituted aldehydes to -nitrostyrenes, involving 
the enantioselective protonation of a nitronate as the crucial step. 
2.2 Objective: 
The conjugate addition of carbonyl compounds to nitroalkenes provides synthetically 
useful -nitroketones that have numerous applications in the synthesis of complex synthetic 
targets.32 This reaction has been exhaustively investigated with -nitrostyrenes as the Michael 
acceptors but the use of -nitrostyrenes, for establishing non-adjacent stereocenters in the product, 
is not well studied (Figure 2.1). The aim of this study was to investigate the organocatalytic 
asymmetric, enamine mediated, Michael addition reaction of cyclic ketones and ,-disubstituted 
aldehydes to in-situ generated -nitrostyrenes and to optimize the diastereoselectivity and the 
enantioselectivity of the reaction. (Figure 2.2) 
 
 
Figure 2.2 Enamine mediated Michael addition reaction of carbon nucleophiles and -
nitrostyrenes 
The nitro group in the Michael adduct is particularly versatile as it may be transformed into 
various functionalities. The conversion of a nitroalkane into a carbonyl compound by Nef reaction 
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or into a hydroxylamine or an amine by reduction are widely used transformations in organic 
synthesis. In addition, nitro compounds are also good precursors for various nitrogen-containing 
organic compounds such as nitriles, oximes, and imines. One such potential use of  
-nitroketone adducts derived from the addition of aliphatic aldehydes to - nitrostyrenes is their 
conversion into chiral functionalized pyrrolidines.33  
2.3 Literature Survey 
The Michael addition reaction of cyclic ketones and aldehydes has been exhaustively 
investigated with -nitrostyrenes as the Michael acceptors but the use of -nitrostyrenes, for 
establishing nonadjacent stereocenters in the product, was not well established when we started 
our investigations. As noted previously, there are only a few studies on the organocatalytic Michael 
addition to -nitroalkenes. In addition, all of these studies were done with -alkyl--nitroalkenes 
and the -aryl analogues were not examined. The following is a brief summary of previous studies 
on the organocatalytic Michael addition of carbon nucleophiles to -alkyl--nitroalkenes these. 
 In 2012, Ellman and co-workers20 reported the enantio- and diastereoselective addition of 
-substituted Meldrum’s acid 1 to -substituted nitroalkenes 2 followed by kinetic protonation of 
the nitronate addition product to provide 4 in good yields (77-98%) and high enantioselectivity 
(87-94%, Scheme 2.1).  
 
Scheme 2.1 
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The catalyst of choice was the N-sulfinyl urea 3 which has chirality at sulfur. The addition 
products 4 were readily converted to pharmaceutically relevant 3,5-disubstituted pyrrolidinones 5 
in high yield. 
In 2013, Peng and co-workers21 reported the first organocatalytic asymmetric Michael 
addition of aldehydes 6 with a series of -substituted nitroolefins 7 by using the (S)-proline derived 
catalyst 8 (Scheme 2.2). The -nitro aldehydes 9 were formed with good yields and good diastereo- 
and enantioselectivity. Reduction of the nitro group followed by intramolecular reductive 
amination successfully afforded various optically active 2,4-disubstituted pyrrolidines 10. 
 
     Scheme 2.2 
In 2015, Peng and co-workers22 also reported the use of a binary catalytic system involving 
the combination of a quinine-based chiral primary amine 13 with a 3,3’-diphenyl BINOL-derived 
phosphoric acid 14 in the asymmetric Michael addition of a series of cyclic ketones 11 to 
nitroalkenes 12 (Scheme 2.3). The resulting Michael addition adducts 15 were transformed into 
chiral octahydroindoles 16 which are potentially biologically active. 
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Scheme 2.3 
2.4 Results and Discussion 
 Our investigations began with the Michael addition reactions of various ketones with  
in situ generated -nitrostyrenes. We noted that -nitrostyrenes such as 18 are reported to be 
unstable and they can undergo polymerization34 and or isomerization35 to the more stable  
-nitrostyrenes. These undesired processes are generally not an issue with -nitrostyrenes. We 
therefore chose to generate -nitrostyrenes 18 in situ from stable precursors (the corresponding 
nitroacetates 17, Figure 2.3) rather than attempting to isolate them (Figure. 2.3).  
 
Figure 2.3 -nitrostyrene generated in situ from the corresponding nitroacetate 17 
The nitroacetates used in this study were synthesized from commercially available aryl 
bromides using reported procedures. Substitution reactions of the aryl bromides 19-21 with NaNO2 
provided the corresponding nitro compounds36 which underwent a nitroaldol reaction in the 
presence of Na2CO3 and 37% formalin solution
37 to afford the nitro alcohols in 65-70% yield. The 
nitro alcohols were subjected to acetylation with acetic anhydride in the presence of scandium 
triflate to afford the nitroacetates 22-24 in 80-90% yield (Scheme 2.4). 
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Scheme 2.4  
The synthesis of nitroacetate 29 was achieved by an alternative method. The reaction of 
commercially available veratraldehyde (25) with the sulfur ylide derived from 
trimethylsulphonium iodide (26) following the Corey-Chaykovsky protocol provided the epoxide 
27. Regioselective ring opening of the epoxide with NaNO2 provided the nitro alcohol 28. 
Acetylation of 28 in the presence of scandium triflate afforded nitroacetate 29 in 90% yield. 
 
Scheme 2.5  
In previous studies conducted in the Pansare group,38 the Michael addition of the cyclic 
ketone 30 to the -nitrostyrene generated in-situ from nitroacetate 29 was selected as the model 
reaction for determining the optimum reaction conditions. After conducting a brief solvent 
survey,38 catalyst and co-catalyst screening, it was determined that the best result was obtained 
with the diamine catalyst38 31 and (1S)-camphorsulfonic acid in DMF at ambient temperature. The 
-nitroketone adduct 32 obtained was used in the synthesis of quinolizidine based alkaloids such 
as (+)-lasubine II and (−)-subcosine II, in the Pansare group.38 The absolute configuration of 32 
was assigned by X-ray crystallographic analysis.38 
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Scheme 2.6 
 Based upon the conditions developed previously in our group for the Michael addition 
reaction of ketone 30, the utility of diamine catalyst 31 was examined for the Michael addition 
reaction of a variety of cyclic (6-membered) ketones 30, 34-36 with for -nitrostyrene precursors 
22 and 23 (Figure. 2.4). 
 
Figure 2.4 Organocatalyzed reaction of ketones 30, 34-36 and 2-nitro-2-arylethyl acetates 22 
and 23 
  These reactions proceeded efficiently with moderate diastereoselectivity (1:1 to 1.9:1) but 
the major diastereomers 37-42 were easily isolated by flash column chromatography and were 
obtained in moderate to good enantiomeric excess (59-89%) as shown in Table 2.1.  
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Table 2.1 Results of organocatalytic Michael addition of a variety of cyclic ketones to in-situ 
generated -nitrostyrenes 
Entry 
a 
Cyclic  
ketones 
Nitroacetate 
precursor 
Product Yield b (%) dr c ee d (%) 
 
1 
 
30 
 
22 
 
37 
 
 
46 
 
 
1.9:1 
 
 
89 
 
2 
 
30 
 
 
23 
 
38 
 
 
43 
 
 
1:1 
 
 
86 
 
3 
 
 
34 
 
 
 
22 
 
39 
 
 
26 
 
 
1.3:1 
 
 
69 
 
4 
 
 
34 
 
 
 
23 
 
40 
 
 
34 
 
 
1.3:1 
 
 
76 
 
5 
 
 
35 
 
 
 
22 
  
41 
 
 
43 
 
 
1:1 
 
 
69 
 
6 
 
 
35 
 
 
 
23 
 
42 
 
 
28 
 
 
1.3:1 
 
 
59 
 
7 
 
36 
 
 
22 
 
 
 
43 
        
 
90e 
 
- 
 
- 
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8 
 
36 
 
 
23  
44 
 
 
90e 
 
- 
 
- 
a All reactions were done in DMF for 72 h at 0 o C with 5 equiv of ketone. b Isolated yields.  
c Determined by 1H NMR of crude product. d Chiral HPLC analysis. e Yield of crude product. 
 
The stereochemistry of the major -nitroketone product is assigned by the observed trend in 
chemical shift, multiplicity and the coupling constants of the distinctive benzylic proton Ha in 37-
42 by comparison to that for 32 as shown in Table 2.2. 
 
Table 2.2 Chemical shift, multiplicity and the coupling constants of the benzylic proton Ha in the 
-nitroketone product. 
Entry Product  Ha (ppm) Multiplicity Coupling 
constants 
 
1 
 
32 
 
5.63  
 
dd  
 
(J = 10.3, 4.4 Hz) 
 
2 
 
37 
 
5.66  
 
dd  
 
(J = 10.2, 4.4 Hz) 
 
3 
 
38 
 
5.85  
 
dd  
 
(J = 10.2, 4.1 Hz) 
 
4 
 
39 
 
5.65  
 
dd  
 
(J = 10.0, 4.5 Hz) 
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5 
 
40 
 
5.87  
 
dd  
 
(J = 10.1, 4.5 Hz) 
 
6 
 
41 
 
5.66  
 
dd  
 
(J = 10.1, 4.7 Hz) 
 
7 
 
42 
 
5.87  
 
dd  
 
(J = 10.1, 4.6 Hz) 
 
The highest levels of diastereoselectivity and enantiomeric excess are obtained with the 
ketone 30 which suggests that the spirocyclic ring system is beneficial for stereoselectivity (entries 
1 and 2, Table 2.1). The Michael addition reaction of cyclic ketone 36 with different precursors of 
-nitrostyrenes was unsuccessful and significant amounts of the isomerized nitroalkenes 43 and 
44 were obtained in these reactions. This rearrangement was not observed in any of the other 
reactions described in Table 2.1. Overall, the organocatalytic Michael addition of cyclic, six-
membered ketones with in situ generated -nitrostyrenes gave the required products with good 
yield, moderate diastereoselectivity and enantioselectivity. A mechanism that explains the 
formation of 32 and 33 is proposed in Figure. 2.5. 
 It is plausible that the Michael addition of the enamine, derived from 30 and the catalyst 
31, to the α-nitrostyrene derived from 29 proceeds via the hydrogen-bonded 39 intermediate E 
(Figure 2.5) in which the nitroalkene is delivered to the re-face of the enamine (Figure 2.5, Path 
I). This step establishes the -stereocenter in the ketone as R, and it probably generates the 1,2-
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oxazine N-oxide intermediate F. Similar intermediates have been characterized40,41 in 
stoichiometric reactions of achiral enamines with -nitrostyrenes. Subsequent opening of the 
oxazine produces the nitronate G, which is protonated stereoselectively to generate H which has 
the R benzylic stereocenter in 32. The reason for the high stereoselectivity of the protonation of G, 
which leads to the formation of R,R-32, is not known at present.  
 
Figure 2.5 Formation of the -nitro ketone 32 and 33 from 30 using the catalyst 31 
 However, since one of the stereocenters is established prior to the protonation step, the observed 
influence of the chirality of the acid additive on the stereoselectivity of protonation is reasonable. 
The low diastereoselectivity of the Michael addition may be due to two reasons: 1) the inherently 
high reactivity of the α-nitrostyrene enables a competing non-hydrogen-bonded addition to the si-
face of the enamine to generate intermediate F’ (Figure. 2.5, Path II) which, via G’, would provide 
ent-33 with S stereochemistry at the ring stereocenter, and 2) the unselective protonation of 
intermediate G (Figure. 2.5, Path III) provides a small amount of 33 with S stereochemistry at the 
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benzylic stereocenter. Although the factors that control the formation of 33 and ent-33 are not 
known at this time, the low enantiomeric excess of 33 suggests that both Path II and Path III 
(Figure. 2.5) are operative. It should also be noted that previous studies in the Pansare group38 had 
determined that the initial Michael addition step is not reversible under the reaction conditions. 
Having established the feasibility of the Michael addition of cyclic ketones to in situ 
generated -nitrostyrenes, we investigated the Michael addition reaction of symmetrical -
disubstituted aldehydes to in situ generated -nitrostyrenes. Symmetrical -Disubstituted 
aldehydes were used as the nucleophilic component in order to avoid the formation of 
diastereomeric Michael addition products. It was noticed that the diamine 31, which is the best 
catalyst for the reactions with ketones, was not useful for the Michael additions of cyclohexane 
carboxaldehyde 45 to -nitrostyrene obtained in situ from 24 (entry 1, Table 2.3). Consequently, 
a survey of chiral amines was conducted for this reaction as shown in Table 2.3.  
Table 2.3 Catalyst screening for the organocatalytic Michael addition of aldehydes to in situ 
generated -nitrostyrenes 
 
Entry Catalyst Time Yield (%) ee (%) 
1 
 
31 
3d - - 
 
2  
47 
 
2d 
 
45 
 
60 
 
3  
48 
 
3d 
 
32 
 
50 
112 
 
 
4 
 
49 
 
16 h 
 
43 
 
70 
 
5  
50 
 
8d 
 
- 
 
- 
 
6  
51 
 
21 h 
 
33 
 
racemic 
 
7 
52 
 
8d 
 
25 
 
84 
 
8  
53 
 
8d 
 
- 
 
- 
a Isolated yield. b Chiral HPLC analysis.  
Studies with the some of these amines were more fruitful and gave better results.  The use 
of cis 4-hydroxy-proline 47 and trans 4-hydroxy-proline 48 as catalysts gave Michael adduct with 
moderate yield and low enantioselectivity (entries 2 and 3, Table 2.3). However, in the case of  
(S)-4-thiazolidinecarboxylic acid 50 and proline amide 53, the desired product was not observed 
(entries 5 and 8, Table 2.3). The use of (S)-tyrosine as the catalyst 52 gave the desired product in 
low yield (25%), but in good enantiomeric excess (84% ee). The use of (S)-proline 49 as the 
catalyst gave us promising results with 43% yield and 70% ee as shown in Table 2.3.  
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Figure 2.6 Organocatalyzed reaction of symmetrical -disubstituted aldehydes with different 
precursors of -nitrostyrene 
After conducting catalyst screening, S-proline was found to be the most suitable catalyst 
for these reactions. We then investigated the reaction of selected aliphatic aldehydes with different 
nitroacetates as shown in Table 2.4.  
Table 2.4 Results of organocatalytic Michael addition of -disubstituted aldehydes to in-situ 
generated -nitrostyrenes 
Entry Aliphatic 
aldehydes 
Nitroacetate  
precursor 
Catalyst Product Yield 
(%) 
ee 
(%) 
Nitroalkene 
(%) 
 
 
1 
45 
 
24 
 
49 
 
55 
 
 
43 
 
 
76 
 
 
58 (38) 
 
 
2  
45 
 
 
 
22  
49 
 
56 
 
 
14 
 
 
52 
 
 
43 (83) 
 
 
3  
54 
 
24 
 
49 
57 
 
 
32 
 
 
45 
 
 
58 (25) 
 
4 
 
45 
 
23 
 
49 
 
not obtained 
 
- 
 
- 
 
44 (90) 
 
5 
 
45 
 
23  
31 
 
not obtained 
 
- 
 
- 
 
44 (85) 
 
6 
 
45 
 
23 
52 
 
not obtained 
 
- 
 
- 
 
44 (37) 
a Isolated yields. b Chiral HPLC analysis. c Isolated yields of rearranged -nitrostyrenes. 
The yields of all these reactions are moderate and formation of the isomerised  
-nitrostyrenes could not be prevented in these reactions. The 1H NMR of these nitroalkenes  
55-57 agreed with those reported in the literature.42 At this stage, the stereochemistry of the major 
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enantiomer of the -aryl  -nitroaldehyde Michael adduct was assigned by analogy to the products 
obtained from the cyclic ketones. 
Surprisingly, the Michael addition reaction of cyclohexane carboxaldehyde 45 and 
naphthalene nitroacetate 23 under the optimised conditions was unsuccessful and we obtained the 
rearranged -nitrostyrene 44 in quantitative yield. The use of other catalysts such as the diamine 
catalyst 31 and S-tyrosine 52 was not fruitful, and we obtained the isomerised nitroalkene 44 in 
both cases. Since other reactions of 45 provide the desired product (entries 1 and 2, Table 2.4), 
these observations suggest that the -nitrostyrene derived from the nitroacetate 23 is unreactive 
towards the enamine derived form 45 and hence it undergoes isomerization to provide 44 under 
the reaction conditions. 
The synthetic utility of the γ-nitro aldehydes was established by the conversion of 57 into 
a functionalized pyrrolidine33 (Scheme 2.7).  
 
 
Scheme 2.7 
 
Reduction of 57 with sodium borohydride to the nitroalcohol 59 followed by mesylation 
with methane sulfonyl chloride provided the nitro mesylate 60. Crude 60 was converted into the 
N-acetyl pyrrolidine 61 by reductive cyclization with iron followed by N-acetylation. The R 
configuration of 61 confirmed the stereochemical assignment for the nitroaldehyde 57 and, by 
analogy, the configurations of 55 and 56. 
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The results indicate that the Michael addition reaction of aliphatic aldehydes to  
-nitrostyrenes has some limitations. The rearrangement of -nitrostyrenes to -nitrostyrenes is a 
competing side-reaction and the enantioselectivity of the Michael addition is not very high. 
2.5 Conclusion 
 In conclusion, the organocatalytic enantioselective Michael addition of  -disubstituted 
aldehydes and cyclic ketones to -nitrostyrenes to provide enantiomerically enriched -aryl--nitro 
ketones and -aryl--nitro aldehydes were developed. These Michael adducts have considerable 
potential as intermediates in the synthesis of pyrrolidines and 4-arylindolizidine alkaloids38 and 
their analogues. The stereoselectivity of the Michael addition reactions is moderate, presumably 
due to the inherent reactivity of the α-nitrostyrene. In view of the high electrophilicity of -
nitrostyrenes, it is notable that the organocatalysts employed in this study are not deactivated by 
N-alkylation with the nitrostyrene. 
 
2.6 Experimental section 
 
All commercially available reagents were used without purification. All reactions requiring 
anhydrous conditions were performed under an atmosphere of dry nitrogen using oven dried 
glassware. CH2Cl2 was distilled from CaH2. Commercial precoated silica gel plates were used for 
TLC. All melting points are uncorrected. Silica gel for flash column chromatography was 230-400 
mesh. IR spectra were recorded on a Bruker TENSOR 27 FT-IR instrument. 1H NMR and 13C 
NMR spectra were recorded on a Bruker AVANCE III 300 or an AVANCE 500 instrument. Mass 
spectra were obtained on an Agilent 1100 series LC/MSD (Trap) or an Agilent 6200 LC/MSD 
(TOF) chromatographic system. HPLC analyses were performed on a Waters chromatographic 
system using the Breeze software. The nitroalcohol precursors of nitroacetates 22-2437 were 
prepared by adaptation of the literature procedures. 
116 
 
General procedure for the synthesis of 2-aryl-2-nitroethanols from aryl nitromethanes (19-
21):  
To a solution of the aryl nitromethane in THF was added Na2CO3 monohydrate followed 
by aqueous formaldehyde (37% w/v) and the mixture was stirred at ambient temperature for 12 h. 
The THF was removed under reduced pressure and ethyl acetate was added to the residue. The 
resulting mixture was washed with water and the solution obtained was dried over sodium sulphate 
and concentrated under reduced pressure to provide the crude product which was purified by flash 
chromatography on silica gel. 
General procedure for the synthesis of 2-aryl-2-nitroethyl acetates (22-24):  
To a solution of the nitro alcohol in acetonitrile was added Ac2O followed by Sc(OTf)3 and 
the reaction mixture was stirred for 15 min at -10 ℃ and then at ambient temperature for 2 h. The 
reaction mixture was cooled to 0 ℃, water was added, and the resulting mixture was extracted 
with ethyl acetate. The organic layer was dried (Na2SO4) and concentrated to provide the crude 2-
aryl-2-nitroethyl acetates. 
2-Nitro-2-(4-methylphenyl)ethyl acetate (22):  
 
Reaction of 1-methyl-4-(nitromethyl)benzene (0.54 g, 3.60 mmol), Na2CO3 monohydrate 
(0.48 g, 3.92 mmol) and aqueous formaldehyde (37% w/v, 0.28 mL, 3.57 mmol) in THF (5 mL) 
according to the general procedure provided, after purification of the crude product by flash 
chromatography on silica gel (hexanes/EtOAc, 8:2) provided 0.51 g (79%) of 2-nitro-2-(4-
methylphenyl)ethanol. 
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Reaction of the nitro alcohol (0.51 g, 2.84 mmol), Ac2O (0.50 mL, 5.68 mmol), and Sc(OTf)3 (11 
mg, 0.022 mmol) in acetonitrile (5 mL) according to the general procedure provided 0.60 g (94%) 
of 22 as a white solid.  
Mp: 45-47 oC; IR (neat): 3012, 2953, 2921, 1734, 1553, 1513, 1365, 1251, 1183, 1049, 930 cm-1; 
1H NMR (300 MHz, CDCl3):  7.34 (d, 2H, J = 8.2 Hz, ArH), 7.22 (d, 2H, J = 8.0 Hz, ArH), 5.68 
(dd, 1H, J = 10.7, 3.4 Hz, CHNO2), 4.94 (dd, 1H, J = 12.3, 10.7 Hz, CH2OCOCH3), 4.48 (dd, 1H, 
J = 12.3, 3.4 Hz, CH2OCOCH3 ), 2.37 (s, 3H, ArCH3), 2.09 (s, 3H, COCH3); 
13C NMR (75 MHz, 
CDCl3):  170.3 (C=O), 140.9 (ArCipso), 130.0 (2 × ArC), 127.8 (ArCipso), 127.6 (2 × ArC), 88.7 
(CHNO2), 63.9 (CH2OCOCH3), 21.3 (COCH3 or ArCH3), 20.6 (ArCH3 or COCH3); HRMS (ESI, 
pos.): m/z 223.0861 (223.0844 calc. for C11H13NO4 (M
+)) and 246.0749 (246.0742 calc. for 
C11H13NNaO4 (M+Na)
+). 
2-(Naphthalen-2-yl)-2-nitroethyl acetate (23):  
 
Reaction of 2-(nitromethyl)naphthalene (0.54 g, 2.91 mmol), Na2CO3 monohydrate (0.39 
g, 3.20 mmol) and aqueous formaldehyde (37% w/v, 0.20 mL, 2.91 mmol) in THF (5 mL) 
according to the general procedure provided, after purification of the crude product by flash 
chromatography on silica gel (hexanes/EtOAc, 8:2), 0.40 g (63%) of the nitroalcohol as a white 
solid. 
Reaction of the nitro alcohol (0.40 g, 1.84 mmol), Ac2O (0.26 mL, 2.76 mmol) and 
Sc(OTf)3 (9.00 mg, 0.018 mmol) in acetonitrile (5 mL) according to the general procedure provided 
0.38 g (85%) of 23 as a pale yellow solid.  
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Mp: 90-92 oC; IR (neat): 2953, 1735, 1552, 1507, 1368, 1333, 1244, 1165, 1054, 1012, 960 cm-1; 
1H NMR (300 MHz, CDCl3):  7.96-7.83 (m, 4H, ArH), 7.60-7.50 (m, 3H, ArH), 5.89 (dd, 1H, J 
= 10.6, 3.4 Hz, CHNO2), 5.07 (dd, 1H, J = 12.3, 10.6 Hz, CH2OCOCH3), 4.60 (dd, 1H, J = 12.3, 
3.4 Hz, CH2OCOCH3), 2.12 (s, 3H, COCH3); 
13C NMR (75 MHz, CDCl3):  170.3 (C=O), 134.0 
(ArCipso), 133.0 (ArCipso), 129.4 (ArC), 128.3 (ArC), 127.9 (ArC), 127.9 (ArCipso), 127.8 (ArC), 
127.6 (ArC), 127.1 (ArC), 124.0 (ArC), 89.0 (CHNO2), 63.9 (CH2OC(O)CH3), 20.7 (COCH3); 
HRMS (ESI, pos.): m/z 259.0849 (259.0844 calc. for C14H13NO4 (M
+)) and 282.0742 (282.0742 
calc. for C14H13NNaO4 (M+Na)
 +). 
2-Nitro-2-phenylethyl acetate (24): 
 
Reaction of (nitromethyl)benzene (0.90 g, 6.60 mmol), Na2CO3 monohydrate (0.89 g, 7.20 
mmol) and aqueous formaldehyde (37% w/v, 0.20 mL, 6.60 mmol) in THF (7 mL) according to 
the general procedure provided, after purification of the crude product by flash chromatography 
on silica gel (hexanes/EtOAc, 8:2), 0.45 g (45%) of the nitroalcohol as a white solid. 
Reaction of the above nitroalcohol (0.50 g, 3.00 mmol), Ac2O (0.42 mL, 4.50 mmol) and 
Sc(OTf)3 (15.0 mg, 0.030 mmol) in acetonitrile (5 mL) according to the general procedure 
provided 0.56 g (90%) of 24 as a dark orange liquid.  
IR (neat): 1744, 1553, 1366, 1304, 1218, 1043 cm-1; 1H NMR (500 MHz, CDCl3):   7.37-7.48 
(m, 5H, ArH), 5.73 (dd, 1H, J = 10.6, 3.4 Hz, CHNO2), 4.95 (dd, 1H, J = 12.3, 10.6 Hz, 
CH2OCOCH3), 4.50 (dd, 1H, J = 12.3, 3.4 Hz, CH2OCOCH3), 2.08 (s, 3H, COCH3); 13C NMR 
(75 MHz, CDCl3):  170.1 (C=O), 130.6 (ArCipso), 130.6 (ArC), 129.3 (2 x ArC), 127.6 (2 x ArC), 
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88.8 (CHNO2), 63.8 (CH2OC(O)CH3), 20.6 (COCH3); HRMS (ESI, pos.): m/z 209.0692 (209.0688 
calc. for C10H11NO4 (M
+)) and 232.0579 (232.0586 calc. for (C10H11NNaO4 (M+Na)
+). 
2-(3,4-Dimethoxyphenyl)-2-nitroethyl acetate (29): 
 
 A mixture of 2-(3,4-dimethoxyphenyl)oxirane 27 (4.00 g, 22.2 mmol), NaNO2 (11.9 g, 173 
mmol) and LaCl3·7H2O (10.9 g, 44.4 mmol) in THF: H2O (1:1, 160 mL) was vigorously stirred at 
ambient temperature for 12 h. The mixture was then extracted with ether (4 × 25 mL) and the 
combined extracts were dried (Na2SO4) and concentrated under reduced pressure. The residue was 
purified by flash column chromatography on silica gel (hexanes/EtOAc, 1:1) to provide 1.50 g 
(30%) of 2-(3,4-dimethoxyphenyl)-2-nitroethanol 28 as a yellow foam. 
Reaction of the above nitroalcohol 28 (1.84 g, 8.1 mmol), Ac2O (1.14 mL, 12.1 mmol) and 
Sc(OTf)3 (40 mg, 0.08 mmol) in aectonitrile (40 mL) according to the general procedure provided 
1.70 g (81%) of 29 as a yellow solid. 
IR (neat): 1742, 1550, 1516, 1448, 1427, 1394, 1366, 1224, 1146, 1022 cm-1; 1H NMR (500 MHz, 
CDCl3):   7.03 (dd, 1H, J = 8.3, 2.0 Hz, ArH), 6.95 (d, 1H, J = 2.0 Hz, ArH), 6.88 (d, 1H, J = 8.3 
Hz, ArH), 5.67 (dd, 1H, J = 10.7, 3.4 Hz, CHNO2), 4.95 (dd, 1H, J = 12.3, 10.7 Hz, CH2OCOCH3), 
4.48 (dd, 1H, J = 12.3, 3.4 Hz, CH2OCOCH3), 3.90 (s, 3H, OCH3 ), 3.89 (s, 3H, OCH3), 2.09 (s, 
3H, OCOCH3); 13C NMR (75 MHz, CDCl3):   (C=O), 150.8 (ArCipso), 149.5 (ArCipso), 
122.9 (ArCipso), 120.7 (ArC), 111.3 (ArC), 110.2 (ArC), 88.6 (CHNO2), 63.9 (CH2OC(O)CH3), 
56.1 (COCH3); HRMS (ESI, pos.): m/z 270.1015 (270.0978 calc. for (C12H16NO6 (M+H)
+) and 
292.0794 (292.0797 calc. for (C12H15NNaO6 (M+Na)
+). 
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General procedure for the Michael addition of ketones to -nitrostyrenes  
To a solution of the ketone, catalyst 31, and (1S)-camphorsulfonic acid in DMF was added 
the nitroacetate and the resulting solution was stirred at 0 ℃ for 72 h except when noted otherwise. 
Ethyl acetate (5 mL) was added and the solution was washed with water, dried (Na2SO4) and 
concentrated. The residue was purified by flash column chromatography on silica gel. 
(R)7-((R)-2-(3,4-Dimethoxyphenyl)-2-nitroethyl)-1,4-dioxaspiro[4.5]decan-8-one (32): 
 
Reaction of ketone 30 (5.80 g, 37.2 mmol) and nitroacetate 29 (2.00 g, 7.40 mmol) in the 
presence of (S)-2-methyl-N-(pyrrolidin-2-ylmethyl)propan-1-amine (31) (252 mg, 1.49 mmol), 
and (1S)-camphorsulfonic acid (345 mg, 1.49 mmol) in DMF (23 mL)  at 0 ℃ for 72 h according 
to the general procedure provided, after purification by flash column chromatography on silica gel, 
1.38 g (51%) 30 with as a white solid with 92% ee and 0.81 g (30%) of 32 as a colourless gum. 
Data for 32 was in agreement with that reported in the literature.37 
Rf = 0.25 (hexanes/EtOAc, 7:3); IR (neat): 2959, 2873, 1708, 1546, 1510, 1264, 1231, 1150, 1137, 
1027 cm-1; 1H NMR (300 MHz, CDCl3): δ 7.03 (dd, 1H, J = 8.30, 2.1 Hz, ArH), 6.96 (d, 1H, J = 
2.1 Hz, ArH), 6.86 (d, 1H, J = 8.3 Hz, ArH), 5.63 (dd, 1H, J = 10.3, 4.4 Hz, CHNO2), 4.03-4.01 
(m, 4H, OCH2CH2O), 3.90 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 2.75-2.63 (m, 2H, COCH, 
CH2CHNO2), 2.35-2.49 (m, 2H, CH2CH2CO, CH2CHNO2), 2.30 (dd, 1H, J = 10.3, 4.1 Hz, 
CH2CH2CO), 2.13-1.99 (m, 2H, COCH2, COCHCH2), 1.97 (dd, 1H, J = 13.6, 4.9 Hz, COCH2) 
1.78 (t, 1H, J = 13.3 Hz, COCHCH2); 
13C NMR (75 MHz, CDCl3): δ 210.4 (CO), 150.2 (ArCipso), 
149.2 (ArCipso), 127.2 (ArCipso), 120.3 (ArC), 111.1 (ArCipso), 110.2 (ArC), 106.8 (OCO), 89.6 
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(CHNO2), 64.9 (OCH2CH2O), 64.7 (OCH2CH2O), 56.0 (OCH3), 55.9 (OCH3), 43.3 (COCH), 41.4 
(CH2CHC(O)O), 38.3 (CH2CHNO2), 34.8 (CH2CO), 34.0 (CH2CH2C(O)O); MS (ESI, neg.): 
364.1 (M-H)¯; HRMS (ESI, neg.): m/z 365.1469 (365.1475 calc. for C18H23NO7(M
-)); HPLC: 
Chiralpak AS-H (hexane/i-PrOH, 60/40, flow rate 1 mL min−1, λ= 247 nm): tmajor = 10. 20 min., 
tminor = 12.98 min., 92% ee. 
 (R*)7-((S*)-2-(3,4-Dimethoxyphenyl)-2-nitroethyl)-1,4-dioxaspiro[4.5]decan-8-one (33): 
 
IR (neat): 2960, 2891, 2839, 1712, 1547, 1515, 1261, 1240, 1142, 1122, 1023, 762, 730 cm-1; 1H 
NMR (500 MHz, CDCl3):   6.97 (dd, 1H, J = 8.3, 2.1 Hz, ArH), 6.92 (d, 1H, J = 2.1 Hz, ArH), 
6.86 (d, 1H, J = 8.3 Hz, ArH), 5.66 (t, 1H, J = 7.8 Hz, CHNO2), 4.00 (s, 4H, O(CH2)2O),   3.91 (s, 
3H, OCH3), 3.90 (s, 3H, OCH3), 2.86 (dt, 1H, J = 14.8, 7.6 Hz, CH2CHNO2), 2.62-2.48 (m , 2H, 
CH2), 2.40-2.34 (m, 1H, CH2), 2.11-2.06 (m, 1H, CH2), 2.05-1.96 (m, 2H, CH2), 1.95 (td, 1H, J = 
13.6, 5.0 Hz, CH2), 1.78 (t, 1H, J = 13.2 Hz, CH2); 
13C NMR (125 MHz, CDCl3):   210.2 (CO), 
150.5 (ArCipso), 149.5 (ArCipso), 126.7 (ArCipso), 120.9 (ArC), 111.3 (O-C-O or ArC), 110.6 (O-C-
O or ArC), 106.9 (ArC), 88.2 (CNO2), 64.9 (OCH2), 64.7 (OCH2), 56.2 (OCH3), 56.1 (OCH3), 
43.1 (CH2), 40.9 (CH2), 38.2 (CH2), 34.7 (CH2CHCH2), 33.5 (CH2); HRMS (ESI, pos.): m/z 
365.1477 (365.1475 calc. for C18H23NO7 (M
+)); 388.1377 (388.1372 calc. for C18H23NNaO7 
(M+Na)+). 
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(R)-7-((R)-2-Nitro-2-(4-methylphenyl)ethyl)-1,4-dioxaspiro[4.5]decan-8-one (37):  
 
Reaction of ketone 30 (174 mg, 1.11 mmol) and nitroacetate 22 (50.0 mg, 0.20 mmol) in 
the presence of catalyst 31 (8.00 mg, 0.044 mmol) and (1S)-camphorsulfonic acid (10.0 mg, 0.044 
mmol) in DMF (0.6 mL) for 72 h at 0 ℃ provided, after purification of the crude product by flash 
column chromatography on silica gel (hexanes/EtOAc, 9:1), 33 mg (46%) of 37 as a white solid.  
Mp: 90-93 oC; IR (neat): 2899, 1712, 1544, 1444, 1352, 1281, 1111, 1051, 990, 934 cm-1; 1H NMR 
(300 MHz, CDCl3):   7.34 (d, 2H, J = 8.1 Hz, ArH), 7.19 (d, 2H, J = 7.9 Hz, ArH), 5.65 (dd, 1H, 
J = 10.2, 4.4 Hz, CHNO2), 4.05-3.98 (m, 4H, OCH2CH2O), 2.74-2.61 (m, 2H, CH2CHNO2 ), 2.47-
2.24 (m, 3H, COCH2, COCH), 2.36 (s, 3H, ArCH3), 2.15-1.89 (m, 3H, CH2CH2, CHCH2 (ring)), 
1.77 (t, 1H, J = 13.0 Hz, CHCH2 (ring)); 
13C NMR (75 MHz, CDCl3):   210.4 (C=O), 139.9 
(ArCipso), 131.9 (ArCipso), 129.7 (2 x ArC), 127.3 (2 x ArC), 106.8 (OCO), 89.6 (CHNO2), 64.93 
(OCH2CH2O), 64.69 (OCH2CH2O), 43.3 (CHC=O), 41.4 (CH2C-O), 38.3 (CH2C-O), 34.8 
(CH2CHNO2), 34.0 (CH2C=O), 21.3 (ArCH3); HRMS (APPI, pos.): m/z 319.1429 (319.1420 calc. 
for C17H21NO5 (M)
+) and 320.1503 (320.1498 calc. for C17H22NO5 (M+H)
+); HPLC: Chiralpak 
AS-H (hexane/i-PrOH, 70/30, flow rate 1 mL min-1, λ = 254 nm): tmajor = 7.46 min., tminor = 8.37 
min., 89% ee. 
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(R)-7-((R)-2-(Naphthalen-2-yl)-2-nitroethyl)-1,4-dioxaspiro[4.5]decan-8-one (38):  
 
Reaction of ketone 30 (151 mg, 0.96 mmol) and nitroacetate 23 (50.0 mg, 0.19 mmol) in 
the presence of catalyst 31 (6.00 mg, 0.038 mmol), and (1S)-camphorsulfonic acid (9.00 mg, 0.038 
mmol) in DMF (0.6 mL) for 72 h at 0 ℃ for provided, after purification of the crude product by 
flash column chromatography on silica gel (hexanes/EtOAc, 9:1), 29 mg (43%) of 38 as a white 
solid.  
Mp: 118-120 oC; IR (neat): 2949, 1716, 1554, 1368, 1307, 1122, 1060, 1025, 983, 923 cm-1; 1H 
NMR (300 MHz, CDCl3):   7.93 (br s, 1H, ArH), 7.90 - 7.81 (m, 3H, ArH), 7.59-7.49 (m, 3H, 
ArH), 5.85 (dd, 1H, J = 10.2 Hz, 4.1 Hz, CHNO2), 4.04-3.99 (m, 4H, OCH2CH2O), 2.82-2.62 (m, 
2H, CH2CHNO2), 2.59-2.35 (m, 3H, COCH2,COCH), 2.19-1.89 (m, 3H, CH2CH2, CHCH2 (ring)), 
1.80 (t, 1H, J = 13.2 Hz, CHCH2 (ring)); 
13C NMR (75 MHz, CDCl3):   210.5 (C=O), 133.7 
(ArCipso), 133.0 (ArCipso), 132.1 (ArCipso), 129.1 (ArC), 128.3 (ArC), 127.8 (ArC), 127.4 (ArC), 
127.1 (ArC), 126.8 (ArC), 124.1 (ArC), 106.9 (OCO), 90.0 (CHNO2), 64.95 (OCH2CH2O), 64.70 
(OCH2CH2O), 43.4 (CHC=O), 41.4 (CH2C-O), 38.3 (CH2C-O), 34.8 (CH2CHNO2), 34.2 
(CH2C=O); HRMS (APPI, pos.): m/z 355.1416 (355.1420 calc. for C20H21NO5 (M
+)) and 356.1491 
(356.1498 calc. for C20H22NO5 (M+H)
+); HPLC: Chiralpak AS-H (hexane/i-PrOH, 90/10, flow 
rate 1 mL min-1, λ = 254 nm): tmajor = 15.81 min., tminor = 23.10 min., 82% ee. 
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(S)-2-((R)-2-Nitro-2-(4-methylphenyl)ethyl)cyclohexanone (39):  
 
Reaction of ketone 34 (0.10 mL, 1.11 mmol) and nitroacetate 22 (50.0 mg, 0.20 mmol) in 
the presence of catalyst 31 (8.00 mg, 0.044 mmol) and (1S)-camphorsulfonic acid (9.00 mg, 0.044 
mmol) in DMF (0.6 mL) for 72 h at 0 ℃ provided, after purification of the crude product by flash 
column chromatography on silica gel (hexanes/EtOAc, 9:1), 14 mg (26%) of 39 as a white solid. 
Mp: 96-97 oC; IR (neat): 2925, 1706, 1541, 1420, 1361, 1292, 1134 cm-1; 1H NMR (300 MHz, 
CDCl3):   7.35 (d, 2H, J = 8.0 Hz, ArH), 7.19 (d, 2H, J = 8.0 Hz, ArH), 5.65 (dd, 1H, J = 10.0, 
4.5 Hz, CHNO2), 2.50-2.37 (m, 2H, CH2CO), 2.36 (s, 3H, ArCH3), 2.35-2.23 (m, 3H, COCHCH2, 
COCHCH2), 2.22-2.05 (m, 2H CH2), 1.93-1.81 (m, 1H, CH), 1.76-1.58 (m, 2H, CH2), 1.51-1.35 
(m, 1H, CH); 13C NMR (75 MHz, CDCl3):   211.7 (C=O), 139.8 (ArCipso), 132.0 (ArCipso), 129.7 
(2 x ArC), 127.4 (2 x ArC), 89.8 (CHNO2), 47.4 (CHCH2), 42.3 (CH2CO), 34.95 (CH2CHNO2), 
34.38 (CH2), 28.1 (CH2), 25.2 (CH2), 21.2 (ArCH3); HRMS (APPI, pos.): m/z 261.1369 (261.1365 
calc. for C15H19NO3 (M
+)) and 262.1444 (262.1443 calc. for C15H20NO3 (M+H)
+); HPLC: 
Chiralpak AD-H (hexane/i-PrOH, 80/20, flow rate 1 mL min-1, λ = 254 nm): tminor = 7.35 min., 
tmajor = 8.49 min., 69% ee. 
(S)-2-((R)-2-(Naphthalen-2-yl)-2-nitroethyl)cyclohexan-1-one (40):  
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Reaction of ketone 34 (91.0 μL, 0.96 mmol) and nitroacetate 23 (50.0 mg, 0.19 mmol) in 
the presence of catalyst 31 (7.00 mg, 0.038 mmol) and (1S)-camphorsulfonic acid (9.00 mg, 0.038 
mmol) in DMF (0.6 mL) for 72 h at 0 ℃ provided, after purification of the crude product by flash 
column chromatography on silica gel (hexanes/EtOAc, 9:1), 20 mg (35%) of 40 as a white solid.  
Mp: 123-125 oC; IR (neat): 2922, 1706, 1542, 1443, 1348, 1290, 1128, 907 cm-1; 1H NMR (300 
MHz, CDCl3):   7.93 (br d, 1H J = 2.0 Hz, ArH), 7.90-7.81 (m, 3H, ArH), 7.60-7.49 (m, 3H, 
ArH), 5.87 (dd, 1H, J = 10.1, 4.5 Hz, CHNO2), 2.61-2.27 (m, 5H, CH2CO, CH2CHNO2, CH(CO) 
), 2.26-2.06 (m, 2H, CH2), 1.95-1.85 (m, 1H, CH), 1.77-1.59 (m, 2H, CH2), 1.54-1.38 (m, 1H, 
CH); 13C NMR (75 MHz, CDCl3):   211.7 (C=O), 133.7 (ArCipso), 133.0 (ArCipso), 132.2 
(ArCipso), 129.0 (ArC), 128.3 (ArC), 127.7 (ArC), 127.5 (ArC), 127.1 (ArC), 126.8 (ArC), 124.2 
(ArC), 90.1(CHNO2), 47.4 (CHCH2), 42.3 (CH2CO), 34.98 (CH2CHNO2), 34.58 (CH2), 28.1 
(CH2), 25.3 (CH2); HRMS (APPI, pos.): m/z 297.1368 (297.1365 calc. for C18H19NO3 (M)
+) and 
298.1444 (298.1443 calc. for C18H20NO3 (M+H)
+); HPLC: Chiralpak AD-H (hexane/i-PrOH, 
90/10, flow rate 1 mL min-1, λ = 254 nm): tminor = 12.35 min., tmajor = 15.45 min., 76% ee. 
(R)-3-((R)-2-Nitro-2-(4-methylphenyl)ethyl)tetrahydro-4H-pyran-4-one (41):  
 
Reaction of ketone 35 (0.1 mL, 1.1 mmol) and nitroacetate 22 (50.0 mg, 0.20 mmol) in the 
presence of catalyst 31 (8.00 mg, 0.044 mmol) and (1S)-camphorsulfonic acid (10.0 mg, 0.044 
mmol) in DMF (0.6 mL) for 72 h at 0 ℃ provided, after purification of the crude product by flash 
column chromatography on silica gel (hexanes/EtOAc, 8:2), 26 mg (44%) of 41 as a colourless 
gum.  
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IR (neat): 2956, 2922, 2853, 1712, 1547, 1364, 1225, 1207, 1150, 1101, 970 cm-1; 1H NMR (300 
MHz, CDCl3):   7.34 (d, 2H, J = 8.1 Hz, ArH), 7.20 (d, 2H, J = 8.1 Hz, ArH), 5.65 (dd, 1H J = 
10.1, 4.7 Hz, CHNO2), 4.33-4.18 (m, 2H, OCH2), 3.66 (td, 1H, J = 11.5, 2.9 Hz, OCH2 ), 3.36 (t, 
1H, J = 10.8 Hz, OCH2), 2.73-2.52 (m, 2H, COCH2), 2.46-2.37 (m, 2H, COCHCH2), 2.36 (s, 3H, 
ArCH3), 2.30-2.16 (m, 1H, COCHCH2); 
13C NMR (75 MHz, CDCl3):   206.9 (C=O), 
140.1(ArCipso), 131.6 (ArCipso), 129.9 (2 x ArC), 127.4 (2 x ArC), 89.2 (CHNO2), 72.7 (OCH2CH), 
68.9 (OCH2CH2), 48.2 (OCH2CH), 42.9 (COCH2), 29.8 (COCHCH2), 21.2 (ArCH3); HRMS 
(APPI, pos.): m/z 263.1151 (263.1158 calc. for C14H17NO4 (M)
 +) and 264.1235 (264.1236 calc. 
for C14H18NO4 (M+H)
 +); HPLC: Chiralpak AD-H (hexane/i-PrOH, 80/20, flow rate 1 mL min-1, 
λ = 254 nm): tminor = 13.73 min., tmajor = 30.59 min., 69% ee. 
(R)-3-((R)-2-(Naphthalen-2-yl)-2-nitroethyl)tetrahydro-4H-pyran-4-one (42):  
 
Reaction of ketone 35 (97.0 μL, 0.96 mmol) and nitroacetate 23 (50.0 mg, 0.19 mmol) in 
the presence of catalyst 31 (7.00 mg, 0.038 mmol) and (1S)-camphorsulfonic acid (9.00 mg, 0.038 
mmol) in DMF (0.6 mL) for 72 h at 0 ℃ provided, after purification of the crude product by flash 
column chromatography on silica gel (hexanes/EtOAc, 8:2), 16 mg (28%) of 42 as a white solid. 
Mp: 124-126 oC; IR (neat): 2921, 1709, 1545, 1365, 1206, 1148, 1101, 970 cm-1; 1H NMR (300 
MHz, CDCl3):  7.93 (br d, 1H, J = 2.0 Hz, ArH ), 7.91 - 7.82 (m, 3H, ArH), 7.58- 7.50 (m, 3H, 
ArH), 5.87 (dd, 1H,  J = 10.1 Hz, 4.6 Hz, CHNO2), 4.33-4.23 (m, 2H, OCH2), 3.67 (td, 1H, J = 
11.7, 3.2 Hz, OCH2 ), 3.39 (t, 1H, J =10.9 Hz, OCH2), 2.76-2.59 (m, 2H, COCH2), 2.57-2.30 (m, 
3H, COCHCH2); 
13C NMR (75 MHz, CDCl3):   207.0 (C=O), 133.8 (ArCipso), 133.0 (ArCipso), 
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131.7 (ArCipso), 129.2 (ArC), 128.3 (ArC), 127.8 (ArC), 127.6 (ArC), 127.2 (ArC), 126.9 (ArC), 
123.9 (ArC), 89.6 (CHNO2), 72.6 (OCH2CH), 68.8 (OCH2CH2), 48.2 (OCH2CH), 42.8 (COCH2), 
29.9 (COCHCH2); HRMS (APPI, pos.): m/z 299.1159 (299.1158 calc. for C17H17NO4 (M
+)) and 
300.1233 (300.1236 calc. for C17H18NO4 (M+H)
+); HPLC: Chiralpak AD-H (hexane/i-PrOH, 
80/20, flow rate 1 mL min-1, λ = 254 nm): tminor = 22.54 min., tmajor = 25.15 min., 59% ee. 
General procedure for the Michael addition of aldehydes to -nitrostyrenes  
To a solution of the aldehyde and (S)-proline in DMF was added the nitroacetate and the 
resulting solution was stirred at ambient temperature for 12 h. After completion of the reaction 
(TLC), ethyl acetate (5 mL) was added and the resulting solution was washed with water (5 mL), 
dried (Na2SO4) and concentrated. The residue was purified by flash column chromatography on 
silica gel. 
(R)-1-(2-nitro-2-phenylethyl)cyclohexanecarbaldehyde (55):  
 
Reaction of 45 (0.14 mL, 1.2 mmol) and 24 (50 mg, 0.24 mmol) in the presence of (S)-
proline 49 (5.40 mg, 0.047 mmol) according to the general procedure gave, after the purification 
of the crude product by flash column chromatography on silica gel (95:5 hexanes/ethyl acetate), 
27 mg (43%) of 55 as a white gum.  
IR (neat): 2932, 2856, 1721, 1552, 1453, 1363 cm-1; 1H NMR (300 MHz, CDCl3):  9.32 (s, 1H, 
CHO), 7.47-7.36 (m, 5H, ArH), 5.48 (dd, 1H, J =  8.0, 5.0, CHNO2), 2.89 (dd, 1H, J = 15.3, 8.0, 
CH2CHNO2), 2.21 (dd, 1H, J = 15.3, 5.0, CH2CHNO2), 1.96-1.84 (m, 2H, CH2), 1.57-1.51 (m, 
2H, CH2), 1.38-1.26 (m, 6H, CH2); 
13C NMR(75 MHz, CDCl3):  204.7 (CHO), 135.3 (ArCipso), 
130.0 (ArC), 129.2 (2 x ArC), 127.6 (2 x ArC), 87.3 (CHNO2), 49.0 (C-CHO), 39.8 (CH2CHNO2), 
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31.4 (CH2), 30.3 (CH2), 25.3 (CH2), 22.09 (CH2), 21.99 (CH2); HRMS (APPI, pos.): m/z 262.1357  
(262.1365 calc. for C15H19NO3[M]
+),  262.1434 (262.1443 calc. for C15H20NO3[M+H]
+); HPLC: 
Chiralpak AS-H (hexane/i-PrOH, 98/2, flow rate 1 mL min−1, λ = 254 nm): tmajor = 28.97 min., 
tminor = 27.70 min., 76% ee. 
(R)-1-(2-Nitro-2-(4-methylphenyl)ethyl)cyclohexanecarbaldehyde (56):  
 
Reaction of 45 (0.13 mL, 1.11 mmol) and 22 (50.0 mg, 0.22 mmol) in the presence of (S)-
proline 49 (5.00 mg, 0.044 mmol) in DMF (0.6 mL) according to the general procedure gave, after 
purification of the crude product by flash column chromatography on silica gel (98:2 hexanes/ethyl 
acetate), 9 mg (14%) of 56 as a colourless gum.  
IR (neat): 2947, 1716, 1553, 1367, 1307, 1121, 1060, 1025, 924 cm-1; 1H NMR (300 MHz, CDCl3): 
 9.30 (s, 1H, CHO), 7.34-7.29 (d, 2H, J = 8.1 Hz, ArH), 7.21-7.15 (d, 2H, J = 8.1 Hz, ArH), 5.44 
(dd, 1H,  J =   7.7, 5.3 Hz, CHNO2), 2.80 (dd, 1H, J = 15.2, 7.7 Hz, CH2CHNO2), 2.35 (s, 3H, 
ArCH3), 2.22 (dd, 1H,  J = 15.2, 5.3 Hz, CH2CHNO2), 1.97-1.81 (m, 2H, CH2), 1.65-1.47 (m, 4H, 
CH2), 1.42-1.18 (m, 4H, CH2); 
13C NMR (75 MHz, CDCl3):   204.7 (CHO), 140.2 (ArCipso), 132.3 
(ArCipso), 129.8 (2 x ArC), 127.5 (2 x ArC), 87.1 (CHNO2), 49.0 (CH(O)-C-CH2), 39.8 
(CH2CHNO2), 31.5 (CH2), 30.3 (CH2), 25.3 (CH2), 22.1 (CH2), 22.0 (CH2), 21.3 (ArCH3); HRMS 
(APPI, pos.): m/z 275.1532 (275.1521 calc. for C16H21NO3 (M
+)) and 276.1606 (276.1600 calc. 
for C17H22NO3 (M+H)
+); HPLC: Chiralpak AD-H (hexane/i-PrOH, 80/20, flow rate 1 mL min-1, λ 
= 254 nm): tminor = 6.21 min., tmajor = 6.78 min., 52% ee. 
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(R)-2,2-Dimethyl-4-nitro-4-phenylbutanal (57):  
 
Reaction of isobuteraldehyde 54 (0.20 mL, 2.30 mmol) and 24 (100 mg, 0.47 mmol) in the 
presence of (S)-proline 49 (11.0 mg, 0.095 mmol) in DMF (1.2 mL) provided, after purification of 
the crude product by flash column chromatography on silica gel, 34 mg (32%) of 57 as a colourless 
gum.  
IR (neat): 2968, 1724, 1549, 1472, 1456, 1364, 1028 cm-1; 1H NMR (300 MHz, CDCl3):  9.33 (s, 
1H, CHO), 7.49-7.43 (m, 2H, ArH), 7.42-7.38 (m, 3H, ArH), 5.53 (dd, 1H, J = 8.3, 4.8 Hz, 
CHNO2), 2.84 (dd, 1H, J = 15.2, 8.3 Hz, CH2CHNO2), 2.32 (dd, 1H, J = 15.2, 4.8 Hz, 
CH2CHNO2), 1.13 (s, 3H, CH3), 1.10 (s, 3H, CH3); 
13C NMR (75 MHz, CDCl3):  203.4 (CHO), 
135.2 (ArCipso), 130.0 (ArCipso), 129.2 (2 x ArC), 127.5 (2 x ArC), 88.0 (CHNO2), 45.3 (CH(O)-
C-(CH3)2), 40.3 (CH2), 22.2 (CH3), 20.7 (CH3); HRMS (APPI, neg.): m/z 221.1041 (221.1052 calc. 
for C12H15NO3 (M)
−) and 220.0969 (220.0974 calc. for C12H14NO3 (M−H)
−); HPLC: Chiralpak 
AD-H (hexane/i-PrOH, 90/10, flow rate 1 mL min-1, λ = 254 nm): tmajor = 9.20 min., tminor = 10.06 
min., 45% ee. 
(R)-2,2-Dimethyl-4-nitro-4-phenylbutan-1-ol (59):  
 
To a solution of 2,2-dimethyl-4-nitro-4-phenylbutanal 57 (52 mg, 0.2 mmol) in MeOH (2 
mL) at 0 oC was added sodium borohydride (13 mg, 0.3 mmol). The mixture was stirred at 0 oC 
for 2 h. Aqueous HCl (1 N, 2 mL) was added and the mixture was concentrated under reduced 
pressure to remove MeOH. The residue was suspended in water (2 mL), the mixture was extracted 
with ethyl acetate (2 x 2 mL) and the combined organic layers were dried and concentrated. The 
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residue was purified by flash chromatography on silica gel (hexanes/EtOAc, 85:15) to provide 21 
mg (40%) of 59 as a colourless gum.  
IR (neat): 3400 (br), 2959, 2926, 2874, 1547, 1473, 1455, 1363, 1041 cm-1; 1H NMR (300 MHz, 
CDCl3):   7.52-7.45 (m, 2H, ArH), 7.41-7.35 (m, 3H, ArH), 5.69 (dd, 1H, J = 8.6, 4.3 Hz, 
CHNO2), 3.32 (s, 2H, CH2OH), 2.73 (dd, 1H, J = 15.1, 8.6 Hz, CH2CHNO2), 2.04 (dd, 1H, J = 
15.1, 4.3 Hz, CH2CHNO2 ), 1.61 (bs, 1H, OH), 0.91 (s, 3H, C(CH3)2); 
13C NMR (75 MHz, CDCl3): 
d 136.3 (ArCipso), 129.7 (ArC), 129.1 (2 x ArC), 127.6 (2 x ArC), 88.6 (CHNO2), 71.3 (CH2OH), 
42.3 (CH2CHNO2), 35.4 (C(CH3)2) , 23.9 (CH3), 29.9 (CH3); HRMS (APPI, pos.): m/z 223.1206 
(223.1208 calc. for C12H17NO3 (M)
+). 
(R)-1-(4,4-dimethyl-2-phenylpyrrolidin-1-yl)ethan-1-one (61):  
 
To a solution of 2,2-dimethyl-4-nitro-4-phenylbutan-1-ol 59 (44 mg, 0.1 mmol) in 
dichloromethane (1.2 mL) was added triethylamine (71 L, 0.5 mmol) followed by methane 
sulfonyl chloride (20 L, 0.2 mmol) at -78 oC and the mixture was stirred at -78 oC for 1 h. Cold 
water (2 mL) was added, the mixture was stirred for a few minutes and the organic layer was 
separated. The aqueous layer was extracted with CH2Cl2 (2 x 2 mL) and the combined extracts 
were dried (Na2SO4) and concentrated to provide the crude mesylate 60 as a colourless gum. This 
was used in the next step without purification. 
A mixture of Fe powder (66 mg, 1.1 mmol), aq. NH4Cl (21 mg, 0.3 mmol in 1 mL water) and the 
above nitro mesylate 60 (59 mg, 0.1 mmol) in ethanol (4 mL) was heated at 80 oC for 3 h. The 
mixture was then cooled to room temperature and filtered through a pad of celite. The filtrate was 
concentrated, and the residue was dissolved in dichloromethane (1 mL). The resulting solution was 
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washed with aq. NaOH (5%, 2 x 2 mL), dried and concentrated to provide 26 mg (76%) of 4,4-
dimethyl-2-phenylpyrrolidine as a colourless gum which gradually decomposed at -5 oC (fridge). 
The freshly prepared pyrrolidine was therefore used immediately in the next step without 
purification. 
To a solution of 4,4-dimethyl-2-phenylpyrrolidine (26 mg, 0.1 mmol) in THF (3 mL) were added 
acetic anhydride (18 L, 0.1 mmol) and DBU (27 L, 0.1 mmol). The mixture was stirred at 
ambient temperature for 1 h and the solvent was removed under reduced pressure. Aqueous HCl 
(0.1 M, 2 mL) was added and the mixture was extracted with dichloromethane (2 x 2 mL). The 
combined extracts were dried (Na2SO4) and concentrated to provide 26 mg (81%) of 61 as a 
colourless gum. 
IR (neat): 2956, 2868, 1640, 1408, 1352, 1284, 1226, 1176, 1128, 1030, 969, 920 cm-1; 1H NMR 
(300 MHz, CDCl3): Major rotamer:   7.38-7.27 (m, 2H, ArH), 7.26-7.15 (m, 3H, ArH), 4.84 (dd, 
1H, J = 8.9, 7.4 Hz, NCH), 3.93 (dd, 1H, J = 11.4, 4.9 Hz, NCH2), 3.24 (d, 1H, J = 11.4 Hz, NCH2), 
2.29-2.20 (m, 1H, CHCH2), 1.78-1.65 (m, 1H, CHCH2), 1.73 (s, 3H, NCOCH3), 1.12 (s, 6H, 
C(CH3)2); minor rotamer:   7.38 -7.27 (m, 2H, ArH), 7.28-7.15 (m, 3H, ArH), 5.06 (t, 1H, J = 8.4 
Hz, NCH)), 3.48-3.39 (m, 2H, NCH2), 2.20-2.15 (m, 1H, CHCH2), 2.09 (s, 3H, NCOCH3), 1.78-
1.65 (m, 1H, CHCH2), 1.09 (s, 6H, C(CH3)2); 
13C NMR (75 MHz, CDCl3): Major rotamer:  171.0 
(N-CO), 144.2 (ArCipso), 129.2 (2 × ArC), 125.5 (3 × ArC), 62.6 (NCH), 59.9 (NCH2), 52.2 
(CHCH2), 37.1 (C(CH3)2), 26.2 (CH3), 26.1 (CH3), 22.5 (NCOCH3); minor rotamer :   169.3 (N-
CO), 143.9 (ArCipso), 128.6 (2 × ArC), 127.4 (2 × ArC), 126.7 (ArC), 62.0 (NCH2), 60.8 (NCH), 
49.6 (CHCH2), 38.6 (C(CH3)2), 26.4 (CH3), 26.1 (CH3), 23.2 (NCOCH3); HRMS (APPI, pos.): 
m/z 217.1473 (217.1467 calc. for C14H19NO (M)
+), 218.1546 (218.1545 calc. for C14H20NO 
(M+H)+). 
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2.8 Selected 1H and 13C NMR spectral data: 
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2.9 Selected HPLC traces: 
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Chapter 3 
 
 
 
 
Functionalization of Diazotetronic Acid and Application in a Stereoselective Modular 
Synthesis of Aspulvinones B, D and Q 
 
 
 
 
 
The work described in this chapter has been published in Organic and Biomolecular Chemistry: 
Manchoju, A.; Annadate, R.A.; Desquien, L.; Pansare, S.V. Org. Biomol. Chem. 2018, 16, 6224-
6238. 
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3.1 Introduction 
The tetronic acid (4-hydroxy-5H-furan-2-one) motif is a characteristic structural unit in 
many fungal metabolites.1,2 Among these, the pulvinones3 (hydroxylated versions of 3-aryl-4- 
hydroxy-5-arylidene furan-2(5H)-ones) constitute a major group of naturally-occurring tetronic 
acids, which were first isolated as yellow pigments from the mushroom Larch Bolete (Suillus 
grevillei) in 1973 by Edwards and Gill.4 Two years later, Seto and co-workers isolated a significant 
number of yellow colored metabolites from the cultures of Aspergillus terreus5 which includes 
several novel prenylated derivatives of pulvinones. These were named as aspulvinones since their 
structures were determined6,7 to be very similar to the pulvinones isolated earlier. A more recent 
addition (2016) to the aspulvinone family was aspulvinone Q which was isolated from the cultures 
of Aspergillus flavipes PJ03-11.8 Prominent examples of naturally occurring aspulvinones are 
shown in Figure 3.1. 
                                                                                    
Figure 3.1 Naturally occurring Aspulvinones  
Natural or synthetic pulvinones display a wide range of biological activities such as 
anticoagulant,9 antibacterial,10 peptidoglycan biosynthesis inhibitory,11 anti-inflammatory,12 
antidiabetic,13 anti-epileptic,14 and antifungal15 activities. Members of the aspulvinone family have 
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shown antiviral,16 α-glucosidase inhibitory17 and firefly luciferase inhibitory18 activity. The wide 
spectrum of biological activity exhibited by pulvinones has contributed to extensive interest in 
their synthesis and the following section provides known synthetic routes to natural as well as non-
natural pulvinones. 
3.2 Known Synthetic Routes to Pulvinones 
3.2.1 The Pattenden synthesis of pulvinones 
  Pattenden and co-workers7 reported a synthesis of pulvinones in 1979 in fourteen steps in 
1% overall yield. They started their synthesis from commercially available  
4-hydroxybenxaldehyde 10 (Scheme 3.01). Reaction of the potassium salt of 10 with 11 afforded 
dimethylprop-2-ynyl ether 12. Partial hydrogenation of the alkyne in 12 followed by a Claisen 
rearrangement of the resulting allyl ether afforded 13.  
 
Scheme 3.01 
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Acid catalyzed cyclization of 13 afforded the chroman 14. This was reduced with LiAlH4 
to provide the alcohol 15 which provided the nitrile 16 via the corresponding chloride. 
Condensation of the carbanion obtained from 16 and diethyl oxalate afforded pyruvate 17. 
Methylation of 17 followed by acid hydrolysis and cyclization afforded anhydride derivative 18. 
Regioselective reduction of the anhydride with lithium aluminum hydride afforded 19. Metallation 
of 19 with lithium N-cyclohexyl-N-isopropylamide (LCPA) followed by addition of the enolate to 
the aldehyde 20 furnished the aldol product 21. Acid catalyzed dehydration of 21 provided the 
pulvinone 22 as a single diastereomer.  
3.2.2 The Bruckner synthesis of pulvinones 
In 2007, Brückner and co-workers19 reported the syntheses of pulvinones which includes 
Heck alkenylations of iodoarenes, transesterification and Dieckmann cyclization reactions as the 
key steps (Scheme 3.02).  
 
Scheme 3.02 
Stereoselective Heck coupling of iodoarenes 23 with trifluoroethyl 2-acetoxyacrylates 24 
provided the corresponding trifluoroethyl (Z)-2-acetoxycinnamates 25. These were converted into 
trifluoroethyl (Z)-2-(arylacetoxy) cinnamates 26 by deacetylation and esterification of the enol 
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form with a selected aryl acetic acid. Dieckmann cyclization of 26 in the presence of potassium 
tert-butoxide (t-BuOK) provided pulvinones 27 as single diastereomers. A total of six naturally 
occurring pulvinones were synthesized, and the overall yields ranged from 24-30%.  
3.2.3 The Ramage synthesis of 3',4',4-trihydroxypulvinone (5):  
In 1984, Ramage and co-workers20 developed a method to synthesize 3',4',4- 
trihydroxypulvinone (35, Scheme 3.03). Bromination of the glycolic acid-derived dioxolanone 28 
with N-bromosuccinimide provided 29, which was immediately treated with triphenylphosphine 
in toluene to provide the phosphonium salt 30. Condensation of the phosphorane obtained from 
30, in the presence of DABCO, and 3,4-dibenzyloxybenzaldehyde provided 31. Claisen 
condensation of 31 and the lithium enolate 32 provided the tetronic acid derivative 35 as a single 
diastereomer which was then debenzylated (Pd-C and HCl) to provide 3',4',4-trihydroxypulvinone 
(5). 
 
Scheme 3.03 
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The use of 2.5 equivalents of ester enolate 32 was necessary in the condensation reaction. The first 
equivalent of 32 opens the dioxolanone ring, resulting in the formation of lithium enolate 33 and 
the second equivalent forms the lithium bis(enolate) 34 which cyclizes to provide 35. 
3.2.4 The Gill synthesis of pulvinones      
In 1990, Gill and coworkers21 reported a synthesis of pulvinones in six steps in 23% overall 
yield from unsymmetrical acyloins (36, Scheme 3.04). Treatment of 36 with LDA generated the 
alcoholate-enolate dianions 37 which upon acylation with carbonyldiimidazole (CDI) and 
subsequent cyclization provided the dihydropulvinones 38. Methylation of 38 with dimethyl 
sulfate provided 39 which was brominated with NBS to give 40 which was not isolated. Direct in-
situ dehydrobromination of 40 with DBU afforded the O-methyl pulvinones 41 as single 
diastereomers. Treatment of 41 with BBr3 followed by treatment with LiBr in DMF under reflux 
condition afforded the corresponding pulvinones 42.  
 
Scheme 3.04 
3.2.5 The Yamada synthesis of aspulvinone E (3): 
Yamada and co-workers22 recently developed a synthesis of Aspulvinone E in three steps 
in 29% overall yield, employing silver-catalyzed reactions of conjugated ynones with CO2. Thus, 
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the acylation of (4-methoxyphenyl)acetylene with ethyl (4-methoxyphenyl)acetate in the presence 
of n-BuLi and BF3.OEt2 provided ynone 43. Silver-catalyzed reaction of 43 with carbon dioxide 
provided 5-arylidene tetronic acid 44 which was then demethylated with BBr3 to give aspulvinone 
E (3) (Scheme 3.05).  
 
Scheme 3.05 
3.3 Objective 
As discussed above, previous syntheses of 3-aryl-5-arylidene tetronic acid motifs rely on 
starting materials that have the functionality present in the target tetronic acid. Pattenden and  
co-workers started their synthesis from 3-aryl tetronic acid which was a key functionality present 
in the target, while the Brückner synthesis relied on the cyclization of a functionalized precursor 
to provide the tetronic acid motif. Also, although the Yamada synthesis claims to be the shortest 
route to aspulvinone E, the steps required to synthesize the phenyl acetates and the functionalized 
acetylene starting materials are ignored in this claim. Notably, all of these the approaches are 
limited by the requirement of starting materials that contain the substituted arene or arenes in the 
target pulvinones. Therefore, we chose to develop a synthesis of pulvinones that would overcome 
these limitations.  
Previous studies in the Pansare group had established that C5-functionalized 
diazotetronates react with various arenes in the presence of a rhodium catalyst to provide the 
corresponding 3-aryl tetronates as a product of net insertion of the diazotetronate into the arene  
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C-H bond.23 We reasoned that a similar strategy could be applied for the synthesis of natural and 
unnatural pulvinones. The key features of our synthetic strategy for pulvinone synthesis are: 1) 
introduction of the C5 alkylidene/arylidene functionality by a stereoselective aldol condensation 
of diazotetronate 45 with various aliphatic and aromatic aldehydes and 2) installation of the C3 
aryl substituent in a single step by a C-H insertion reaction involving the diazo functionality to 
provide the pulvinone motif 47 (Figure 3.2).   
 
Figure 3.2 Synthetic approaches to pulvinones and two-step strategy 
During the initial stages of our studies on pulvinone synthesis, we had noted that the 
syntheses of aspulvinone D (7, Figure 3.1) and aspulvinone Q (2) were not reported and that the 
sole reported synthesis of aspulvinone B (6) had provided the target as an inseparable mixture with 
unidentified by-products. Hence, aspulvinones B, D and Q were selected as the synthetic targets 
of this study. Aspulvinones A, C, E, G and 3',4',4-trihydroxypulvinone were also synthesized in 
parallel studies conducted by Dr. A. Manchoju in the Pansare group.24 
3.4 Results and Discussion 
One of the key steps in our proposed methodology is the stereoselective aldol condensation 
of diazotetronate 45 to provide 46 which are potentially the immediate precursors of the required 
pulvinones. Diazotetronate 45 is easily prepared from commercially available tetronic acid in one 
step,25 and the aldol condensation reaction of 45 was therefore the subject of our initial 
investigations. p-Tolualdehyde was selected as the representative aldehyde for these studies and 
its aldol condensation reaction with 45 was investigated under a variety of conditions. It should be 
mentioned that the formation of an aldol product (instead of an aldol condensation product) was 
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considered to be a distinct possibility and, if so, dehydration to the aldol product to the required 
arylidene derivative would be necessary. Since previous studies26 on related compounds had 
shown that this two-step process often leads to an isomeric mixture of E and Z arylidene tetronates, 
our objective was to develop a direct, stereoselective aldol condensation reaction of 45. The 
diazotetronic acid 45 was prepared by modification of the reported procedure (Scheme 3.06).    
 
Scheme 3.06 
Initially, an aldol condensation of 45 and p-tolualdehyde was attempted with the titanium 
enolate of 45 (using the TiCl4-Et3N reagent
27 Table 3.1, entry 1). To our delight, this directly 
provided the aldol condensation product 50 as a single diastereomer, but in low yield (41%). 
Replacing TiCl4 with BF3.OEt2 (Table 3.1 entry 2) provided only the aldol addition product 51 as 
a mixture of diastereomers (dr = 1:1).  
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Table 3.1 Optimization of the aldol condensation of 45 with p-tolualdehyde. 
                     
Entry Reagents and conditions 50a 51a 
1. TiCl4, -78 
oC, 20 min; Et3N, -78 
oC, 40 min to  
0 oC, 1.5 h 
41 - 
2. BF3.OEt2, -78 
oC, 20 min; Et3N, -78 
oC, 40 min;  
0 oC, 1 h; rt, 1 h 
- 38 
3. TiCl4, -78 
oC, 20 min; pyridine, -78 oC, 30 min;  
0 oC, 2 h; rt, 41 h 
82 - 
4. TiCl4, -78 
oC, 20 min; N-methylimidazole, -78 
oC, 30 min; 0 oC, 1 h 20 min; rt, 18 h 
77 - 
5. TiCl4, -78 
oC, 20 min; 2,4,6-collidine, -78 oC,  
30 min; 0 oC, 30 min 
82 - 
                           aisolated yields 
Changing the base from triethylamine to heteroaromatic bases such as pyridine, N-
methylimidazole and 2,4,6-collidine prevented the formation of aldol addition product 51 and 
improved the yield of the aldol condensation product 50. With pyridine and N-methylimidazole 
(Table 3.1, entries 3 and 4), alkene 50 was obtained in good yields (82% and 77% respectively), 
but the reaction was sluggish. Finally, the use of 2,4,6-collidine as the base not only provided 50 
in good yield (82%, Table 3.1, entry 5), but the reaction was significantly faster (80 min) than 
those with N-methylimidazole (~20 h) or pyridine (~43 h) as the base. With these optimal 
conditions in hand, the scope of the reaction was tested with the variety of aldehydes to provide 
alkylidene diazotetronates 50-57 (Figure 3.3). 
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We were pleased to find that the aldol condensation reaction of 45 with electron-rich and 
electron-deficient aromatic aldehydes, as well as aliphatic aldehydes, provided 5-arylidene-3-
diazofuran-2,4(3H,5H)-diones 50-57 as single diastereomers in excellent to moderate yields 
(Figure 3.3). Notably, the arylidene diazotetronates 53, 56 and 57 are potentially the immediate 
precursors of aspulvinones Q, B and D. In case of aliphatic aldehydes, the reaction of 45 with 
hydrocinnamaldehyde did not provide any of the required product, and the reaction with 
pivalaldehyde was less efficient providing 54 in modest yield (40%). 
                           
Figure 3.3 Aldol condensation products of 45 with selected aldehydes 
At this stage, we assigned the stereochemistry of the double bond present in the diazo 
alkene 50 as Z based on selected 13C-1H coupling constant. The 3JC(4)-H(6) (three bond 
13C-1H 
coupling constant) for the exocyclic methine and the ketone carbonyl carbon in 50 is 3.9 Hz and 
2JC(5)-H(6) (two bonds 
13C-1H coupling constant) in 50 is 4.3 Hz (Figure 3.4). These values are in 
good agreement with those reported28 for several Z-aurones (3JC-H = 3.1-3.6 Hz; 
2JC-H = 3.7-4.7 Hz) 
that are structurally related to 50. Notably, the reported 3JC-H and 
2JC-H values for E-aurones are 
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higher (7.0-8.5 Hz). The stereochemical assignment was eventually confirmed by the conversion 
several diazo alkenes to naturally occurring pulvinones, thus providing unambiguous evidence for 
the alkene geometry in 50-57. 
Figure 3.4 Determination of the stereochemistry of the aldol condensation products 
Having established a general synthesis of 5-arylidene-3-diazofuran-2,4(3H,5H)-diones, 
our next target was the introduction of an aryl substituent at C3 to construct the C3-aryl-C5-
arylidene/alkylidene tetronic acid (pulvinone) motif. This would help us to confirm the Z-geometry 
of the diazo alkene by the synthesis of known pulvinones. Previous studies in the Pansare group 
for the synthesis of aspulvinones A and C had identified Rh2(esp)2 (Du Bois catalyst) as the catalyst 
of choice for the C-H insertion reaction using PhCF3 as a solvent.
29 Hence, these conditions were 
also used in the studies described here. 
3.4.1 Retrosynthetic analysis for Aspulvinones 
A retrosynthetic analysis for the synthesis of aspulvinones B and D is outlined in Figure 
3.5. We reasoned that these natural products could be obtained from net C-H insertion reaction of 
diazo tetronates 58 and chromans 59. The diazo tetronates 58 could be obtained by the aldol 
condensation reaction of diazotetronate 45 and corresponding aldehydes 60.  
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Figure 3.5 Retrosynthetic route for synthesis of aspulvinones B and D 
3.4.2 Synthesis of naturally occurring pulvinones 
Our initial attempt at the synthesis of aspluvinone B started with the preparation of 
aldehyde 62 in which the phenol was protected as a benzyl group (Scheme 3.07). The synthesis of 
62 began with prenylation of 4-hydroxy benzaldehyde (10) with prenyl bromide in the presence of 
10% KOH to provide 61 which was subsequently benzylated to provide 62.30  
 
Scheme 3.07  
The 5-arylidene diazo tetronate 57 was obtained by the aldol condensation of 62 and diazotetronate 
45 (Scheme 3.07) using our optimized aldol condensation procedure (Table 3.1 and Figure 3.3). 
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The synthesis of the 2,2-dimethylchromane 65, a nucleophilic partner for the net C-H insertion 
reaction was achieved by the acid catalysed reaction of phenol 63 with isoprene 64 (Scheme 3.07). 
Initially, a C-H insertion reaction of the diazotetronic acid derivative 57 with four 
equivalents of chromane 65 in the presence of the Du Bois catalyst (Rh2(esp)2) was conducted in 
PhCF3 at 50 
oC. This provided the required product 66 (Scheme 3.08), but in low yield (37%). 
Increasing the reaction temperature to 100 oC was beneficial and a higher yield of 66 (51%) was 
obtained. With 66 in hand, its conversion to aspulvinone B (6) was examined. Unfortunately, the 
attempted debenzylation of 66 Raney Nickel in the absence of an atmosphere of H2
31 led to a 
complex mixture of products which did not contain any aspulvinone B (Scheme 3.08). This 
observation was surprising, since previous studies31 in the Pansare group had successfully used 
this procedure for the selective hydrogenolysis of a benzyl ether in the presence of a 
tetrasubstituted alkene. 
 
Scheme 3.08  
Given the failure of the debenzylation reaction, an alternative protecting group for the 
phenolic functionality in 61 became necessary. The TBS protected aldehyde 67 was selected as an 
alternative to 62 and it was prepared by adaptation of the procedure reported in the literature32 
(Scheme 3.09). 
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Scheme 3.09  
Initially the reaction of the 5-arylidene diazo tetronate 56 with the chromane 65 was 
examined by using the Du Bois catalyst and PhCF3 as the solvent, but the yield of the C-H insertion 
product was extremely low (15%). After some experimentation, it was observed that changing the 
solvent from PhCF3 to 1,2-dichloroethane was crucial. With this modification, the C-H insertion 
reaction of 56 with chromane 65 provided 68 in 59% yield. Subsequent removal of the TBS 
protecting group in 68 with TBAF provided aspulvinone B (6, 56%, Scheme 3.10). The 
spectroscopic data (1H and 13C) of 6 are in agreement with those reported in the literature.19 The 
formation of aspulvinone B supports our initial assumption that the aldol condensation reaction of 
diazotetronate 45 and aldehyde 67 provides Z-56 stereoselectively. 
 
Scheme 3.10  
Next, the synthesis of aspulvinones D (7) and Q (2) was investigated using the strategy 
described for the synthesis of aspulvinone B. Due to the successful desilylation reaction described 
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above, we chose to synthesize the TBS protected chroman derivative 71 for the C-H insertion 
reaction to be employed in the synthesis of aspulvinone D. The synthesis of TBS ether 71 was 
achieved by an acid catalysed reaction of resorcinol 69 with isoprene 64 to provide the 
corresponding hydroxychroman 70 and subsequent protection of the phenol functionality with 
TBSCl (Scheme 3.11). 
 
Scheme 3.11  
The Rh (II)-catalyzed C-H insertion reaction of 56 with tert-butyl-((2,2-dimethylchroman-7-
yl)oxy)-dimethylsilane 71 provided 72 in 43% yield. Desilylation of 72 provided aspulvinone D 
(7, 86%, Scheme 3.12). 
 
Scheme 3.12  
Our next objective was the synthesis of aspulvinone Q. To this effect, the C-H insertion 
reaction of 56 with tert-butyldimethyl(phenoxy)silane 73 in the presence of Rh2(esp)2 provided 74 
in 40% yield. Interestingly, the regioisomeric product which is observed with anisole as the 
reacting partner (C-H insertion ortho to the OMe group), was not observed in this reaction. It is 
reasonable to assume that this selectivity is due to steric reasons (the OTBS group is sterically 
186 
 
more demanding than the OMe group). Removal of the TBS protecting group in 72 with TBAF 
provided aspulvinone Q (2) in good yield (86%, Scheme 3.13). 
 
Scheme 3.13  
3.4.3 Synthesis of an unnatural pulvinone 
 Over the years, interest in the biological activity of pulvinones and aspulvinones has 
resulted in intense investigation of the synthesis of structural variants of the natural isolates.33,34 In 
a study aimed at preparing a focused library of tetronic acid-indole hybrid structures, the C-H 
insertion reaction of 55 with 5-bromoindole was examined under the optimized reaction conditions 
(Rh2(esp)2, PhCF3, 50 
oC, Scheme 3.14). Gratifyingly, the expected product 75 was obtained in 
excellent yield (90%). Studies of other diazotetronates and indoles are being investigated in the 
Pansare group. 
 
Scheme 3.14  
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3.5 Conclusion  
 In conclusion, we have developed a versatile methodology for the synthesis of naturally 
occurring as well as unnatural pulvinones and their derivatives. The syntheses of aspulvinones B, 
D and Q were achieved in three steps from the diazoteronate 45. The methodology provides direct 
access to a wide range of stereoisomerically pure (Z)-5-arylidene/alkylidene-3-diazofuran-
2,4(3H,5H)-diones in a single step and 5-arylidene-4-hydroxy-3-aryl-5-furan-2(5H)-ones in just 
two steps from diazotetronic acid. This strategy has potential for application in a rapid synthesis 
of focused libraries of aspulvinone-like natural product analogues. 
3.6 Experimental section 
Unless otherwise stated, all reagents were purchased from commercial suppliers and used 
without purification. All reactions were carried out under an atmosphere of nitrogen in flame or 
oven-dried glassware with magnetic stirring. Commercially available -trifluorotoluene was 
used as received. CH2Cl2 and DCE were distilled from CaH2. Commercial precoated silica gel 
plates were used for TLC. All melting points are uncorrected. Silica gel for flash column 
chromatography was 230-400 mesh. IR spectra were recorded on a Bruker TENSOR 27 FT-IR 
instrument. 1H NMR and 13C NMR spectra were recorded on a Bruker AVANCE III 300 or an 
AVANCE 500 instrument. Mass spectra were obtained on an Agilent 6200 LC/MSD (TOF) 
chromatographic system.  
General procedure for the aldol condensation of diazotetronate 45 and aldehydes: 
 To a solution of 45 (1.0 equiv) and aldehyde (1.0 equiv) in CH2Cl2 was added TiCl4 (3.0 
equiv) at -78 °C. The solution was stirred for 20 min, 2,4,6-collidine (3.0 equiv) was added and 
the mixture was stirred at -78 °C for 30 min and at 0 °C for 30 min. Saturated aqueous NH4Cl (~ 
3 mL) was added followed by cold water (~ 2 mL). The resulting mixture was extracted with 
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CH2Cl2 (3 x 6 mL). The combined organic layers were washed with brine, dried (Na2SO4) and 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica 
gel to provide the arylidene or alkylidene diazotetronates 50-57. 
(Z)-3-Diazo-5(4-methylbenzylidene)furan-2,4(3H,5H)-dione (50): 
 
The reaction of 45 (126 mg, 1.00 mmol), 4-methylbenzaldehyde (118 µL, 1.00 mmol), 
TiCl4 (0.32 mL, 3.0 mmol) and 2,4,6-collidine (0.40 mL, 3.0 mmol) in CH2Cl2 (5 mL) according 
to the general procedure provided, after purification by flash column chromatography on silica gel 
(hexanes/EtOAc, 9:1), 188 mg (82%) of 50 as a white solid.  
Rf = 0.32 (hexanes/EtOAc, 8.5:1.5); mp: 147-150 °C; IR (neat): 2157, 1758, 1689, 1634, 1602, 
1362, 1339, 1313, 1251, 1078, 1048, 962, 917 cm-1; 1H NMR (300 MHz, CDCl3): δ 7.66 (d, 2H, 
J = 8.1 Hz, ArH), 7.23 (d, 2H, J = 8.1 Hz, ArH), 6.68 (s, 1H, ArCH=C), 2.39 (s, 3H, CH3); 
13C 
NMR (75 MHz, CDCl3): δ 174.8 (C=O), 160.5 (OC=O), 141.6 (O-C=CHAr or ArCipso), 141.3 (O-
C=CHAr or ArCipso), 131.6 (2 × ArC), 129.9 (2 × ArC), 128.3 (ArCipso), 112.2 (ArCH=C), 21.8 
(CH3); HRMS (APPI, pos.): m/z 228.0537 (228.0535 calc. for C12H8N2O3, (M)
+). 
 (Z)-3-Diazo-5-(2-ethoxybenzylidene)furan-2,4(3H,5H)-dione (51): 
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The reaction of 45 (75 mg, 0.6 mmol), 2-methoxybenzaldehyde (81 mg, 0.6 mmol), TiCl4 
(0.2 mL, 1.8 mmol) and 2,4,6-collidine (0.2 mL, 1.8 mmol) in CH2Cl2 (5 mL) according to the 
general procedure provided, after purification by flash column chromatography on silica gel 
(hexanes/EtOAc, 9:1), 77 mg (53%) of 51 as a yellow solid.  
Rf  = 0.23 (hexanes/EtOAc, 9:1); IR (neat): 3080, 2923, 2840, 2152, 1775, 1699, 1648, 1592, 1483, 
1462, 1359, 1305, 1283, 1254, 1233, 1193, 1138, 1070, 1045, 1018, 955 cm-1; 1H NMR (300 MHz, 
CDCl3):  8.05 (dd, 2H, J = 7.6, 1.7, ArH), 7.37 (ddd, 1H J = 8.3, 7.6, 1.7 Hz), 7.28 (s, 1H, ArCH), 
7.01 (br t, 1H, J = 7.6, ArH), 6.91 (br d, 1H, J = 8.3, ArH), 3.88 (s, 3H, OCH3); 
13C NMR (75 
MHz, CDCl3):  174.7 (C=O), 160.5 (O-C=O), 158.7 (ArCipso), 141.8 (ArCipso), 132.1 (O-
C=CHAr), 131.7 (ArH), 121.0 (ArH), 119.9 (ArCH), 110.8 (ArH), 106.2 (ArH), 55.6 (OCH3); 
HRMS (APPI, pos.): m/z 244.0847 (244.0484 calc. for C12H8N2O4 (M
+)), 245.0560 (245.0562 
calc. for C12H9N2O4 (M+H)
+). 
(Z)-3-Diazo-5-(4-nitrobenzylidene)furan-2,4(3H,5H)-dione (52): 
 
The reaction of 45 (75 mg, 0.59 mmol), 4-nitrobenzaldehyde (90 mg, 0.59 mmol), TiCl4 
(0.20 mL, 1.78 mmol) and 2,4,6-collidine (0.2 mL, 1.78 mmol) in CH2Cl2 (5 mL) according to the 
general procedure provided, after purification by flash column chromatography on silica gel 
(hexanes/EtOAc, 4:1), 95 mg (62%) of 52 as a light brown solid. 
Rf  = 0.20 (hexanes/EtOAc, 4:1);  IR (neat): 2922, 2850, 2162, 1767, 1706, 1643, 1504, 1362, 1338, 
1296, 1240, 1070, 962, 911, 857, 828, 750 cm-1; 1H NMR (500 MHz, DMSO-d6):  8.34 (d, 2H, J 
= 8.9, ArH), 8.09 (d, 2H, J = 8.9, ArH), 6.92 (s, 1H, ArCH); 13C NMR (125 MHz, DMSO-d6):  
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174.4 (C=O), 160.1 (O-C=O), 147.2 (ArCipso), 144.5 (ArCipso), 137.8 (O-C=CHAr), 131.7 (2 x 
ArH), 124.0 (2 x ArH), 106.5 (ArCH); HRMS (APPI, pos.): m/z 259.0224 (259.0229 calc. for 
C11H5N3O5 (M
+)), 260.0296 (260.0307 calc. for C11H6N3O6 (M+H)
+). 
(Z)-5-(4-(tert-Butyldimethylsilyloxy)-3-methoxybenzylidene)-3-diazofuran-2,4(3H,5H)-
dione (53): 
 
 The reaction of 45 (100 mg, 0.79 mmol), 4-(tert-butyldimethylsilyloxy)-3-
methoxybenzaldehyde (211 mg, 0.790 mmol), TiCl4 (0.25 mL, 2.38 mmol) and 2,4,6-collidine 
(0.3 mL, 2.38 mmol) in CH2Cl2 (5 mL) according to the general procedure provided, after 
purification by flash column chromatography on silica gel (hexanes/EtOAc, 9.2:0.8), 257 mg 
(87%) of 53 as a yellow solid. 
Rf = 0.30 (hexanes/EtOAc, 9.2:0.8); IR (neat): 2957, 2931, 2856, 2147, 1786, 1708, 1649, 1591, 
1508, 1463, 1419, 1364, 1344, 1310, 1276, 1248, 1169, 1132, 1072 cm-1; 1H NMR (300 MHz, 
CDCl3): δ 7.34 (d, 1H, J = 2.1 Hz, ArH), 7.24 (dd, 1H, J = 8.3, 2.1 Hz, ArH), 6.88 (d, 1H, J = 8.3 
Hz, ArH), 6.65 (s, 1H, ArCH), 3.86 (s, 3H, OCH3), 1.00 (s, 9H, C(CH3)3), 0.18 (s, 6H, Si(CH3)2). 
13C NMR (75 MHz, CDCl3): δ 174.7 (C=O), 160.5 (O-C=O), 151.4 (ArCipso), 148.0 (ArCipso), 
140.7 (ArCipso), 126.1 (ArC), 124.9 (O-C=CHAr), 121.4 (ArH), 114.5 (ArCH), 112.6 (ArC), 55.7 
(OCH3), 25.8 (C(CH3)3), 18.7 (C(CH3)3), -4.4 (Si(CH3)2); HRMS (ESI, pos.): m/z 374.1295 
(374.1298 calc. for C18H22N2O5Si (M)
+), 397.1187 (397.1196 calc. for C18H22N2NaO5Si 
(M+Na)+). 
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(Z)-3-Diazo-5-(2,2-dimethylpropylidene)furan-2,4(3H,5H)-dione (54): 
 
The reaction of 45 (75 mg, 0.59 mmol), pivalaldehyde (64 μL, 0.59 mmol), TiCl4 (0.2 mL, 1.78 
mmol) and 2,4,6-collidine (0.23 mL, 1.78 mmol) in CH2Cl2 (5 mL) according to the general 
procedure provided, after purification by flash column chromatography on silica gel 
(hexanes/EtOAc, 9.5:0.5), 49 mg (43%) of 54 as a colourless gum. 
Rf = 0.19 (hexanes/EtOAc, 9.5:0.5); IR (neat): 2963, 2907, 2870, 2148, 1780, 1712, 1622, 1356, 
1241, 1083, 988 cm-1; 1H NMR (300 MHz, CDCl3): δ 5.91 (s, 1H, ((CH3)3C)-CH), 1.23 (s, 9H, 
(CH3)3). 
13C NMR (75 MHz, CDCl3): δ 175.2, (C=O), 160.3 (O-C=O), 142.3 (O-C=CH(C(CH3)3)), 
124.8 (ArCH), 33.0 (C(CH3)3), 29.7 (CH3)3; HRMS (APPI, pos.): m/z 194.0699 (194.0691 calc. 
for C9H10N2O3 (M)
+), 195.0769 (195.0770 calc. for C9H11N2O3 (M+H)
+). 
(Z)-3-Diazo-5-((2,2-dimethylchroman-6-yl)methylene)furan-2,4(3H,5H)-dione (55): 
 
The reaction of 45 (200 mg, 1.59 mmol), 2,2-dimethylchroman-6-carbaldehyde (302 mg, 
1.59 mmol), TiCl4 (0.52 mL, 4.8 mmol) and 2,4,6-collidine (0.63 mL, 4.8 mmol) in CH2Cl2 (9 
mL) according to the general procedure provided, after purification by flash column 
chromatography on silica gel (hexanes/EtOAc, 4:1 to 7:3), 430 mg (91%) of 55 as a yellow-orange 
solid.  
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Rf = 0.46 (hexanes/EtOAc, 7:3); mp: 156-161 °C; IR (neat): 2979, 2926, 2163, 1774, 1702, 1641, 
1598, 1570, 1490, 1364, 1308, 1269, 1116, 1074, 1054, 948 cm-1; 1H NMR (300 MHz, CDCl3): δ 
7.53 (br s, 1H, ArH), 7.50 (dd, 1H, J = 8.3, 2.1 Hz, ArH), 6.81 (d, 1H, J = 8.3 Hz, ArH), 6.64 (s, 
1H, ArCH=C), 2.81 (t, 2H, J = 6.7 Hz, ArCH2CH2), 1.83 (t, 2H, J = 6.7 Hz, ArCH2CH2), 1.36 (s, 
6H, 2 × CH3); 
13C NMR (75 MHz, CDCl3): δ 174.6 (C=O), 160.6 (OC=O), 156.6 (ArCipso), 140.1 
(O-C=CHAr), 133.3 (ArC), 131.4 (ArC), 122.6 (ArCipso), 121.7 (ArCipso), 118.1 (ArC), 112.7 
(ArCH=C), 75.5 (Ar-O-C(CH3)2), 32.5 (ArCH2CH2), 26.9 (2 × CH3), 22.4 (ArCH2CH2); HRMS 
(ESI, pos.): m/z 298.0939 (298.0954 calc. for C16H14N2O4, (M)
+), 299.1012 (299.1032 calc. for 
C16H15N2O4, (M+H)
+) and 321.0827 (321.0851 calc. for C16H14N2NaO4, (M+Na)
+). 
(Z)-5-(4-((tert-Butyldimethylsilyl)oxy)-3-(3-methylbut-2-en-1-yl)benzylidene)-3-diazofuran-
2,4(3H,5H)-dione (56): 
 
The reaction of 45 (350 mg, 2.78 mmol), 4-((tert-butyldimethylsilyl)oxy)-3-(3-methylbut-
2-en-1-yl)benzaldehyde (846 mg, 2.78 mmol), TiCl4 (0.90 mL, 8.3 mmol) and 2,4,6-collidine (1.10 
mL, 8.33 mmol) in CH2Cl2 (12 mL) according to the general procedure provided, after purification 
by flash column chromatography on silica gel (hexanes/EtOAc, 19:1), 902 mg (79%) of 56 as a 
yellow solid. 
Rf = 0.63 (hexanes/EtOAc, 7:3); mp: 118-121 °C; IR (neat): 2961, 2929, 2858, 2137, 1782, 1708, 
1648, 1598, 1497, 1364, 1276, 1076, 931 cm-1; 1H NMR (300 MHz, CDCl3): δ 7.59 (dd, 1H, J = 
8.4, 2.3 Hz, ArH), 7.49 (d, 1H, J = 2.3 Hz, ArH), 6.82 (d, 1H, J = 8.4 Hz, ArH), 6.66 (s, 1H, 
ArCH=C), 5.24-5.33 (m, 1H, (CH3)2C=CH), 3.30 (d, 2H, J = 7.1 Hz, C=CHCH2), 1.77 (br d, 3H, 
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J = 1.0 Hz, CH3), 1.71 (br s, 3H, CH3), 1.02 (s, 9H, 3 × CH3), 0.27 (s, 6H, 2 × CH3); 
13C NMR (75 
MHz, CDCl3): δ 174.7 (C=O), 160.4 (OC=O), 156.0 (ArCipso), 140.4 (O-C=CHAr), 133.61 (ArC), 
133.57 (ArCipso or (CH3)2C=CH), 133.1 (ArCipso or (CH3)2C=CH), 130.6 (ArC or (CH3)2C=CH), 
123.9 (ArCipso or (CH3)2C=CH), 121.7 (ArC or ArCH=C), 118.9 (ArC or ArCH=C), 112.6 (ArC 
or ArCH=C), 28.4 (CH2), 25.7 (4 × CH3), 18.3 (Si-C(CH3)3), 17.9 (CH3), -4.1 (2 × SiCH3); HRMS 
(APPI, pos.): m/z 412.1827 (412.1818 calc. for C22H28N2O4Si, (M)
+) and 413.1859 (413.1897 calc. 
for C22H29N2O4Si, (M+H)
+). 
(Z)-5-(4-(Benzyloxy)-3-(3-methylbut-2-enyl)benzylidene)-3-diazofuran-2,4(3H,5H)-dione 
(57): 
 
The reaction of 45 (100 mg, 0.79 mmol), 4-(benzyloxy)-3-(3-methylbut-2-
enyl)benzaldehyde (222 mg, 0.79 mmol), TiCl4 (0.25 mL, 2.38 mmol) and 2,4,6-collidine (0.3 mL, 
2.38 mmol) in CH2Cl2 (5 mL) according to the general procedure provided, after purification by 
flash column chromatography on silica gel (hexanes/EtOAc, 9:1), 180 mg (60%) of 57 as a yellow 
solid. 
Rf = 0.25 (hexanes/EtOAc, 9:1); IR (neat): 2962, 2913, 2854, 2142, 1773, 1701, 1644, 1596, 1497, 
1463, 1453, 1419, 1359, 1283, 1079, 981 cm-1; 1H NMR (300 MHz, CDCl3): δ 7.65 (dd, 1H, J = 
8.6, 2.3 Hz, ArH), 7.55 (d, 1H, J = 2.3 Hz, ArH), 7.46-7.30 (m, 5H, ArH), 6.95 (d, 1H, J = 8.6 Hz, 
ArH), 6.66 (s, 1H, ArCH), 5.34-5.26 (m, 1H, CH2CH=C(CH3)2), 5.15 (s, 2H, CH2Ph), 3.40 (d, J 
= 7.4 Hz, CH2CH=C(CH3)2), 1.76 (d, 3H, J =  0.9 Hz, (CH3)), 1.67 (s, 3H, CH3). 
13C NMR (75 
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MHz, CDCl3): δ 174.8 (C=O), 160.6 (O-C=O), 158.5 (ArCipso), 140.5 (ArCipso), 136.7, (ArCipso or 
(CH3)2C=C), 133.6 (O-C=CHAr), 133.2 (ArH), 131.4 (ArCipso or (CH3)2C=C), 131.2 (ArH), 128.7 
(2 x ArC), 128.1 (ArC), 127.3 (2 x ArC), 123.7 (ArCipso), 121.8 ((CH3)2C=C), 112.6 (ArC), 112.0 
(Ar-CH), 70.0 (ArCH2), 28.7 (CH2), 25.9 (CH3), 18.0 (CH3); HRMS (APPI, pos.): m/z 388.1441 
(388.1423 calc. for C23H20N2O4 (M)
+), 389.1514 (389.1501 calc. for C23H21N2O4 (M+H)
+). 
General procedures for the insertion reactions of (Z)-5-arylidene/alkylidene-3-diazofuran-
2,4(3H,5H)-diones and arenes: 
To a suspension of (Z)-5-arylidene/alkylidene-3-diazofuran-2,4(3H,5H)-dione (1 equiv) in 
,-trifluorotoluene or DCE was added the aromatic compound (4 equiv) followed by the Rh(II) 
catalyst (1 mol%) at room temperature and the reaction mixture was placed in an oil bath that was 
pre-heated to 50 °C or to 100 °C. The mixture was heated until complete consumption of the diazo 
compound (TLC), then cooled to room temperature and concentrated. The residue was purified by 
flash chromatography on silica gel. 
(Z)-5-(4-(tert-Butyldimethylsilyloxy)-3-(3-methylbut-2-enyl)benzylidene)-3-(2,2-
dimethylchroman-6-yl)-4-hydroxyfuran-2(5H)-one (68): 
The reaction of (Z)-5-(4-(tert-butyldimethylsilyloxy)-3-(3-methylbut-2-
enyl)benzylidene)-3-diazofuran-2,4(3H,5H)-dione (56) (50 mg, 0.12 mmol), 2,2-
dimethylchromane (65, 78 mg, 0.48 mmol) Rh2(esp)2 (0.9 mg, 0.001 mmol) in DCE at reflux for 
2 h according to the general procedure provided, after purification of by flash column 
chromatography on silica gel (hexanes/EtOAc, 9:1), 39 mg (59%) of 68 as a yellow solid. 
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Rf = 0.19 (hexanes/EtOAc, 9:1); IR (neat): 2929, 2856, 1711, 1599, 1495, 1258, 1223, 1156, 1117, 
991, 935, 890 cm-1; 1H NMR (300 MHz, CDCl3): δ 7.64 (dd, 1H, J = 8.4, 2.1 Hz, ArH), 7.46 (d, 
1H, J = 2.0 Hz, ArH) 7.39 (br s, 1H, ArH), 7.34 (br dd, 1H, J = 8.4, 1.8 Hz, ArH), 6.84 (d, 1H, J 
= 8.4 Hz, ArH), 6.79 (d, 1H, J = 8.5 Hz, ArH), 6.71-6.54 (bs, 1H, OH), 6.26 (s, 1H, ArCH), 5.34-
5.25 (m, 1H, (CH3)2C=CH), 3.32 (d, 2H, J = 7.0 Hz, CH2CH=(CH3)2), 2.80 (t, 2H, J = 6.7 Hz, 
ArCH2CH2),  1.80 (t, 2H, J = 6.7  Hz, ArCH2CH2), 1.76 (s, 3H, CH=C(CH3)2), 1.71 (s, 3H, 
CH=C(CH3)2), 1.33 (s, 6H, O-C(CH3)2), 1.02 (s, 9H, C(CH3)3), 0.26 (s, 6H, Si(CH3)2). 
13C NMR 
(75 MHz, CDCl3): δ 169.1 (C=O or C=COH), 160.6 (C=O or C=COH), 154.8 (ArCipso), 154.3 
(ArCipso), 140.1 (O-C=CHAr), 133.1 (ArCipso or (CH3)2C=C), 132.9 (ArCipso or (CH3)2C=C), 132.7 
(ArC), 129.6 (ArC), 129.2 (ArCipso), 126.9 (ArC), 125.8 (ArC), 122.4 (ArCipso), 122.0 (ArCipso), 
119.9 ((CH3)2C=CH), 119.0 (ArC), 118.1 (ArC), 108.7 (Ar-CH), 103.1 (C=COH), 74.9 (O-
C(CH3)2), 32.8 (CH2), 28.7 (CH2), 27.0 ((O-C(CH3)2), 25.9 ((Si-C(CH3)3) and 1 × C=C(CH3)2), 
22.6 (CH3), 18.5 ((Si-C(CH3)3), 18.0 (1 × C=C(CH3)2), -4.0 (Si(CH3)2); HRMS (ESI, pos.): m/z 
546.2799 (546.2802 calc. for C33H42O5Si (M)
+) and 547.2872 (547.2880 calc. for C33H43O5Si 
(M+H)+) and 569.2690 (569.2699 calc. for C33H42NaO5Si (M+Na)
+).  
(Z)-3-(7-(tert-Butyldimethylsilyloxy)-2,2-dimethylchroman-6-yl)-5-(4-(tert-
butyldimethylsilyloxy)-3-(3-methylbut-2-enyl)benzylidene)-4-hydroxyfuran-2(5H)-one (72):  
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The reaction of (Z)-5-(4-(tert-butyldimethylsilyloxy)-3-(3-methylbut-2-
enyl)benzylidene)-3-diazofuran-2,4(3H,5H)-dione (56, 47 mg, 0.11 mmol), tert-butyl(2,2-
dimethylchroman-7-yloxy)dimethylsilane (71, 133 mg, 0.450 mmol), Rh2(esp)2 (0.8 mg, 0.001 
mmol) in DCE at reflux for 6 h according to the general procedure provided, after purification of 
by flash column chromatography on silica gel (hexanes/EtOAc, 9.7:0.3), 29 mg (38%, 43% based 
on recovered SM) of 72 as a yellow solid. 
Rf = 0.18 (hexanes/EtOAc, 9.7:0.3); IR (neat): 2955, 2929, 2857, 1753, 1611, 1600, 1495, 1471, 
1325, 1276, 1254, 1119, 1091, 837 cm-1; 1H NMR (300 MHz, CDCl3): δ 8.73 (s, 1H, OH), 7.68 
(dd, J = 8.5, 2.4 Hz, ArH), 7.60 (br s, 1H, ArH), 7.49 (d, 1H, J = 2.4 Hz, ArH), 6.83 (d, 1H, J = 
8.5 Hz, ArH), 6.39 (s, 1H, ArH), 6.27 (s, 1H, ArCH), 5.36-5.28 (m, 1H, (CH3)2C=CH), 3.33 (d, 
2H, J = 7.2 Hz, CH2CH=(CH3)2), 2.78 (t, 2H, J = 6.8 Hz, ArCH2CH2), 1.80 (t, 2H, J = 6.8 Hz, 
ArCH2CH2), 1.77 (s, 3H, CH=C(CH3)2), 1.73 (s, 3H, CH=C(CH3)2), 1.33 (s, 6H, C(CH3)2) 1.02 
(s, 9H, C(CH3)3), 0.96 (s, 9H, C(CH3)3), 0.26 (s, 6H, Si(CH3)2), 0.20 (s, 6H, Si(CH3)2); 
13C NMR 
(75 MHz, CDCl3): δ 168.7 (C=O or C=COH), 161.6 (C=O or C=COH), 154.9 (ArCipso), 154.5 
(ArCipso), 150.4 (ArCipso), 140.4 (O-C=CHAr), 133.1 (ArCipso or (CH3)2C=C) , 132.8 (ArCipso or 
(CH3)2C=C), 132.5 (ArC), 130.4 (ArC), 129.5 (ArC), 126.2 (ArCipso), 122.4 ((CH3)2C=C), 119.0 
(ArC), 116.7 (ArCipso), 113.3 (ArCipso), 109.2 (Ar-CH) , 107.8 (ArC) , 100.3 (C=COH), 75.1 
(C(CH3)2), 32.9 (CH2), 28.7 (CH2), 27.0 ((O-C(CH3)2), 25.9 (2 × (Si-C(CH3)3), 1 × C=C(CH3)2), 
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22.0 (CH2). 18.53 (Si-C(CH3)2), 18.48 (Si-C(CH3)2), 18.1 (1× C=C(CH3)2), -3.9 (Si(CH3)2), -4.2 
(Si(CH3)2); HRMS (APPI, pos.): m/z 676.3616 (676.3615 calc. for C39H56O6Si2 (M)
+) and 
677.3686 (677.3694 calc. for C39H57O6Si2 (M+H)
+). 
(Z)-5-(4-(tert-Butyldimethylsilyloxy)-3-methoxybenzylidene)-3-(4-(tert 
butyldimethylsilyloxy)phenyl)-4-hydroxyfuran-2(5H)-one (74): 
 
The reaction of (Z)-5-(4-(tert-butyldimethylsilyloxy)-3-methoxybenzylidene)-3-
diazofuran-2,4(3H,5H)-dione (53, 150 mg, 0.40 mmol), tert-butyldimethyl(phenoxy)silane (73, 
334 mg, 1.60 mmol), Rh2(esp)2 (3 mg, 0.004 mmol) in DCE at reflux for 3 h according to the 
general procedure provided, after purification of by flash column chromatography on silica gel 
(hexanes/EtOAc, 9.2:0.8), 29 mg (40%) of 74 as a yellow solid. 
Rf = 0.19 (hexanes/EtOAc, 9.2:0.8); IR (neat): 3012, 2950, 2927, 2884, 2855, 1693, 1658, 1627, 
1597, 1510, 1468, 1426, 1399, 1360, 1292, 1264, 1248, 1149, 1130, 967, 911 cm-1; 1H NMR (300 
MHz, DMSO-d6): δ 7.88-7.82 (m, 2H, ArH), 7.34 (d, 1H, J = 2.0 Hz, ArH), 7.25 (dd, 1H,  J = 8.4, 
2.0 Hz, ArH), 6.95-6.89 (m, 3H, ArH), 6.63 (s, 1H, ArCH), 3.82 (s, 3H, OCH3), 0.97 (s, 9H, Si-
C(CH3)3), 0.96 (s, 9H, Si-C(CH3)3), 0.21 (s, 6H, Si(CH3)2), 0.16 (s, 6H, Si(CH3)2). 
13C NMR (75 
MHz, DMSO-d6): δ 168.0 (C=O or C=COH), 162.6 (C=O or C=COH), 154.1 (ArCipso), 150.6 
(ArCipso), 145.3 (O-C=CHAr), 141.0 (ArCipso), 128.5 (2 × ArC), 126.8 (ArCipso), 123.7 (ArC), 
123.2 (ArCipso), 120.9 (ArC), 119.7 (2 × ArC), 113.7 (ArC), 107.4 (Ar-CH), 99.6 (C=COH), 55.4 
(OCH3), 25.6 (C(CH3)3), 25.5 (C(CH3)3), 18.2 (C(CH3)3), 18.0 (C(CH3)3), -4.5 (Si(CH3)2), -4.7 
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(Si(CH3)2); HRMS (ESI, pos.): m/z 554.2508 (554.2520 calc. for C30H42O6Si2 (M)
+), 555.2581 
(555.2598 calc. for C30H43O6Si2 (M+H)
+), 577.2400 (577.2418 calc. for  C30H42NaO6Si2 
(M+Na)+).  
(Z)-3-(5-Bromo-1H-indol-3-yl)-5-((2,2-dimethylchroman-6-yl)methylene)-4-hydroxyfuran-
2(5H)-one (75): 
 
The reaction of (Z)-3-diazo-5-((2,2-dimethylchroman-6-yl)methylene)furan-2,4(3H,5H)-
dione (55, 50 mg, 0.16 mmol), 5-bromoindole (131 mg, 0.67 mmol), Rh2(esp)2 (1.2 mg, 0.001 
mmol) in PhCF3 at 50 
oC for 24 h according to the general procedure provided, after purification 
by flash column chromatography on silica gel (hexanes/EtOAc, 1:1), 70 mg (90 %,) of 75 as a 
green solid. 
Rf = 0.2 (hexanes/EtOAc, 3:2); IR (neat): 3427, 2972, 2926, 1711, 1605, 1574, 1531, 1496, 1453, 
1295, 1264, 1254, 1153, 1116 cm-1; 1H NMR (500 MHz, DMSO-d6): δ 11.57 (s, 1H, OH), 8.22 (s, 
1H, ArH), 7.78 (s, 1H, ArH), 7.50-7.42 (m, 2H, ArH), 7.39 (d, 1H, J = 8.5 Hz, ArH), 7.24 (d, 1H, 
J = 8.5 Hz, ArH), 6.80 (s, 1H, J = 8.5 Hz, ArH), 6.47 (s, 1H, ArCH), 2.79 (br t, 2H, J = 6.8 Hz, 
CH2), 1.80 (br t, 2H, J = 6.8 Hz, CH2), 1.30 (s, 6H, (CH3)2); 
13C NMR (75 MHz, DMSO-d6): δ 
168.6 (C=O or C=COH), 161.5 (C=O or C=COH), 154.2 (ArCipso), 141.5 (O-C=CHAr), 134.7 
(ArCipso), 131.4 (ArC), 129.4 (ArC), 127.2 (ArCipso), 126.5 (ArC), 124.7 (ArCipso), 124.0 (ArC), 
123.8 (ArC), 121.4 (ArCipso), 117.4 (ArC), 113.6 (ArC), 111.4 (ArCipso), 106.2 (ArCH), 104.2 
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(C=COH), 96.7 (ArCipso), 74.9 (O-C(CH3)2), 32.0 (CH2), 26.6 (CH3)2, 21.8 (CH2); HRMS (ESI, 
pos.): m/z 465.0589 (465.0576 calc. for C24H20Br
79NO4 (M)
+), 466.0662 (467.0654 calc. for 
C24H21Br
79NO4 (M+H)
+), 468.0646 (469.0633 calc. for C24H21Br
81NO4 (M+H)
+), 488.0482 
(488.0473 calc. for C24H20
79BrNNaO4 (M+Na)
+), 490.0465 (491.0452 calc. for C24H20
81BrNNaO4 
(M+Na)+). 
General procedure for the deprotection of TBS ethers 68, 72, 74: 
To a solution of the TBS protected substrate in THF was added TBAF (1M in THF) at 0 
oC. The mixture was warmed to room temperature and stirred until consumption of the starting 
material (TLC). The solvent was removed under educed pressure, the residue suspended in water 
and the mixture was extracted with EtOAc. The combined organic layers were dried over 
anhydrous sodium sulphate and concentrated. The residue was purified by flash chromatography 
on silica gel. 
(Z)-3-(2,2-Dimethylchroman-6-yl)-4-hydroxy-5-(4-hydroxy-3-(3-methylbut-2-
enyl)benzylidene)furan-2(5H)-one (Aspulvinone B (6)):19 
 
The reaction of 68 (50 mg, 0.091 mmol) and TBAF (0.18 ml, 0.18 mmol) in THF (2 mL) 
according to the general procedure for 1 h. provided, after purification by flash column 
chromatography on silica gel (hexanes/EtOAc, 7.5:2.5, 1% AcOH), 22 mg (56%) of 6 as a yellow 
solid. 
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Rf = 0.23 (hexanes/EtOAc, 7.5:2.5, 1% vol AcOH); mp: 146-149 
oC; IR (neat): 3310 (br), 2973, 
2927, 1704, 1598, 1496, 1434, 1261, 1221, 1156, 1116, 989 cm-1; 1H NMR (300 MHz, DMSO-
d6): δ 9.87 (s, 1H, OH), 7.70-7.63 (m, 2H, ArH), 7.47-7.41 (m, 2H, ArH), 6.87 (d, 1H, J = 8.2, 
ArH), 6.75 (d, 1H, J = 8.5, ArH), 6.54 (s, 1H, ArCH) 5.29 (br t, 1H, J = 7.4 Hz, CH2CH=(CH3)2), 
3.24 (d, 2H, J = 7.4 Hz, CH2CH=(CH3)2), 2.76 (br t, 2H, J = 6.7 Hz, ArCH2CH2), 1.78 (br t, 2H, 
J = 6.7 Hz,  ArCH2CH2) 1.72 (s, 3H, CH=(CH3)2), 1.70 (s, 3H, CH=(CH3)2),  1.29 (s, 6H, C(CH3)2); 
13C NMR (75 MHz, DMSO-d6): δ 168.3 (C=O or C=COH), 162.6 (C=O or C=COH), 156.0 
(ArCipso), 152.6 (ArCipso), 140.1 (O-C=CHAr), 131.9 (ArCipso or (CH3)2C=C), 131.6 (ArC), 129.3 
(ArC), 128.2 (ArC), 128.0 (ArCipso or (CH3)2C=C), 126.2 (ArC), 123.9 (ArCipso), 122.4 
((CH3)2C=C), 121.6 (ArCipso), 120.5 (ArCipso), 116.5 (ArC), 115.4 (ArC), 107.5 (ArCH), 99.1 
(C=COH), 74.3 (O-C(CH3)2), 32.2 (CH2), 27.8 (CH2), 26.6 ((O-C(CH3)2), 25.5 (C=C(CH3)2), 22.0 
(CH2), 17.7 (C=C(CH3)2); HRMS (APPI, pos.): m/z 432.1929 (432.1937 calc. for C27H28O5 (M)
+), 
433.2001 (433.2015 calc. for C27H29O5 (M+H)
+).  
(Z)-4-Hydroxy-3-(7-hydroxy-2,2-dimethylchroman-6-yl)-5-(4-hydroxy-3-(3-methylbut-2-
enyl)benzylidene)furan-2(5H)-one (Aspulvinone D (7)):6,35 
 
The reaction of 72 (165 mg, 0.243 mmol) and TBAF (0.70 ml, 0.73 mmol) in THF (3 mL) 
according to the general procedure provided, after purification by flash column chromatography 
on silica gel (hexanes/EtOAc, 8.0:2.0, 1% AcOH), 90 mg (83%) of 7 as a yellow solid.  
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Rf = 0.20 (hexanes/EtOAc, 8.0:2.0, 1% vol AcOH); MP: 199-201 
oC (decomposed); IR (neat): 
3300 (br), 2973, 2925, 1696, 1662, 1589, 1505, 1425, 1344, 1276, 1229, 1157, 1090, 990 cm-1; 1H 
NMR (500 MHz, DMSO-d6): δ 9.81 (bs, 1H, OH), 7.47 (br d, 1H, J = 1.9 Hz, ArH), 7.45 (br dd, 
1H, J = 8.3, 1.9 Hz, ArH), 7.10 (s, 1H, ArH), 6.86 (d, 1H, J = 8.3 Hz, ArH), 6.27 (s, 1H, ArH or 
ArCH), 6.24 (s, 1H, ArCH or ArH), 5.29 (br t, 1H, J = 6.7 Hz, CH2CH=(CH3)2), 3.24 (d, 2H, J = 
6.7 Hz, CH2CH=(CH3)2), 2.64 (br t, 2H, J = 6.5 Hz, ArCH2CH2), 1.73 (t, 2H, J = 6.5 Hz, 
ArCH2CH2), 1.72 (s, 3H, CH=C(CH3)2), 1.70 (s, 3H, CH=C(CH3)2), 1.27 (s, 6H, C(CH3)2); 
13C 
NMR (75 MHz, DMSO-d6): δ 168.6 (C=O or C=COH), 163.3 (C=O or C=COH), 155.8 (ArCipso), 
154.1 (2 × ArCipso), 140.6 (O-C=CHAr), 131.8 (ArCipso or (CH3)2C=C), 131.6 (ArC), 130.7 (ArC), 
129.2 (ArC), 128.0 (ArCipso or (CH3)2C=C), 124.0 (ArCipso), 122.5 ((CH3)2C=C), 115.3 (ArC), 
111.6 (ArCipso), 108.7 (ArCipso), 106.1 (Ar-CH), 103.4 (ArC), 98.0 (C=COH), 74.1 (O-C(CH3)2), 
32.4 (CH2), 27.9 (CH2), 26.6 (C(CH3)2), 25.5 (C=C(CH3)2),  21.2 (CH2), 17.7 (C=C(CH3)2); 
HRMS (ESI, pos.): m/z 448.1890 (448.1886 calc. for C27H28O6 (M)
+), 449.1963 (449.1964 calc. 
for C27H29O6 (M+H)
+), 471.1778 (471.1784 calc. for C27H28NaO6 (M+Na)
+). 
(Z)-4-Hydroxy-5-(4-hydroxy-3-methoxybenzylidene)-3-(4-hydroxyphenyl)furan-2(5H)-one 
(Aspulvinone Q (2)):36 
 
The reaction of 74 (75 mg, 0.135 mmol) and TBAF (0.40 ml, 0.40 mmol) in THF (2 mL) 
according to the general procedure provided, after purification by flash column chromatography 
on silica gel (hexanes/EtOAc, 3:2 1% AcOH), 38 mg (86%) of 2 as a yellow solid. 
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Rf = 0.23 (hexanes/EtOAc, 3:2, 1% vol AcOH); mp: 223-225 oC; IR (neat): 3300 (br), 3129, 2931, 
1692, 1624, 1592, 1512, 1432, 1406, 1277, 1234, 1148, 1130, 1095 cm-1; 1H NMR (500 MHz, 
DMSO-d6): δ 9.49 (bs, 2H, OH), 7.80 (d, 2H, J = 8.7 Hz, ArH), 7.30 (s, 1H, ArH), 7.18 (dd, 1H, 
J = 8.1, 2.0 Hz,), 6.86 (d, 1H, J = 8.1 Hz, ArH), 6.80 (d, 2H, J = 8.7 Hz, ArH), 6.53 (br s, 1H, 
ArCH), 3.80 (s, 3H, OCH3). 
13C NMR (75 MHz, DMSO-d6): δ 168.6 (C=O or C=COH), 163.6 
(C=O or C=COH), 156.1 (ArCipso), 147.7 (ArCipso), 147.6 (ArCipso), 141.0 (O-C=CHAr), 128.1 
(2 × ArC), 124.6 (ArCipso), 124.0 (ArC), 121.5 (ArCipso), 115.9 (ArC), 115.0 (2 × ArC), 113.7 
(ArC), 106.7 (Ar-CH), 98.5 (C=COH), 55.6 (OCH3); HRMS (APPI, pos.): m/z 326.0781 
(326.0790 calc. for C18H14O6 (M)
+), 327.0853 (327.0869 calc. for C18H15O6 (M+H)
+). 
2,2-Dimethylchromane (65):37 
 
To a solution of phenol (1.00 g, 10.6 mmol) in dichloroethane (25 mL) was added isoprene 
(1.60 mL, 15.9 mmol) followed by triflic acid (5.0 µL, 5.3 × 10-2 mmol) at room temperature and 
the mixture was stirred for 3 h. The mixture was then concentrated, and the residue was directly 
purified by flash column chromatography on silica gel (hexanes) to provide 647 mg (38%) of 65 
as a colorless liquid. 
Rf = 0.21 (hexanes/EtOAc, 9.5:0.5); IR (neat): 2974, 2927, 1582, 1489, 1452, 1368, 1305, 1254, 
1219, 1155, 1121, 947 cm-1; 1H NMR (300 MHz, CDCl3): δ 7.12-7.01 (m, 2H, ArH), 6.82 (dd, 
1H, J = 7.3, 1.2 Hz, ArH), 6.77 (br d, 1H, J = 8.4 Hz, ArH), 2.77 (t, 2H, J = 6.7 Hz, ArCH2CH2), 
1.80 (t, 2H, J = 6.7 Hz, ArCH2CH2), 1.33 (s, 6H, 2 × CH3); 
13C NMR (75 MHz, CDCl3): δ 154.0 
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(ArCipso), 129.4 (ArC), 127.2 (ArC), 120.9 (ArCipso), 119.6 (ArC), 117.2 (ArC), 74.1 (Ar-O-
C(CH3)2), 32.8 (ArCH2CH2), 26.9 (2 × CH3), 22.5 (ArCH2CH2). 
tert-Butyl(2,2-dimethylchroman-7-yloxy)dimethylsilane (71): 
 
 
 
To a solution of 2,2-dimethylchroman-7-ol36 (650 mg, 3.65 mmol) in DMF (8 mL) was 
added imidazole (348 mg, 5.11 mmol) followed by TBSCl (715 mg, 4.74 mmol) at room 
temperature and the mixture was stirred for 2 h. Cold water (8 mL) was added and the resulting 
mixture was extracted with ethyl acetate (3 × 20 mL). The combined organic layers were washed 
with water (1 × 10 mL), brine, dried (Na2SO4) and concentrated under reduced pressure to provide 
850 mg (80%) of 71 as a colorless liquid. 
Rf = 0.6 (hexanes/EtOAc, 9:1); IR (neat): 2974, 2929, 2895, 2857, 1617, 1576, 1501, 1472, 1344, 
1307, 1281, 1253, 1168, 1149, 1120, 1106, 999, 836, 777 cm-1. 1H NMR (500 MHz, CDCl3): δ 
6.88 (d, 1H, J = 8.2 Hz, ArH), 6.33 (dd, 1H, J = 8.2, 2.4 Hz, ArH), 6.29 (d, 1H, J = 2.4 Hz, ArH), 
2.69 (t, 2H, J = 6.8 Hz, ArCH2CH2), 1.77 (t, 2H, J = 6.8 Hz, ArCH2CH2) 1.31 (s, 6H, 2 × CH3), 
0.97 (s, 9H, C(CH3)3), 0.18 (s, 6H, Si(CH3)2)). 
13C NMR (125 MHz, CDCl3): δ 155.2 (ArCipso), 
155.0 (ArCipso), 130.0 (ArC), 114.2 (ArCipso), 112.4 (ArC), 108.9 (ArC), 74.5 (Ar-O-C(CH3)2), 
33.4 (ArCH2CH2), 27.3 (2 × CH3), 26.1 (C(CH3)3), 22.3 (Si-C(CH3)3), 18.6 (ArCH2CH2), -4.0 
(Si(CH3)2). HRMS (APPI, pos.): m/z 292.1865 (292.1858 calc. for C17H28O2Si (M)
+) and 293.1944 
(239.1937 calc. for C17H29O2Si (M+H)
+). 
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4-((tert-Butyldimethylsilyl)oxy)-3-(3-methylbut-2-en-1-yl)benzaldehyde (67):32 
 
To a solution of 4-hydroxybenzaldehyde (10, 3.20 g, 26.5 mmol) in 10% aqueous 
potassium hydroxide (15 mL) was added prenyl bromide (5.50 mL, 47.6 mmol) dropwise over 10 
min at room temperature and the mixture was stirred for 45 h. The reaction mixture was then 
cooled to 0 °C and acidified to pH~3 with 2 N HCl. The resulting suspension was extracted with 
dichloromethane (3 × 30 mL). The combined organic layers were washed with brine, dried 
(Na2SO4) and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (hexanes/EtOAc, 9:1) to provide, 1.04 g (21%) of 4-hydroxy-3-(3-
methylbut-2-en-1-yl)benzaldehyde as a pale-yellow liquid 61. 
To a solution of 4-hydroxy-3-(3-methylbut-2-en-1-yl)benzaldehyde (61, 500 mg, 2.63 
mmol) in DMF (10 mL) was added imidazole (250 mg, 3.67 mmol) followed by TBSCl (515 mg, 
3.42 mmol) at room temperature and the mixture was stirred for 7 h. Cold water (8 mL) was added 
and the resulting mixture was extracted with dichloromethane (3 × 20 mL). The combined organic 
layers were washed with water (1 × 10 mL), brine, dried (Na2SO4) and concentrated under reduced 
pressure. The residue was purified by flash chromatography on silica gel (hexanes/EtOAc, 98:2) 
to provide 641 mg (80%) of 67 as a colorless liquid. 
Rf = 0.33 (hexanes/EtOAc, 9.5:0.5); IR (neat): 2956, 2930, 2858, 1693, 1598, 1493, 1256, 1110, 
1093 cm-1; 1H NMR (300 MHz, CDCl3): δ 9.85 (s, 1H, CO), 7.67 (d, 1H, J = 2.1 Hz, ArH), 7.62 
(dd, 1H, J = 8.2, 2.1 Hz, ArH), 6.88 (d, 1H, J = 8.2 Hz, ArH), 5.36-5.27 (m, 1H,  C=CH), 3.34 (d, 
1H, J = 7.5 Hz, CH2CH=C), 1.77 (br d, 3H, J = 0.9 Hz, CH3), 1.70 (s, 3H, CH3), 1.03 (s, 
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9H,C(CH3)3), 0.29 (s, 6H, Si(CH3)2); 
13C NMR (75 MHz, CDCl3): δ 191.2 (CHO), 159.3 (ArCipso), 
133.6 (ArCipso or C=C(CH3)2), 133.3 (ArCipso or C=C(CH3)2), 131.4 (ArC), 130.2 (ArCipso or 
C=C(CH3)2), 129.6 (ArC), 121.5 (ArC or HC=C(CH3)2), 118.4 (ArC and HC=C(CH3)2, or 2 × 
ArC), 28.4 (CH2), 25.8 (CH3), 25.7 (SiC(CH3)3), 18.3 (SiC(CH3)3), 17.9 (CH3), -4.1 (Si(CH3)2). 
4-(Benzyloxy)-3-(3-methylbut-2-en-1-yl)benzaldehyde (62): 
 
To a solution of 4-hydroxy-3-(3-methylbut-2-en-1-yl)benzaldehyde (61) (85 mg, 0.45 
mmol) in DMF (1 mL) was added K2CO3 (74 mg, 0.54 mmol) followed by benzyl bromide (64 
µL, 0.54 mmol) at room temperature and the mixture was stirred for 5 h. Cold water (2 mL) was 
added and the resulting mixture was extracted with dichloromethane (3 × 4 mL). The combined 
organic layers were washed with water (1 × 4 mL), brine, dried (Na2SO4) and concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel (hexanes/EtOAc, 
95:5) to provide 101 mg (81%) of 62 as colorless liquid. 
Rf = 0.32 (hexanes/EtOAc, 9:1); IR (neat): 2968, 2913, 2730, 1684, 1597, 1496, 1453, 1435, 1250, 
1112, 1005 cm-1; 1H NMR (500 MHz, CDCl3): δ 9.86 (s, 1H, CHO), 7.70 (s, 1H, ArH), 7.69 (dd 
(partial overlap with s at 7.70), 1H, J = 8.2, 2.2 Hz, ArH), 7.45-7.38 (m, 4H, ArH), 7.37-7.32 (m, 
1H, ArH) 6.99 (d, 1H, J = 8.2 Hz, ArH), 5.34-5.29 (m 1H, C=CH), 5.18 (s, 2H, PhCH2), 3.41 (d, 
1H, J = 7.3 Hz, CH2CH=), 1.75 (br s, 3H, CH3), 1.65 (s, 3H, CH3); 
13C NMR (75 MHz, CDCl3): 
δ 191.3 (CHO), 161.6 (ArCipso), 136.4 (ArCipso), 133.6 (ArCipso), 131.5 (ArCipso or C=C(CH3)2), 
130.65 (ArC), 130.63 (ArC), 129.9 (ArCipso or C=C(CH3)2), 128.8 (2 × ArC), 128.2 (ArC), 127.3 
(2 × ArC), 121.5 (HC=C(CH3)2), 111.3 (ArC), 70.3 (PhCH2), 28.7 (H2CHC=C), 25.9 (CH3), 17.9 
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(CH3); HRMS (ESI, pos.): m/z 280.1467 (280.1463 calc. for C19H20O2, (M)
+), 281.1535 (281.1542 
calc. for C19H21O2, (M+H)
+) and 303.1356 (303.1361 calc. for C19H20NaO2, (M+Na)
+). 
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3.8 Selected 1H and 13C NMR spectral data: 
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Chapter 4 
 
 
 
 
 
 
 
Organocatalytic Direct Vinylogous Aldol Reaction of Isatins with -Angelicalactone 
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4.1 Introduction 
The aldol reaction (Fig. 4.1) is one of the most powerful C-C bond forming reactions in 
synthetic organic chemistry. An extension of the aldol reaction, the vinylogous aldol reaction, has 
also been intensively investigated.1 Within the domain of vinylogous aldol reactions, the 
vinylogous Mukaiyama aldol (VMA) reaction employing silyloxy dienes has also been extensively 
investigated.2 In terms of atomic economy, the organocatalytic direct vinylogous aldol (ODVA) 
reaction, which uses unmodified aldehydes and ketones as nucleophiles, is the most attractive 
version. However, this strategy may be limited by the problems of regioselectivity associated with 
the dienolate nucleophiles. 
 
Figure 4.1 Various types of aldol reactions 
In recent years, the synthesis of 3-alkyl-3-hydroxy-2-oxindoles has received considerable 
attention because of their biological importance and the occurrence of these motifs in several 
bioactive indole derivatives3,4 (Figure 4.2). 
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Figure 4.2 Biologically active 3-alkyl-3-hydroxy-2-oxindoles 
In addition, 3-alkyl-3-hydroxy-2-oxindoles are potential precursors of spirocyclic indole 
derivatives (Figure 4.3) which are known pharmacophores with useful biological activities.5,6  
                      
Figure 4.3 Some examples of bioactive spirocyclic alkaloids 
The spirocyclic indole motif is found in numerous naturally occurring alkaloids and 
pharmaceutically active compounds and has been demonstrated to have a wide range of biological 
activities such as antitumor,7 antibacterial,8 analgesic9 or antitubercular10 activities (Figure 4.3). 
Given their utility as precursors of indole-based alkaloid motifs, the synthesis of functionalized 
3-hydroxy-2-oxindoles has attracted significant attention. In this context, the stereoselective 
addition of carbon nucleophiles, particularly -butyrolactone-derived enolates, to isatins has been 
thoroughly examined and, in recent years, the use of metal catalysts and organocatalysts (metal-
free organic catalysts) for the VMA reaction of isatin derivatives has also been demonstrated 
(Figure 4.4).11 Notably, the generation of two adjacent stereogenic centers in this reaction poses a 
stereochemical challenge.12 
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Figure 4.4 Vinylogous Mukaiyama aldol and vinylogous direct aldol reaction of isatins with 
-butyrolactone nucleophiles 
4.2 Objectives: 
Our objective was the development of an organocatalytic direct vinylogous aldol reaction 
of -angelicalactone 13 to isatins for the construction of 3-substituted 3-hydroxyindoles 14 (Figure 
4.5). The previously synthesized phosphoramide-aminothiourea catalysts (Chapter 1) as well as 
some new analogues of these catalysts were examined in these studies.  
 
Figure 4.5 Vinylogous direct aldol reaction of isatin with -angelicalactone 
We also envisioned the synthesis of spirocyclic indoles such as 16 (Figure 4.6) from the 
aldol products 14 via the intermediacy of the amino compounds 15. We anticipated that 
intramolecular ring opening of the lactone by the amine in 15 would provide 16. This approach 
could potentially lead to a method for the synthesis of bioactive indoles such as those shown in 
Figure 4.3. It may be noted that the conversion of 3-alkyl-3-hydroxy-2-oxindoles such as 14 to the 
corresponding 3-alkyl-3-amino-2-oxindoles 15 is well known,13 but a diastereoselective version 
of this reaction is not reported. 
 
Figure 4.6 Conversion of aldol adducts into spirocyclic core compounds 
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Since the objective of the present study was to develop a vinylogous aldol reaction of  
-angelicalactone and isatins, the following section provides a brief summary of the reported 
vinylogous aldol reactions of isatins. 
4.3 Previous reports on the aldol reactions of isatins and butenolide derivatives 
4.3.1 Diastereoselective vinylogous Mukaiyama aldol reaction by Meshram: 
 In 2011, Meshram and co-workers11a developed an efficient method to synthesize  
3-substituted 3-hydroxyindole which involves the Mukaiyama aldol reaction of  
2-(trimethylsilyloxy) furan 9 with various N-alkyl isatins 8 catalysed by Lewis acid. These 
reactions proceeded rapidly and provided an inseparable mixture of diastereomeric VMA products 
17 and 18 in high yields (82-93%) and with good diastereoselectivity (anti/syn up to 95:5). 
  
Scheme 4.01 
4.3.2 Diastereoselective vinylogous Mukaiyama aldol reaction by Kong: 
 In 2014, Kong and co-workers11b achieved the diastereoselective formation of  
-hydroxyalkyl butenolide oxindoles 17 and 18 via a vinylogous Mukaiyama aldol reaction of 
various N-alkyl isatins 8 with 2-(trimethylsilyloxy) furan 9 by using quinine as the catalyst. The 
reaction worked well and afforded an inseparable mixture of VMA products in good yields (83-
94%) with high diastereoselectivities (anti/syn ratio up to 96:4).  
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Scheme 4.02 
4.3.3 A direct vinylogous Aldol reaction by Meshram and co-workers: 
 In 2017, Meshram and co-workers14 developed the first direct vinylogous aldol reaction of 
furan-2(3H)-one 19 with isatins 8 by using DABCO as an organocatalyst at room temperature. The 
synthetic protocol is atom-economical and provides easy access to a variety of oxindole derivatives 
20 in high yield (86-97%) and with excellent diastereoselectivity (dr ratio up to 99:1). The 
stereochemistry of the major diastereomer (anti or syn) was not defined in this study.  
 
Scheme 4.03 
4.3.4 Catalytic asymmetric direct vinylogous Aldol reaction by Feng and co-workers 
 Recently, Feng and co-workers15 developed a highly diastereo- and enantioselective direct 
vinylogous aldol reaction of , -unsaturated butenolides 21 with isatins 8 by using an efficient  
L-PrPr2-Sc(OTf)3 complex as the catalyst. A range of chiral -hydroxy -disubstituted butenolide 
carbonyl derivatives with adjacent stereocenters were obtained in high yields (71-90%) and with 
good diastereoselectivity (anti/syn = 5.7:1-19:1) and enantioselectivity.  
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Scheme 4.04 
As discussed above, there are only a few reported examples of vinylogous aldol reactions 
with isatins and most of these methods have some limitations. For example, the use of  
2-(trimethylsilyloxy) furan 2 in Mukaiyama aldol rection11 is not convenient since it has to be 
prepared separately and it gradually decomposes upon storage. Although this issue is avoided in 
the synthesis by Meshram which uses the direct vinylogous aldol reaction, an enantioselective 
version of this reaction is more desirable. The Feng15 protocol is enantioselective, but it involves 
metal-based catalysts. Notably, there are no reports on the enantioselective organocatalytic direct 
vinylogous aldol reaction of -angelicalactone 13 with isatins. 
4.4 Results and discussions: 
In initial studies, the phosphoramide-aminothiourea catalysts (Figure 4.7, I and II, 
described in Chapter 1 of this thesis) were examined in the organocatalytic direct vinylogous aldol 
reaction of -angelicalactone 13 with isatins.  
 
Figure 4.7 Chiral phosphoramide-aminothiourea catalysts examined for the vinylogous aldol 
reaction 
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 The vinylogous aldol reaction of -angelicalactone 13 with N-methylisatin 23 was selected 
as the model reaction for optimisation studies. Firstly, phosphoramide catalyst I (10 mol%) was 
examined in toluene at room temperature (Table 4.1). Although I did promote the reaction, the 
required products 26 were obtained as an inseparable mixture of diastereomers in only 17% yield. 
In addition, the diastereoselectivity and the enantioselectivity of the reaction was moderate (Table 
4.1, entry 1). An increase in diastereoselectivity and enantioselectivity was observed when catalyst 
II was employed (entry 2 Table 4.1).  
Table 4.1 Asymmetric Vinylogous Aldol Reaction of -Angelica lactone 13 and Isatin 
 
Entrya Isatin Catalyst Time syn/anti b 
 
Yield (%) Product syn  
ee (%)c 
1 23 I 12 h 3.7:1 17 26 14 
2 23 II 7 h 5.9:1 17 26 57 
3 24 II 7 h 4.8:1 21 27 35 
4 25 II 12 h 3.8:1 13 28 - 
5 23 II 26 h 6.6:1 15d 26 50 
6 23 II 24 h 4.3:1 7e 26 45 
7 23 II 6h 12.5:1 16f 26 50 
a 1.5 equiv. of -angelicalactone. b Determined by 1H NMR. c Determined by chiral HPLC. d reaction at 0 oC. e 4 Å 
MS. f 3 equiv. of butenolide   
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The reaction of N-benzyl isatin 24 with -angelicalactone 13 in the presence of catalyst II 
afforded a diastereomeric mixture of the required products 27 in 21% yield and 35% ee (entry 3, 
Table 4.1). The reaction of isatin 25, lacking the N-alkyl group, was also investigated but the 
diastereoselectivity as well as the yield was not good and hence the enantioselectivity of the 
reaction was not determined (entry 4, Table 4.1). These initial results suggested that catalyst II 
performs better than catalyst I. Further optimization studies were therefore conducted with II. The 
reaction of N-methyl isatin 23 with -angelicalactone 13 was conducted at 0 oC but failed to 
improve the yield as well as the enantioselectivity of the reaction, although a small increment in 
the diastereoselectivity was observed (compare entries 2 and 5, Table 4.1). The use of molecular 
sieves was detrimental to the reaction and 26 was obtained in only 7% yield (entry 6, Table 4.1). 
A significant increase in the diastereoselectivity (syn/anti 12.5:1) was observed when the amount 
of -angelicalactone 15 was increased to a 3-fold excess with respect to isatin (entry 7, Table 4.1). 
Low to moderate enantioselectivities were obtained with both the catalysts and the highest 
enantioselectivity was observed with catalyst II. These results are summarized in Table 4.1. The 
absolute configuration of the major diastereomer 26 was determined to be (3S,2’R) by X-ray 
crystallographic analysis. The absolute configuration of the minor diastereomer was not 
determined in this study. 
                      
Figure 4.8. X-ray crystal structure of major (syn) diastereomer 26 
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 From the above results, it was observed that the best result was obtained with catalyst II. 
Based on these results, a solvent survey was conducted for the vinylogous aldol reaction of 13 with 
isatin 23 (Table 4.2). The reaction proceeded smoothly in most of the solvents examined, and the 
expected aldol products were obtained as an inseparable mixture of diastereomers with 26 as the 
major product.  
Table 4.2 Solvent Survey for Organocatalytic Direct Vinylogous Aldol Reaction of N-methyl 
Isatin 23 and -Angelicalactone 13 
 
Entrya Solvent Time syn/antib Yield (%) Product syn ee (%)c 
1 DMF 9 h 1.5:1 21 26 23 
2 DMSO 9 h 1.1:1 32 26 16 
3 CF3CH2OH 3 h 1.4:1 12  26 4 
4 THF 9 h 16:1 10 26 52 
5 CF3Ph 6 h 10:1 17 26 60 
6 DME 8 h 5:1 13 26 67 
7 CHCl3 7 h 6.6:1 11 26 43 
8 DCM 8h 5:1 18 26 47 
9 DCE 8 h 5:1 17 26 47 
10 CH3CN 6 h 2.4:1 15 26 43 
11 EtOAc 6 h 6.3:1 17 26 46 
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12 H2O 12 h 1:1 - 26 - 
13 Et2O 19 h 20:1 25 26 77 
14 MTBE 48 h 20:1 15 26 56 
a 1.5 equiv. of -angelicalactone. b Determined by 1H NMR. c Determined by chiral HPLC. 
Overall, catalyst II provided moderate to good enantioselectivities for the major product 26, except 
in DMF, DMSO and trifluoroethanol (entries 1-3, Table 4.2). Trifluorotoluene, THF and DME 
emerged as promising solvents, in terms of enantioselectivity, but the low diastereoselectivity in 
DME precluded further studies in this solvent (entries 4-6, Table 4.2). Nonetheless, the yield of 26 
in THF (10%), trifluorotoluene (17%) and in DME (13%) was low. Moderate enantioselectivities 
and low yields for 26 were also observed in chlorinated solvents (entries 7-9, Table 4.2). In 
comparison, much better results were obtained in ethereal solvents like MTBE and diethyl ether 
(entries 13 and 14, Table 4.2). Since the results with diethyl ether were better than those with DME 
with respect to both yield (25%) and enantioselectivity (77%), it was the solvent of choice for 
further investigations. 
 Based on the results in Table 4.1 and 4.2, the phosphoramide catalyst II bearing a chiral 
cyclohexane diamine-derived phosphoramide functionality and a stilbene diamine-derived basic 
functionality on the thiocarbonyl moiety was the most promising. In order to improve the 
enantioselectivity and yield of the vinylogous aldol reaction, we turned our focus to the synthesis 
of analogues of II in which the N-alkyl group in the cyclohexanediamine portion was  
2-naphthylmethyl (IV) or neopentyl (III). In order to examine the effect of changing the tertiary 
amine functionality, catalysts incorporating a piperidinyl (V) and a pyrrolidinyl (VI) moiety were 
also prepared. These newly synthesized catalysts are shown in Figure 4.9.  
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Figure 4.9 Phosphoramide-thiourea organocatalysts used for direct vinylogous aldol reaction 
The synthesis of the phosphoramide-thiourea catalysts (III-VI) began with the preparation 
of the requisite starting materials. Reductive amination16 of the respective aromatic or aliphatic 
aldehyde with 29 afforded (1S,2S)-N,N’-diaryl/dialkyl cyclohexane-1,2-diamines 30-32 which on 
condensation with phosphorous oxychloride furnished bisamidophosphoryl compounds 33-35. 
Treatment of 33-35 with potassium isothiocyanate17 afforded the key intermediates 36-38 (Scheme 
4.05). 
 
Scheme 4.05 
Simultaneously, (1S,2S)-N,N-dimethyl-1,2-diphenylethane-1,2-diamine 4218 was prepared 
according to the procedure described in Chapter 1 of this thesis (see page 16). The intermediates 
(1S,2S)-1,2-diphenyl-2-(piperidin-1-yl)ethanamine  44 and (1S,2S)-1,2-diphenyl-2-(piperidin-1-
yl)ethanamine 46 were prepared according to the literature procedure.19 The protection of (1S,2S)-
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1,2-diphenylethane-1,2-diamine 39 with phthalic anhydride produced the mono-phthalimido 
derivative 40. Dimethylation of 40 followed by removal of the imide functionality with hydrazine 
hydrate afforded 42. Alternatively, 43 (60%) and 45 (68%) were obtained by the reaction of 40 
with 1,5-diiodopentane and 1,4-diiodopentane respectively in the presence of potassium carbonate 
in refluxing acetonitrile (Scheme 4.06).  
 
Scheme 4.06 
Removal of the imide functionality in 43 and 45 with hydrazine hydrate afforded diamine 44 (92%) 
and the diamine 46 (96%), respectively. The coupling of the intermediates 42, 44, and 46 with the 
respective isothiocyanate (36-38) afforded catalysts III-VI in excellent yields (Scheme 4.07) 
 
Scheme 4.07  
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With the catalysts III-VI in hand, studies aimed at identifying the optimal catalyst, were 
conducted in diethyl ether. The results obtained from this catalyst survey are summarized in Table 
4.3. 
Table 4.3 Catalysts Screening for Asymmetric Vinylogous Aldol Reaction 
 
 
Entry Isatin Catalyst Time syn/antia Yield 
(%) 
Product syn 
ee (%)b 
1 23 III 48 h Single 
diastereomer 
25 26 43 
2 23 IV 48 h 20:1 20c 26 72 
3 23 V 48 h 8.3:1 20c 26 65 
4 23 VI 48 h 20:1 19 26 73 
5 23 VII 16 h 5:1 20 26 44 
6 23 VIII 16 h 3.2:1 17 26 6 
7 45 II 48 h 2.4:1 21 47 nd 
8 46 II 12 h - 13 48 nd 
a Determined by 1H NMR. b Determined by chiral HPLC. c 20 mol % Catalyst. nd not determined. 
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 Exclusive formation of major diastereomer 26 was observed when catalyst III was 
employed in the direct vinylogous aldol reaction, but 26 was obtained in only 25% yield and with 
43% enantiomeric excess. Interestingly, the use of catalyst IV (N-2-naphthylmethyl) afforded the 
required product with higher enantiomeric excess (72%), but the yield remained low (20%). 
(entries 1 and 2, Table 4.3). Incorporation of a piperidine (catalyst V) or a pyrrolidine (catalyst VI) 
as a basic unit did not improve the yield or the enantioselectivity of the reaction (entries 3 and 4, 
Table 4.3). The use of N-Boc isatin (45) or N-Cbz isatin (46) was not beneficial. The 
enantioselectivity of both the reactions was not determined due to the low diastereomeric ratio of 
the products 47 and 48, respectively (entries 7 and 8, Table 4.3). The use of previously synthesized 
“switched” phosphoramide catalysts such as VII and VIII, in which the phosphoramide portion 
was derived from stilbenediamine, was not helpful and the level of stereoselection (average dr = 
4:1) was lower than that obtained with phosphoramide catalysts (entries 5 and 6, Table 4.3).  
A direct comparison of catalyst II to the well-known, commercially available, 
aminothiourea catalyst IX (the Takemoto catalyst) in the direct vinylogous aldol reaction of  
N-methyl isatin 23 and -angelicalactone 13 was also carried out. As mentioned before, the 
phosphoramide catalyst II afforded the required aldol products with excellent diastereoselectivity 
and moderate enantioselectivity of the major diastereomer 26 at ambient temperature in diethyl 
ether as a solvent (entry 1, Table 4.2). This observation prompted us to conduct the reaction at 
lower temperature. Unfortunately, cooling the reaction mixture was not beneficial (entry 2, Table 
4.4). In comparison, the same reaction in the presence of Takemoto catalyst IX afforded a mixture 
of products with opposite diastereoselectivity compared to the diastereoselectivity observed with 
catalyst II. 
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Table 4.4 Comparison of the Takemoto catalyst (IX) and the Aminophosphoramide catalyst (II) 
 
Entrya Temp Catalyst Time syn/antib Yield 
(%) 
Product ee (%)c 
1 rt II 19 h 20:1 25 26 77 
2 0 oC II 3 d 5:1 12 26 67 
3 rt IX 30 min 1:2.6 23 49 3 
4 0 oC IX 30 h 1:8.3 23 49 4 
 a 1.5 equiv. of a-angelicalactone. b Determined by 1H NMR. c Determined by chiral HPLC. 
It was also observed that the use of Takemoto catalyst IX was not beneficial either at ambient 
temperature or at 0 oC, and the enantiomeric excess of 26 was negligible (entries 3 and 4, Table 
4.4). These results suggest that, for the described reaction, catalyst II is much superior than the 
Takemoto catalyst (IX). 
A plausible transition state assembly that explains the observed stereochemical outcome of 
the reaction is shown in Figure 4.10. It is reasonable to assume hydrogen bonding of the phosphoryl 
N-H functionality in II with N-methyl isatin 23, and an ionic interaction of the deprotonated  
-angelica lactone and the resultant ammonium functionality in II (Figure 4.10). In the 
arrangement shown, the re face of the ketone in the isatin is shielded by the N-benzyl group in the 
catalyst. Reaction of the si face of -angelicalactone and the si face of the ketone leads to 3S,2’R-
26 as the major product. 
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Figure 4.10 Proposed transition state assembly for the formation of 26 
4.6 Conclusion: 
In summary, we have successfully developed an organocatalytic direct vinylogous aldol 
reaction of natural -angelica lactone 13 with isatins by employing a novel series of 
phosphoramide-aminothiourea catalysts and a plausible transition state has been proposed to 
explain the origin of the asymmetric induction. Results of the direct vinylogous aldol reaction are 
promising and future efforts will focus on improving the yield and the enantioselectivity of the 
reaction. These studies are ongoing in the Pansare group. 
 
4.6 Experimental Section: 
General procedure for the vinylogous aldol reaction of -angelicalactone 13 with N-methyl 
isatin 23: 
To the solution of catalyst (10 mol%) in a diethyl ether (1 mL), were added -
angelicalactone (1 mmol) and N-alkyl isatin (1.5 mmol) at room temperature and the mixture was 
stirred at ambient temperature for specific period. After completion, reaction mixture was 
concentrated and purified by flash column chromatography on silica gel (EtOAc/Hexanes) to 
provide the inseparable mixture of aldol addition products. 
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(S)-3-Hydroxy-1-methyl-3-((R)-2-methyl-5-oxo-2,5-dihydrofuran-2-yl)indolin-2-one (26): 
 
The reaction of N-methyl isatin 23 (40 mg, 0.2 mmol), -angelicalactone 13 (33 µL, 0.3 
mmol) in the presence of phosphoramide catalyst II (16 mg, 0.02 mmol) in Et2O (1mL) for 19 h 
according to the general procedure provided, after purification by flash column chromatography 
on silica gel (hexanes/EtOAc, 4:2), 30 mg (25%) of 26 as a light yellow solid. 
IR (neat): 3407, 3364, 3077, 2923, 2853, 1754, 1706, 1609, 1495, 1467, 1364, 1295, 1254, 1204, 
1164, 1116, 1088, 1047, 951, 906, 866, 824, 751 cm-1. 1H NMR (300 MHz, CDCl3) δ 7.45 (ddd, 
1H, J = 7.6, 1.4, 0.6 Hz, ArH), 7.39-7.31 (m, 2H, ArH  and CH=CHCO), 7.09 (td, 1H, J = 7.6, 0.9 
Hz, ArH), 6.83 (d, 1H, J = 7.8 Hz, ArH), 5.94 (d, 1H, J = 5.7 Hz, CH=CHCO), 3.19 (s, 3H, NCH3), 
1.71 (s, 3H, CH3). 
13C NMR (75 MHz, CDCl3) δ 174.6 (O-,C=O), 171.9 (N-CO), 156.3 (C=C-
CO), 143.6 (ArC ipso), 130.8 (ArC), 126.5 (ArC ipso),125.7 (ArC), 123.6 (ArC), 122.9 (ArC), 
108.9 (C=C-CO), 90.4 (C-OH), 79.0 (CH3CO), 26.6 (NCH3), 18.3 (CH3). HRMS (APPI, pos.): 
m/z 259.0847 (259.0844 calc. for C14H13NO4 (M)
+) and 260.0920 (260.0923 calc. for C14H14NO4 
(M+H)+). HPLC: Chiralpak IA (hexane/i-PrOH, 90/10, flow rate 1 mL min−1, λ= 247 nm): tmajor = 
19.46 min., tminor = 22.42 min., 77% ee. 
(S)-1-Benzyl-3-hydroxy-3-((R)-2-methyl-5-oxo-2,5-dihydrofuran-2-yl)indolin-2-one (27): 
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The reaction of N-benzyl isatin 24 (40 mg, 0.2 mmol), -angelicalactone 13  (29 µL, 0.3 
mmol) in the presence of  phosphoramide catalyst II (14 mg, 0.02 mmol) in Et2O (1mL) for 22 h 
according to the general procedure provided, after purification by flash column chromatography 
on silica gel (hexanes/EtOAc, 8:2), 20 mg (21%) of 27 as a light yellow solid. 
IR (neat): 3414, 3074, 2985, 2925, 2855, 1756, 1696, 1608, 1489, 1466, 1449, 1373, 1351, 1222, 
1120, 1078, 1052, 1025, 959, 911, 866, 824, 755, 737, 698 cm-1. 1H NMR (300 MHz, CDCl3) δ 
7.46 (ddd, 1H, J = 7.5, 1.3, 0.6 Hz, ArH), 7.38-7.27 (m, 6H, ArH  and CH=CHCO), 7.26-7.22(m, 
1H, ArH), 7.06 (td, 1H, J = 7.5, 1.0 Hz, ArH), 6.76 (d, 1H, J = 7.8 Hz, ArH), 5.95 (d, 1H, J = 5.8 
Hz, CHCO), 5.03 (d, 1H, J = 15.6 Hz, CH2Ph), 4.72 (d, 1H, J = 15.6 Hz, CH2Ph), (3.07 (s, 1H, 
OH), 1.74 (s, 3H, CH3). 
13C NMR (75 MHz, CDCl3) δ 174.5 (O-C=O), 171.6 (N-CO), 156.1 (C=C-
CO), 142.8 (ArC ipso), 135.0 (ArC ipso), 130.6 (ArC), 129.0 (2 x ArC), 128.0 (ArC), 127.3 (2 x 
ArC), 126.4 (ArC ipso), 125.7 (ArC), 123.4 (ArC), 122.7 (ArC), 109.8 (C=C-CO), 90.2 (C-OH), 
78.8 (CH3CO), 44.2 (CH2Ph), 18.3 (CH3). HRMS (APPI, pos.): m/z 335.1156 (335.1158 calc. for 
C20H17NO4 (M)
+) and 336.1229 (336.1236 calc. for C20H18NO4 (M+H)
+). 
General procedure for the synthesis of phosphoryl chlorides 33 and 35: 
To a solution of the diamine in methylene dichloride, was added phosphorous oxychloride. 
Triethylamine was added dropwise to the reaction mixture at 0 oC and the reaction mixture was 
stirred at room temperature for 24 h. The reaction mixture was then concentrated, and the residue 
was purified by flash column chromatography on silica gel to the provide phosphoryl chloride. 
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(3aS,7aS)-2-Chloro-1,3-dineopentyloctahydro-1H-benzo[d][1,3,2]diazaphosphole 2-oxide 
(33): 
 
The reaction of 30 (1.95 mg, 7.66 mmol), POCl3 (1.02 ml, 10.7 mmol) and TEA (2.7 ml, 
18.4 mmol) in dichloromethane (20 ml), according to the general procedure provided, after 
purification by flash column chromatography on silica gel, 2.07 gm (81%) of 33 as a colorless 
gum; Rf  = 0.21 (hexanes/EtOAc, 9:1). 
IR (neat): 2950, 2866, 1475, 1400, 1365, 1327, 1270, 1168, 1124, 1102, 1073, 1020, 843, 800, 
749, 665, 614, 542, 520 cm -1; 1H NMR (300 MHz, CDCl3): δ 3.13 (dd, 1H, J = 13.9, 12.8 Hz, 
CH2C(CH3)3), 2.88-2.73 (m, 2H, CH2C(CH3)3 and CH2CHN), 2.62-2.50 (m, 1H, CH2CHN), 2.28 
(dd, 1H, J = 20.2, 14.6 Hz, CH2C(CH3)3), 2.21 (dd, 1H, J = 15.3, 14.6, Hz, CH2C(CH3)3), 1.93-
1.80 (m, 2H, CH2), 1.76-1.62 (m, 2H, CH2), 1.25-1.05 (m, 4H, CH2), 0.83 (s, 9H, C(CH3)3), 0.81 
(s, 9H, C(CH3)3; 
13C NMR (75 MHz, CDCl3): δ 65.5 (d, 
2JCP = 9.6 Hz, CH2CHN), 62.7 (
2JCP = 
11.5 Hz, CH2CHN), 56.5 (d, 
2JCP = 2.2 Hz, CH2C(CH3)3), 55.0 (CH2C(CH3)3), 32.2 (d, 
3JCP = 0.4 
Hz, C(CH3)3), 31.2 (d, 
3JCP = 3.4 Hz, C(CH3)3), 29.9 (d, 
3JCP = 7.8 Hz, CH2), 29.8 (d, 
3JCP = 14.0 
Hz, CH2), 27.97 (C(CH3))3 , 27.90 (C(CH3))3  24.2 (d, 
4JCP = 0.6 Hz, CH2), 23.9 (d, 
4JCP = 1.8 Hz, 
CH2); HRMS (APPI, pos.): m/z 334.1928 (334.1941 calc. for C16H32ClN2OP (M)
+), 335.2000 
(335.2019 calc. for C16H33ClN2OP (M+H)
+). 
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(3aS,7aS)-2-Chloro-1,3-bis(naphthalen-2-ylmethyl)octahydro-1H-
benzo[d][1,3,2]diazaphosphole 2-oxide (35): 
 
The reaction of 32 (1.00 g, 2.53 mmol), Et3N (0.80 ml, 5.82 mmol) and POCl3 (0.34 mL, 
3.54 mmol) according to the general procedure provided, after purification by flash column 
chromatography on silica gel, 500 mg (42%) of 35 as a colorless gum; Rf  = 0.23 (hexanes/EtOAc, 
8:2). 
Mp: 192.1-193.3 oC; IR (neat): 3055, 2923, 2855, 1600, 1508, 1431, 1349, 1293, 1258, 1220, 
1189, 1139, 1108, 1078, 1054, 957, 919, 899, 850, 812, 785, 767, 745, 722 cm -1; 1H NMR (300 
MHz, CDCl3): δ 7.90-7.78 (m, 8H, ArH), 7.66 (dd, 1H, J = 8.5, 1.3 Hz, ArH), 7.58 (dd, 1H, J = 
8.4, 0.9 Hz, ArH), 7.52-7.41 (m, 4H, ArH), 4.71 (t, 1H, J = 15.0 Hz, NCH2), 4.64 (t, 1H, J = 15.0 
Hz, NCH2), 4.39 (dd, 1H, J = 15.8, 10.4 Hz, NCH2), 3.91 (dd, 1H, J = 15.8, 6.9 Hz, NCH2), 3.10-
2.92 (m, 2H, CHN), 1.84-1.74 (m, 1H, CH2), 1.72-1.63 (m, 1H, CH2), 1.62-1.49 (m, 2H, CH2), 
1.22-0.82 (m, 4H, CH2); 
13C NMR (75 MHz, CDCl3): δ 135.7 (d, 
3JCP = 10.2 Hz, ArCipso), 135.2 
(d, 3JCP = 3.8 Hz, ArCipso), 133.3 (ArCipso) 133.2 (ArCipso), 132.9 (2 x ArCipso), 128.4 (ArC), 128.2 
(ArC), 127.83 (ArC), 127.78 (ArC), 127.7 (2 x ArC), 126.6 (ArC), 126.3 (ArC), 126.17 (ArC), 
126.15 (ArC), 126.1 (ArC), 126.0 (ArC), 125.9 (ArC), 125.8 (ArC), 64.6 (d, 2JCP = 10.4 Hz, 
CH2CHN), 63.3 (d, 
2JCP = 18.5 Hz, CH2CHN), 47.9 (d, 
2JCP = 2.7 Hz, -NCH2), 46.9 (d, 
2JCP = 4.5 
Hz, -NCH2), 29.3 (d, 
3JCP = 12.5 Hz, CH2), 29.1 (d, 
3JCP = 7.6 Hz, CH2), 24.1 (d, 
4JCP = 0.8 Hz, 
CH2), 23.8 (d, 
4JCP = 1.7 Hz, CH2); HRMS (APPI, pos.): m/z 474.1647 (474.1628 calc. for 
C28H28ClN2OP (M)
+), 475.1718 (475.1706 calc. for C28H29ClN2OP (M+H)
+). 
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General procedure for the synthesis of isothiocyante intermediates 36 and 38:  
To a solution of diaminophosphoryl chloride in dry CH3CN was added 
tetrabutylammonium thiocyanate or potassium thiocyanate. The solution was heated to reflux for 
indicated time and then cooled to room temperature and concentrated under reduced pressure. The 
residue was purified by flash column chromatography on silica gel to provide corresponding 
isothiocyanate.  
(3aS,7aS)-2-Isothiocyanato-1,3-dineopentyloctahydro-1H-benzo[d][1,3,2]diazaphosphole 2-
oxide (36): 
 
To a solution of phosphoryl chloride 33 (300 mg, 0.89 mmol) in dry CH3CN was added 
potassium thiocyanate (174 mg, 1.79 mmol), the solution was heated to reflux for 3 h and then 
cooled to room temperature and concentrated under reduced pressure. The residue was purified by 
flash chromatography on silica gel to provide 245 mg (77%) of isothiocyanate 36 as white solid; 
Rf  = 0.22 (hexanes/EtOAc, 9:1). 
IR (neat): 2942, 2863, 2023, 1476, 1445, 1363, 1328, 1274, 1167, 1125, 1100, 1071, 1016, 935, 
842, 802, 765, 745, 617, 566, 502 cm -1;1H NMR (300 MHz, CDCl3): δ 3.32 (t, 1H, J = 14.1 Hz, 
CH2C(CH3)3), 2.86 (dd, 1H, J = 18.2, 14.1 Hz, CH2C(CH3)3), 2.85-2.76 (m, 1H, CH2CHN), 2.75-
2.65 (m, 1H, CH2CHN), 2.45 (dd, 1H, J = 16.2, 14.5 Hz, CH2C(CH3)3), 2.34 (dd, 1H, J = 19.3, 
14.5 Hz, CH2C(CH3)3), 2.05 - 1.95 (m, 2H, CH2), 1.90-1.78 (m, 2H, CH2), 1.36-1.22 (m, 4H, CH2), 
0.96 (s, 9H, C(CH3)3), 0.95(s, 9H, C(CH3)3); 
13C NMR (75 MHz, CDCl3): δ 141.4 (C=S), 65.8 (d, 
2JCP = 10.2 Hz, CH2CHN), 63.1 (d, 
2JCP = 11.3 Hz, CH2CHN), 57.3 (d, 
2JCP = 1.8 Hz, 
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CH2C(CH3)3), 55.4 (CH2C(CH3)3), 32.3 (d, 
3JCP = 0.6 Hz, C(CH3)3), 31.7 (d, 
3JCP = 2.5 Hz, 
C(CH3)3), 30.8 (d 
3JCP = 9.3 Hz, CH2), 30.2 (
3JCP = 12.8 Hz, CH2), 28.2 (C(CH3)3), 28.1 (C(CH3)3), 
24.4 (d, 4JCP = 1.1 Hz, CH2), 24.3 (d, 
4JCP = 1.8 Hz, CH2); HRMS (APPI, pos.): m/z 357.2015 
(357.2004 calc. for C17H32N3OPS (M)
+) and 358.2087 (358.2082 calc. for C17H33N3OPS (M+H)
+). 
(3aS,7aS)-2-Isothiocyanato-1,3-bis(naphthalen-2-ylmethyl)octahydro-1H 
benzo[d][1,3,2]diazaphosphole 2-oxide (38): 
 
To a solution of phosphoryl chloride 35 (300 mg, 0.63 mmol) in dry CH3CN was added 
potassium thiocyanate (123 mg, 1.26 mmol), the solution was heated to reflux for 30 h and then 
cooled to room temperature and concentrated under reduced pressure. The residue was purified by 
flash chromatography on silica gel to provide 257 mg (80%) of isothiocyanate 38 as white solid; 
Rf  = 0.23 (hexanes/EtOAc, 8:2). 
Mp: 148.2-149.0 oC; IR (neat): 3059, 2937, 2863, 2020, 1970, 1600, 1509, 1437, 1297, 1249, 
1224, 1196, 1146, 1109, 1078, 1017, 964, 920, 899, 877, 854, 815, 776, 763, 747, 722 cm -1; 1H 
NMR (300 MHz, CDCl3): δ 7.90-7.78 (m, 8H, ArH), 7.64-7.53 (m, 2H, ArH), 7.52-7.40 (m, 4H, 
ArH), 4.61 (td, 2H, J = 15.9, 4.0 Hz, NCH2), 4.29 (dd, 1H, J = 15.7, 10.8 Hz, NCH2), 4.06 (dd, 
1H, J = 15.7, 8.4 Hz, NCH2), 3.06-2.90 (m, 2H, CH2CHN), 1.88-1.78 (m, 1H, CH2), 1.76-1.68 (m, 
1H, CH2), 1.64-1.51 (m, 2H, CH2), 1.22-0.83 (m, 4H, CH2); 
13C NMR (75 MHz, CDCl3): δ 142.4 
(d, 2JCP = 7.0 Hz, C=S), 135.4 (d, 
3JCP = 7.7 Hz, ArCipso), 135.1 (d, 
3JCP = 3.5 Hz, ArCipso) 133.34 
(ArCipso), 133.27 (ArCipso), 132.9 (2 x ArCipso), 128.5 (ArC), 128.3 (ArC), 127.84 (ArC), 127.81 
(ArC), 127.7 (2 x ArC), 126.6 (ArC), 126.3 (ArC), 126.2 (2 x ArC), 126.0 (ArC), 125.9 (3 x ArC), 
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63.5 (d, 2JCP = 9.1 Hz, CH2CHN), 63.3 (d, 
2JCP = 9.4 Hz, CH2CHN), 47.2 (d, 
2JCP = 1.9 Hz, NCH2), 
47.1 (d, 2JCP = 3.2 Hz, NCH2), 29.3 (d, 
3JCP = 9.4 Hz, CH2), 29.2 (d, 
3JCP = 12.0 Hz, CH2), 24.0 (d, 
4JCP = 0.7 Hz, CH2), 23.8 (d, 
4JCP = 1.5 Hz, CH2); HRMS (APPI, pos.): m/z 497.1703 (497.1691 
calc. for C29H28N3OPS (M)
+) and 498.1775 (498.1769 calc. for C29H29N3OPS (M+H)
+). 
General procedure for the synthesis of catalysts III-VI: 
To the solution of corresponding isothiocyante in THF (3 ml), N,N-dimethyl diamine was 
added at ambient temperature. The mixture was stirred for 3 h, the solvent was removed, and the 
residue was purified by flash column chromatography on silica gel to provide requisite catalyst in 
good yield. 
1-((1S,2S)-2-(Dimethylamino)-1,2-diphenylethyl)-3-((3aS,7aS)-1,3-dineopentyl-2-
oxidohexahydro-1H-benzo[d][1,3,2]diazaphosphol-2(3H)-yl)thiourea (III): 
 
The reaction of 36 (200 mg, 0.55 mmol) in THF (3 ml) was added  N,N-dimethyl stilbene 
diamine (134 mg, 0.55 mmol) according to the general procedure provided, after purification by 
flash column chromatography on silica gel, 304 mg (90%) of III as a white solid; Rf  = 0.22 
(hexanes/EtOAc, 7:3). 
IR (neat): 3066, 3031, 2939, 2861, 2829, 2781, 1540, 1498, 1478, 1365, 1338, 1200, 1129, 1102, 
1075, 1060, 1020, 847, 798, 757, 746, 707, 631, 613, 527 cm -1; 1H NMR (300 MHz, CDCl3): δ 
10.4 (d, 1H, J = 7.2 Hz, PhCHNH), 7.24-7.09 (m, 5H, ArH), 7.08-6.96 (m, 5H, ArH), 6.38 (d, 1H, 
J = 9.0 Hz, P(O)NH), 5.80 (dd, 1H, J = 11.1, 7.2 Hz, PhCHNH), 3.88 (d, 1H, J = 11.1 Hz, 
PhCHN(CH3)2), 3.19 (t, 1H, J = 14.9 Hz, CH2C(CH3)3), 2.95 (t, 1H, J = 15.1 Hz, CH2C(CH3)3), 
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2.83-2.75 (m, 1H, CH2CHN), 2.69-2.59 (m, 1H, CH2CHN), 2.46 (t, 1H, J = 15.1 Hz, CH2C(CH3)3), 
2.33 (t, 1H, J = 14.9 Hz, CH2C(CH3)3), 2.17 (s, 6H, N(CH3)2), 2.01-1.89 (m, 2H, CH2), 1.86-1.74 
(m, 2H, CH2), 1.35-1.19 (m, 4H, CH2), 0.99 (s, 9H, C(CH3)3), 0.78 (s, 9H, C(CH3)3); 
13C NMR 
(75 MHz, CDCl3): δ 181.8 (d, 
2JCP = 5.6 Hz, C=S), 140.3 (ArCipso), 133.3 (ArCipso), 129.7 (2 x 
ArC), 128.3 (2 x ArC), 127.6 (2 x ArC), 127.5 (2 x ArC), 127.3 (ArC), 126.6 (ArC), 73.6 
(PhCHN(CH3)2), 64.9 (d, 
2JCP = 10.1 Hz, CH2CHN), 64.4 (d, 
2JCP = 11.0 Hz, CH2CHN)3, 60.1 
(PhCH), 56.4 (CH2C(CH3)3, 55.7 (CH2C(CH3)3, 40.9 (N(CH3)2), 32.1 (d, 
3JCP = 0.9 Hz, C(CH3)3), 
31.7 (d, 3JCP = 1.8 Hz, C(CH3)3), 30.7 (d, 
3JCP = 11.1 Hz, CH2), 30.6 (d, 
3JCP = 9.7 Hz, CH2),  28.3 
(CH3)3, 28.1 (CH3)3, 24.5 (CH2), 24.3 (CH2); HRMS (APPI, pos.):  597.3653 (597.3630 calc. for 
C33H52N5OPS (M)
+) and 598.3724 (598.3708 calc. for C33H53N5OPS (M+H)
+). 
1-((3aS,7aS)-1,3-Bis(naphthalen-2-ylmethyl)-2-oxidohexahydro-1H 
benzo[d][1,3,2]diazaphosphol-2(3H)-yl)-3-((1S,2S)-2-(dimethylamino)-1,2 
diphenylethyl)thiourea (IV): 
 
The reaction of 38 (225 mg, 0.45 mmol) in THF (3 ml) was added  N,N-dimethyl stilbene 
diamine (109 mg, 0.45 mmol) according to the general procedure provided, after purification by 
flash column chromatography on silica gel, 220 mg (74%) of IV as a white solid; Rf  = 0.23 
(hexanes/EtOAc, 7:3). 
M.P. – 229.2 - 230.5 oC; IR (neat): 3056, 2925, 2856, 2783, 1555, 1492, 1452, 1364, 1339, 1307, 
1184, 1169, 1144, 1106, 1075, 1052, 967, 900, 851, 814, 744, 697, 632, 546, 472 cm -1; 1H NMR 
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(300 MHz, CDCl3): δ 10.5 (d, 1H, J = 7.6 Hz, PhCHNH), 7.92-7.80 (m, 4H, ArH), 7.79-7.63 (m, 
5H, ArH), 7.58 (d, 1H, J = 8.6 Hz, ArH), 7.52-7.37 (m, 4H, ArH), 7.31 (d, 1H, J = 8.6 Hz, ArH), 
7.20 (d, 2H, J = 7.1 Hz, ArH), 7.16-7.08 (m, 3H, ArH), 7.06-6.94 (m, 5H, ArH & P(O)NH), 5.91 
(dd, 1H, J = 10.8, 7.6 Hz, PhCHNH), 4.89 (t, 1H, J = 14.5 Hz, CH2-napthyl), 4.36-4.20 (m, 2H, 
CH2-napthyl), 4.19-4.10 (m, 1H, CH2-napthyl), 3.92 (d, 1H, J = 10.8 Hz, PhCHN(CH3)3), 3.04-
2.83 (m, 2H, CH2CHN), 1.94 (s, 6H, N(CH3)2), 1.72-1.62 (m, 2H, CH2), 1.58-1.45 (m, 2H, CH2), 
1.13-0.93 (m, 4H, CH2); 
13C NMR (75 MHz, CDCl3): δ 181.8 (d, 
2JCP = 3.9 Hz, C=S), 139.7 
(ArCipso), 136.9 (d, 
3JCP = 7.0 Hz, ArCipso), 134.7 (d, 
3JCP = 3.0 Hz, ArCipso), 133.4 (ArCipso), 133.2 
(ArCipso), 132.9 (ArCipso), 132.84 (ArCipso), 132.77 (ArCipso), 129.7 (2 x ArC), 128.4 (ArC), 128.3 
(ArC), 128.2 (2 x ArC), 127.9 (3 x ArC), 127.8 (ArC), 127.71 (ArC), 127.66 (ArC), 127.5 (2 x 
ArC), 127.3 (ArC), 126.9 (ArC), 126.6 (ArC), 126.2 (ArC), 126.08 (ArC), 126.07 (ArC), 126.05 
(ArC), 126.0 (ArC), 125.8 (ArC), 125.7 (ArC), 73.6 (PhCHN(CH3)2), 64.0 (d, 
2JCP = 10.1 Hz, 
CH2CHN), 62.0 (d, 
2JCP = 10.9 Hz, CH2CHN), 59.9 (PhCHNH), 46.6 (d, 
2JCP = 4.0 Hz, CH2Ph), 
46.2 (d, 2JCP = 3.6 Hz, CH2Ph), 41.0 (N(CH3)2), 29.4 (d, 
3JCP = 10.4 Hz, CH2), 28.6 (d, 
3JCP = 9.2 
Hz, CH2), 24.1 (CH2), 23.9 (CH2); HRMS (APPI, pos.): 737.3324 (737.3317 calc. for 
C45H48N5OPS (M)
+) and 738.3395 (738.3395 calc. for C45H49N5OPS (M+H)
+). 
1-((3aS,7aS)-1,3-Dibenzyl-2-oxidohexahydro-1H-benzo[d][1,3,2]diazaphosphol-2(3H)-yl)-3-
((1S,2S)-1,2-diphenyl-2-(piperidin-1-yl)ethyl)thiourea (V): 
 
The reaction of 37 (208 mg, 0.52 mmol) in THF (3 ml) was added (1S,2S)-N,N-dimethyl-
1,2-diphenyl-2-(piperidin-1-yl)ethanamine (146 mg, 0.52 mmol) according to the general 
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procedure provided, after purification by flash column chromatography on silica gel, 314 mg 
(89%) of V as a white solid; Rf  = 0.22 (hexanes/EtOAc, 7:3). 
IR (neat): 3061, 3029, 2931, 2853, 2804, 1550, 1492, 1450, 1331, 1205, 1174, 1152, 1106, 1068, 
1047,990, 966, 856, 805, 735, 696, 607, 547 cm -1; 1H NMR (300 MHz, CDCl3): δ 10.5 (d, 1H, J 
= 6.9 Hz, PhCHNH), 7.46  (d, 2H, J = 7.3 Hz, ArH), 7.42-7.35 (m, 1H, ArH), 7.34-7.22 (m, 5H, 
ArH), 7.21-7.07 (m, 8H, ArH), 7.06-9.93 (m, 5H, ArH & P(O)NH), 5.83 (dd, 1H, J = 10.9, 6.9 Hz, 
PhCHNH), 4.70 (dd, 1H, J =15.8, 13.6 Hz, CH2Ph), 4.04 (d, 2H, J = 12.4 Hz, CH2Ph), 3.90 (dd, 
1H, J = 16.9, 6.8 Hz, CH2Ph) 3.88 (d, 1H, J = 10.9 Hz, PhCHN), 2.99-2.82 (m, 2H, CH2CHN), 
2.46-2.32 (m, 2H, CH2), 2.24-2.14 (m, 2H, CH2), 1.65-1.53 (m, 4H, CH2), 1.35-1.10 (m, 5H, CH2), 
1.08-0.83 (m, 5H, CH2); 
13C NMR (75 MHz, CDCl3): δ 181.6 (d, 
2JCP = 4.4 Hz, C=S), 140.4 
(ArCipso), 139.2 (d, 
3JCP = 6.7 Hz, ArCipso), 137.2 (d, 
3JCP = 3.1 Hz, ArCipso), 134.0 (ArCipso), 129.6 
(2 x ArC), 128.4 (2 x ArC), 128.3 (2 x ArC), 128.1 (2 x ArC), 127.9 (2 x ArC), 127.7 (2 x ArC), 
127.4 (2 x ArC), 127.3 (2 x ArC), 127.12 (ArC), 127.08 (2 x ArC), 126.6 (ArC), 74.9 (PhCHN), 
64.4 (d, 2JCP = 10.2 Hz, CH2CHN), 61.9 (d, 
2JCP = 10.9 Hz, CH2CHN), 59.5 (PhCHNH), 50.3 (2 
x NCH2), 46.9 (d, 
2JCP = 4.2 Hz, CH2Ph), 46.0 (d, 
2JCP = 3.4 Hz, CH2Ph), 29.5 (d, 
3JCP = 9.9 Hz, 
CH2), 28.5 (d, 
3JCP = 9.3 Hz, CH2), 26.1 (2 x CH2), 24.3 (CH2), 24.1 (CH2), 24.0 (CH2); HRMS 
(APPI, pos.): m/z 677.3320 (677.3317 calc. for C40H48N5OPS (M)
+) and 678.3390 (678.3395 calc. 
for C40H48N5OPS (M+H)
+). 
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1-((3aS,7aS)-1,3-Dibenzyl-2-oxidohexahydro-1H-benzo[d][1,3,2]diazaphosphol-2(3H)-yl)-3-
((1S,2S)-1,2-diphenyl-2-(pyrrolidin-1-yl)ethyl)thiourea (VI): 
 
The reaction of 37 (245 mg, 0.61 mmol) in THF (3 ml) was added (1S,2S)-N,N-dimethyl-
1,2-diphenyl-2-(pyrrolidin-1-yl)ethanamine (164 mg, 0.61 mmol) according to the general 
procedure provided, after purification by flash column chromatography on silica gel, 401 mg 
(96%) of VI as a white solid; Rf  = 0.23 (hexanes/EtOAc, 7:3). 
IR (neat): 3130, 3031, 2940, 2862, 2827, 2782, 2038, 1552, 1495, 1478, 1452, 1362, 1339, 1186, 
1167, 1126, 1101, 1073, 1059, 1019, 846, 798, 760, 745, 696, 633, 616, 550 cm-1; 1H NMR (300 
MHz, CDCl3): δ 10.4 (d, 1H, J = 7.7 Hz, PhCHNH), 7.48 (d, 2H, J = 7.3 Hz, ArH), 7.40-7.25 (m, 
6H, ArH), 7.22-7.07 (m, 8H, ArH), 7.06-6.93 (m, 5H, ArH, P(O)NH), 5.91 (t, 1H, J = 7.7 Hz, 
PhCHNH), 4.54 (dd, 1H, J = 15.8, 13.6 Hz, CH2Ph), 4.04 (dd, 2H, J = 11.3, 5.8 Hz, CH2Ph), 3.98 
(d, 1H, 7.7 Hz, PhCHN), 3.92 (dd, 1H, J = 15.8, 6.7 Hz, CH2Ph), 3.00-2.79 (m, 2H, CH2CHN),  
2.56-2.42 (m, 4H, CH2), 1.75-1.53 (m, 4H, CH2), 1.48-1.37 (m, 4H, CH2) 1.20-0.93 (m, 4H, CH2); 
13C NMR (75 MHz, CDCl3): δ 181.9 (d, 
2JCP = 4.2 Hz, C=S), 139.3 (ArCipso), 139.0 (d, 
3JCP = 6.3 
Hz, ArCipso), 136.8 (d, 
3JCP = 2.7 Hz, ArCipso), 136.3 (ArCipso), 129.5 (2 x ArC), 128.5 (2 x ArC), 
128.4 (2 x ArC), 128.1 (2 x ArC), 128.0 (2 x ArC), 127.7 (2 x ArC), 127.6 (2 x ArC), 127.4 (2 x 
ArC), 127.27 (ArC), 127.26 (ArC), 127.1 (ArC), 126.7 (ArC), 71.9 (PhCHN), 64.1 (d, 2JCP = 10.2 
Hz, CH2CHN), 61.9 (d, 
2JCP = 10.8 Hz, CH2CHN), 61.5 (PhCHNH), 50.4 (CH2), 46.7 (d, 
3JCP = 
4.1 Hz, CH2), 46.1 (d, 
3JCP = 3.5 Hz, CH2), 29.4 (d, 
3JCP = 9.7 Hz, CH2), 28.4 (d, 
3JCP = 9.4 Hz, 
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CH2), 24.1 (CH2), 23.9 (CH2), 23.0 (2 x CH2); HRMS (APPI, pos.): m/z 663.3150 (633.3161 calc. 
for C39H46N5OPS (M)
+) and 664.3239 (664.3220 calc. for C39H47N5OPS (M+H)
+). 
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4.7 X-Ray crystallographic data for 26  
Experimental details 
 
Single-crystal X-ray diffraction data was collected at 291(2) K on a XtaLAB Synergy-S, Dualflex, 
HyPix-6000HE diffractometer using Cu-K  radiation (λ = 1.5406 Å). Crystal was mounted on 
nylon CryoLoops with Paraton-N. The data collection and reduction were processed within 
CrysAlisPro (Rigaku OD, 2019). A Gaussian absorption correction was applied to the collected 
reflections. Using Olex2 [1], the structure was solved with the ShelXT [2] structure solution 
program using Intrinsic Phasing and refined with the ShelXL [3] refinement package using Least 
Squares minimisation. All non-hydrogen atoms were refined anisotropically. The hydroxyl 
hydrogen atom was located in difference Fourier maps and refined by using the HTAB command. 
The organic hydrogen atoms were generated geometrically.  
 
1. Dolomanov, O.V., Bourhis, L.J., Gildea, R.J, Howard, J.A.K. & Puschmann, H. (2009), J. 
Appl. Cryst. 42, 339-341. 
2. Sheldrick, G.M. (2015). Acta Cryst. A71, 3-8. 
3. Sheldrick, G.M. (2015). Acta Cryst. C71, 3-8. 
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Table 1.  Crystal data and structure refinement 
  
Empirical formula C14H13NO4 
Formula weight 259.25 
Temperature/K 291(2) 
Crystal system monoclinic 
Space group P21 
a/Å 9.08200(9) 
b/Å 5.49247(5) 
c/Å 12.75023(12) 
β/° 99.3659(9) 
Volume/Å3 627.536(11) 
Z 2 
ρcalcg/cm3 1.372 
μ/mm-1 0.847 
F(000) 272.0 
Crystal size/mm3 0.449 × 0.135 × 0.09 
Radiation Cu Kα (λ = 1.54184) 
2Θ range for data collection/° 7.026 to 154.592 
Index ranges -11 ≤ h ≤ 11, -6 ≤ k ≤ 6, -16 ≤ l ≤ 16 
Reflections collected 20947 
Independent reflections 2635 [Rint = 0.0563, Rsigma = 0.0244] 
Data/restraints/parameters 2635/1/178 
Goodness-of-fit on F2 1.081 
Final R indexes [I>=2σ (I)] R1 = 0.0449, wR2 = 0.1283 
Final R indexes [all data] R1 = 0.0490, wR2 = 0.1367 
Largest diff. peak/hole / e Å-3 0.33/-0.20 
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Flack parameter 0.04(6) 
 
Table 2. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement Parameters 
(Å2×103). Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
O1 -34(2) 6027(4) 744.5(15) 49.6(5) 
O2 1512.0(19) 1405(3) 1366.9(14) 37.3(4) 
O3 4590.5(18) 2903(3) 1600.0(14) 38.5(4) 
O4 6910(2) 3088(6) 2519(2) 67.3(7) 
N1 632(2) 6631(4) 2537.2(16) 36.6(5) 
C1 749(2) 5612(4) 1591.8(18) 33.6(5) 
C2 2021(2) 3693(4) 1773.6(16) 30.6(5) 
C3 2397(2) 3652(4) 2971.2(17) 31.5(5) 
C4 3355(3) 2217(5) 3665.2(19) 40.1(6) 
C5 3515(3) 2688(7) 4755(2) 49.9(6) 
C6 2738(3) 4578(7) 5131(2) 50.7(7) 
C7 1741(3) 6011(6) 4445(2) 46.1(6) 
C8 1586(2) 5492(4) 3370.7(18) 34.0(5) 
C9 -488(3) 8402(6) 2699(3) 49.2(7) 
C10 3375(2) 4582(4) 1259.6(17) 31.4(5) 
C11 3983(3) 6983(4) 1681(2) 37.8(5) 
C12 5370(3) 6720(5) 2169(2) 42.0(6) 
C13 5780(3) 4132(6) 2153(2) 42.6(5) 
C14 3059(3) 4586(7) 52.9(19) 48.6(7) 
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Table 3.  Selected Bond Distances (Å) 
Atom Atom Length/Å  Atom Atom Length/Å 
O1 C1 1.214(3)  C3 C4 1.382(3) 
O2 C2 1.408(3)  C3 C8 1.395(3) 
O3 C10 1.449(3)  C4 C5 1.398(3) 
O3 C13 1.368(3)  C5 C6 1.384(5) 
O4 C13 1.202(3)  C6 C7 1.396(4) 
N1 C1 1.349(3)  C7 C8 1.383(3) 
N1 C8 1.404(3)  C10 C11 1.496(3) 
N1 C9 1.446(3)  C10 C14 1.518(3) 
C1 C2 1.553(3)  C11 C12 1.319(4) 
C2 C3 1.510(3)  C12 C13 1.470(4) 
C2 C10 1.563(3)     
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Table 4.  Selected Bond Angles 
Atom Atom Atom Angle/˚  Atom Atom Atom Angle/˚ 
C13 O3 C10 109.85(19)  C6 C5 C4 120.5(3) 
C1 N1 C8 111.3(2)  C5 C6 C7 121.4(2) 
C1 N1 C9 124.5(2)  C8 C7 C6 117.1(3) 
C8 N1 C9 123.6(2)  C3 C8 N1 110.1(2) 
O1 C1 N1 126.7(2)  C7 C8 N1 127.5(2) 
O1 C1 C2 125.0(2)  C7 C8 C3 122.4(2) 
N1 C1 C2 108.26(19)  O3 C10 C2 106.78(17) 
O2 C2 C1 111.06(17)  O3 C10 C11 103.57(17) 
O2 C2 C3 111.46(18)  O3 C10 C14 108.3(2) 
O2 C2 C10 110.96(18)  C11 C10 C2 113.23(18) 
C1 C2 C10 110.01(17)  C11 C10 C14 111.2(2) 
C3 C2 C1 101.64(17)  C14 C10 C2 113.18(19) 
C3 C2 C10 111.37(17)  C12 C11 C10 109.9(2) 
C4 C3 C2 132.2(2)  C11 C12 C13 108.9(2) 
C4 C3 C8 119.6(2)  O3 C13 C12 107.7(2) 
C8 C3 C2 108.19(19)  O4 C13 O3 121.2(3) 
C3 C4 C5 118.9(2)  O4 C13 C12 131.1(3) 
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Table 5.  Hydrogen Bonds 
 
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
O2 H2 O11 0.93(5) 1.91(5) 2.814(3) 164(5) 
1-X,-1/2+Y,-Z 
 Table 6.  Selected Torsion Angles 
 
A B C D Angle/˚  A B C D Angle/˚ 
O1 C1 C2 O2 -51.5(3)  C3 C4 C5 C6 -0.7(4) 
O1 C1 C2 C3 -170.2(3)  C4 C3 C8 N1 -176.9(2) 
O1 C1 C2 C10 71.7(3)  C4 C3 C8 C7 2.5(4) 
O2 C2 C3 C4 56.1(3)  C4 C5 C6 C7 2.2(5) 
O2 C2 C3 C8 -124.9(2)  C5 C6 C7 C8 -1.3(5) 
O2 C2 C10 O3 -65.4(2)  C6 C7 C8 N1 178.3(2) 
O2 C2 C10 C11 -178.72(18)  C6 C7 C8 C3 -1.0(4) 
O2 C2 C10 C14 53.6(3)  C8 N1 C1 O1 172.0(3) 
O3 C10 C11 C12 1.6(3)  C8 N1 C1 C2 -5.2(3) 
N1 C1 C2 O2 125.8(2)  C8 C3 C4 C5 -1.6(4) 
N1 C1 C2 C3 7.1(2)  C9 N1 C1 O1 1.0(4) 
N1 C1 C2 C10 -111.0(2)  C9 N1 C1 C2 -176.3(2) 
C1 N1 C8 C3 0.9(3)  C9 N1 C8 C3 172.0(2) 
C1 N1 C8 C7 -178.4(3)  C9 N1 C8 C7 -7.3(4) 
C1 C2 C3 C4 174.5(2)  C10 O3 C13 O4 179.4(2) 
C1 C2 C3 C8 -6.5(2)  C10 O3 C13 C12 -1.2(3) 
C1 C2 C10 O3 171.31(17)  C10 C2 C3 C4 -68.4(3) 
C1 C2 C10 C11 58.0(2)  C10 C2 C3 C8 110.6(2) 
C1 C2 C10 C14 -69.7(3)  C10 C11 C12 C13 -2.3(3) 
C2 C3 C4 C5 177.3(2)  C11 C12 C13 O3 2.2(3) 
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C2 C3 C8 N1 4.0(2)  C11 C12 C13 O4 -178.4(3) 
C2 C3 C8 C7 -176.7(2)  C13 O3 C10 C2 -119.92(19) 
C2 C10 C11 C12 116.8(2)  C13 O3 C10 C11 -0.2(2) 
C3 C2 C10 O3 59.4(2)  C13 O3 C10 C14 117.9(2) 
C3 C2 C10 C11 -53.9(2)  C14 C10 C11 C12 -114.4(2) 
C3 C2 C10 C14 178.4(2)       
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4.10 Selected 1H NMR, 13C NMR Spectra: 
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4.10 Selected HPLC traces: 
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Chapter 5 
Conclusions 
 
5.1 Summary of the thesis 
 
Novel phosphoramide-aminothiourea catalysts were synthesized and examined in selected 
vinylogous Mannich reactions. Reactions of piperidine based iminium ion precursors with various 
nucleophiles were examined in the presence of the phosphoramide-thiourea catalysts as well as 
other bifunctional catalysts such as aminothioureas and aminosquaramides (Chapter 1). Many of 
the reactions that were examined either did not provide the required product or provided unwanted 
byproducts arising from side reactions of the iminium ions generated in situ. The precise reasons 
for the failure of the vinylogous Mannich reaction are not known at this time.  
 
Figure 5.1 Attempted reactions of piperidine based iminium ion precursors with different 
nucleophiles 
The Mannich reaction of indoles and in-situ generated iminium ions was also examined. 
Although some of these reactions proceeded with high enantioselectivity, small changes in the 
substitution of the indole nucleus at sites remote to the reaction site had a drastic, and detrimental 
effect on the enantioselection. Details of these studies are described in Chapter 1 of the thesis. 
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Figure 5.2 Mannich reactions of N-alkyl indoles and piperidine based iminium ion precursors 
The enamine mediated Michael addition of cyclic ketones 6-8 and ,-disubstituted 
aldehydes (19 and 20) to in situ generated  -nitrostyrenes (9, 10 and 21) proceeds with moderate 
to good levels of 1,3-asymmetric induction. In case of cyclic ketones, a (S)-proline derived diamine 
11 was found to be the optimal catalyst and in case of cyclic aldehydes (S)-proline 22 gave the 
best result. The optimized conditions were employed in the study of the scope of the reaction with 
a variety of cyclic ketones and aldehydes with various precursor of  -nitrostyrenes and provides 
access to enantiomerically enriched -aryl--nitro ketones (12-18) and -aryl- -nitro aldehydes 
(22-26). The Michael adducts were obtained with moderate diastereoselectivities (1:1 to 1.9:1) and 
moderate to good enantioselectivities (59-89%). Details of these studies are described in Chapter 
2 of the thesis. 
 
Figure 5.3 Organocatalyzed reaction of cyclic ketones and aldehydes with 2-nitro-2-arylethyl 
acetates 
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A two‐step synthesis of 3-aryl-5-arylidene tetronates 29 was developed from diazotetronic 
acid 27 as the starting material. This synthetic approach follows highly stereoselective aldol 
condensation of 27 with a variety of aliphatic or aromatic aldehydes under optimized conditions 
(TiCl4, 2,4,6-collidine) to provide (Z)-5-arylidene/alkylidene-3-diazofuran-2,4(3H,5H)-diones 28 
in excellent yields (8 examples, Scheme 5.1) as single diastereomers. The aryl substituents at C-3, 
required in the targeted pulvinones, were installed by employing undirected, intermolecular C-H 
insertion reactions.  
 
Figure 5.4 A two-step strategy for 3‐aryl‐5‐arylidene tetronates 
 
The utility of the methodology was demonstrated by application in the synthesis of naturally 
occurring aspulvinones (B, D, and Q Scheme 5.1) as well as non-natural pulvinones.  
 
Scheme 5.1  
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 This strategy provides the shortest route to functionalized tetronates and has potential for the rapid 
synthesis of focused libraries of aspulvinone-like natural product analogues (Scheme 5.1). Details 
of this study are described in Chapter 3. 
An organocatalytic direct vinylogous aldol reaction of -angelica lactone 32 with isatins 
was developed by employing a novel series of phosphoramide-aminothiourea catalysts. A range 
of chiral 3-substituted 3-hydroxyindoles with congested, vicinal tetrasubstituted stereocenters 
were obtained in up to 25% yield, 20:1 d.r. and 77% ee.  
 
Figure 5.5 Organocatalytic Direct Vinylogous Aldol Reaction of isatin and -angelicalactone 32 
Details of this study are described in Chapter 4.  
5.2 Future work 
 The use of phosphoramide-thiourea catalysts (I and II) in the addition of indole 
nucleophiles to N-Cbz-2-hydroxy piperidine 36 is a possibility. 
 
Figure 5.6 Reaction of iminium ion precursors with N-alkyl indoles 
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A direct vinylogous aldol reaction of N-alkyl isatins with -angelicalactone was developed for 
the construction of 3-substituted 3-hydroxyindoles intermediates. These intermediates have 
received considerable attention because of their biological importance and the occurrence of these 
motifs in several bioactive indole derivatives1,2 (Chapter 4). Results of the direct vinylogous aldol 
reaction are promising and future efforts will focus on improving the yield and the 
enantioselectivity of the reaction. These studies are ongoing in the Pansare group. 
 
Figure 5.7 Asymmetric Vinylogous Aldol Reaction of -Angelica lactone 32 and Isatin 
The conversion of aldol product into spirocyclic indole such as 43 via the intermediacy of 
the amino compounds 42. The spirocyclic indole motif is found in numerous naturally occurring 
alkaloids and pharmaceutically active compounds (Chapter 4). 
 
Figure 5.8 Conversion of Aldol adducts into spirocyclic core compounds 
It may be noted that the conversion of 3-alkyl-3-hydroxy-2-oxindoles such as 41 to the 
corresponding 3-alkyl-3-amino-2-oxindoles 42 is well known,3 but a diastereoselective version of 
this reaction is not reported. 
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